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ABSTRACT
This thesis describes the development of a new, powerful concept and approach to study 
signalling pathways based on top-down quantitative phosphoproteomics. This approach, called 
the Phospho-SILAC strategy, combines a first step of in-house developed phosphoprotein 
enrichment using Immobilized Affinity Metal Chromatography (IMAC), and Stable Isotope 
Labelling in Cell Culture (SILAC) with labelled arginine containing six 13C atoms. NRK49F 
cells grown in medium containing 13C6 Arg (heavy arginine, hR) were stimulated for short 
times with EG F and the cell lysate obtained was mixed in a ratio 1:1 with the lysate from 
unlabelled cells, used as control. Phosphoproteins were then enriched from the protein 
mixture using IMAC and displayed on 2D gels, allowing multiple isoform separation. 
Individual post-translational changes in different proteins and in different isoforms of the 
same protein upon EGF stimulation are described.
Major focus was given to Hsp8 isoforms, as they were found to be differentially involved in 
EG F signalling when tested with antibodies against M APK/CDK and PCK substrates. A 
potential MAPK phosphorylation site on Hsp8 N-terminal sequence was identified. The 
Phospho-SILAC strategy was also applied to Rho and Rab GTPases and their corresponding 
GDI (guanidine nucleotide dissociation inhibitor) molecules. Phosphorylation might regulate 
the binding between GTPase-GDI. The results obtained also suggested that RhoGDI-1 
activity could be regulated by arginine methylation.
A potent new concept and methodology is outlined for wider investigations of molecular 
dynamics and for guiding the selection of candidate proteins and their modification for further 
studies.
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CHAPTER 1
INTRODUCTION
The role o f proteom ics in elucidating signalling 
netw orks
The term PROTEOMICS refers to the analysis of all proteins in a living system, including the 
description o f co- and post-translationally modified proteins and alternatively spliced variants. 
Together with protein expression analysis, proteomics includes the study of covalent and non- 
covalent protein associations and their spatial and temporal distributions within the cell. 
Ultimately, proteomics helps understand how biochemical and trafficking events are affected 
by changes in extracellular and intracellular conditions. Mass spectrometry (MS) is at the heart 
of virtually all proteomics experiments as it provides the key tools for the analysis of proteins. 
Developments in technology and methodology in the field of mass spectrometry and 
proteomics have been rapid over the last five years and are providing improved and novel 
strategies for global understanding of cellular function.
The history of proteomics dates back to the invention of two-dimensional gels in the 1970s, 
which provided the first feasible way of resolving and displaying hundreds or even thousands 
o f proteins on a single gel. Identification of the spots separated on these gels increased 
enormously when biological mass spectrometry developed into a sufficiendy sensitive and 
robust technique.
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Mass spectrometry in proteomics
Principles and instrumentation
Mass spectrometers consist of three basic components: an ion source, a mass analyser, and an 
ion detector. MS measurements are carried out on ionised analytes in the gaseous phase, 
requiring a method to transfer molecules from solution or solid phase into this state. The two 
most commonly used techniques, which have been used in this study are: matrix-assisted laser 
desorption/ionisation (MALDI) and electrospray ionisation (ESI) (Fenn et al. 1989; Karas et 
al. 1988). Both MALDI and ESI are soft ionisation techniques in which ions are created with 
low internal energies and thus undergo little fragmentation. MALDI ionisation technique 
tolerates a reasonable amount of impurities in the sample to be analysed. Many different 
samples can be processed rapidly in an automated manner and they can be kept on the target 
for several days without compromising the quality of the analysis, allowing easy re-analysis 
when required.
ESI is based on spraying an electrically generated fine mist of ions into the inlet of a mass 
spectrometer at atmospheric pressure. This technique ionises molecules direcdy from solution, 
so it can easily be interfaced with liquid separation methods. Steady advances in the application 
o f ESI to the analysis o f peptides and proteins have been made, and the most notable 
improvements have come from reduction in the flow rate of the liquid used to create the 
electrospray, leading to more efficient creation of ions (Yates 2004).
After ionisation, the sample reaches the mass analyser, which separates ions by their mass-to- 
charge (m/z) ratios. Ion motion in the mass analyser can be manipulated by electric or 
magnetic fields to direct ions to a detector, which registers the numbers of ions at each 
individual m /z value. In proteomics research, four basic kinds of mass analysers are currendy 
being used: time-of-flight (TOF), ion trap, quadrupole, and Fourier transform ion cyclotron
16
resonance (FTICR) analysers. All four differ considerably in sensitivity, resolution, mass 
accuracy and the possibility to fragment peptide ions. The latter results in mass spectra with an 
especially high content o f information (MS/MS spectra) (Aebersold et al. 2003).
The combination of ion source, mass analyser and detector is usually determined by the 
application. MALDI is usually coupled to TOF analysers, which separate ions according to 
their flight time down a field-free tube. Ions' time-of-flight is directly related to their m /z 
values and thus a mass spectrum can be acquired. The biggest drawback to TOF analysers is 
their inability to routinely perform MS /MS.
The ESI used for these experiments was coupled to ion traps (also called three-dimensional 
ion traps). Ions are first captured in the centre of the device for a certain time interval and are 
then scanned from the trap to the detector (Yates 2004). With this type of mass analyser it is 
possible to determine the mass of a given peptide as well as the sequence. Ions with specific 
m /z  ratios can be selected in the 'trap' for fragmentation, induced by collision of the ion with 
an inert gas or a surface in a process called collision induced fragmentation (CID). This energy 
causes the peptide ion to fragment at different points, commonly at the peptide bond. The 
recorded ion product represents the tandem mass spectrum (MS/MS or MS2 
spectrum)(Aebersold et al. 2001), which contain information on the amino acid sequence.
Protein identification
The identification of proteins in proteomics is almost exclusively achieved by mass 
spectrometry (Aebersold et al. 2003). Current MS methods can identify any protein for which a 
primary structure is known. MS is highly sensitive: proteins present in femtomoles quantities 
can be identified on a routine basis and extension to low zeptomole amounts has been 
achieved (Shen et al. 2004; Trauger et al. 2004). Additionally, MS can in principle characterise
17
the exact covalent structure of a protein, allowing detection of splice variants and post- 
translational modifications, without prior knowledge of the types of modifications or their 
locations.
Mass fingerprinting (MFP)
The most common MS strategies analyse peptides rather than full-length proteins. MALDI- 
TOF mass spectrometry is relatively simple and robust to operate, has good mass accuracy, 
high resolution and sensitivity. It is widely used in proteomics to identify proteins from simple 
mixtures by a process called peptide mass fingerprinting (Cottrell 1994).
In this approach, proteins of interest are digested with a sequence-specific enzyme such as 
trypsin. Tryptic peptides obtained are co-crystallised with an organic matrix on a metal
target. A pulsed laser is used to excite the matrix, which causes rapid thermal heating of the 
molecules and eventually desorption of ions into the gas phase. An electrical field accelerates 
the ions towards the detector. Because of the usage of a pulsed laser, MALDI produces 
packets of ions rather than a continuous beam; it therefore needs to be coupled to a mass 
analyser that can measure either a complete mass spectrum without scanning a mass range, or 
trap all the ions for subsequent mass analysis. All the ions are given the same amount of kinetic 
energy so, because they differ in mass, they arrive at the detector at different times (a heavy ion 
will take longer to arrive than an ion with a smaller mass). If the machine is suitably calibrated 
with a range of known masses then the mass of the sample ions can be determined by the time 
they took to reach the detector. Trypsin is known to cleave proteins after a lysine or arginine 
residue. Therefore if the sequence of a protein is known, it is possible to predict what masses 
would be produced if that peptide were cleaved by trypsin. Several internet-based databases 
now exist in which the theoretical digests of known proteins are stored. By matching the 
spectrum of masses obtained by mass spectrometry, usually in the range of 800-3000 m /z,
18
with theoretical masses in the databases it is possible to identify the starting protein from a 
tryptic digest sample. This technique is known as “mass fingerprinting” (MFP) (Mann et al. 
1993; Pappin et al. 1993). Searching the database provides a list of possible matches and a 
score for each indicating the probability that that protein is the correct match. The larger the 
number of peptides compared, and the more accurate the mass measurements made, the more 
likely it is that this method of protein identification will be successful. However, possible 
matches may have similar probabilities, and factors such as post-translational modification may 
interfere with database matching. If a clear match can not be found, or the location of a post- 
translational modification is to be pinpointed, the remaining sample can be sequenced using an 
ESI-Ion Trap mass spectrometer.
This form of protein identification ideally requires an essentially purified protein. The 
technique is therefore very often used in conjunction with two-dimensional gel electrophoresis 
(2D PAGE).
Sample +  
matrix on 
target plate laser ionisation Electric field
Time-of-flight
Detector
Figure 1. M ALDI-TOF Mass Spectrometry
The sample is ionised, then accelerated by the electric field. The heavier ions are slower to 
reach the detector than ions of lower mass. The mass of each ion can be calculated using the 
time it took to reach the detector. When looking at low-mass ions, a reflector is often used to 
increase the distance that the ions travel and thus improve the separation of similar masses.
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Protein sequencing: Tandem M S  or M S / M S  or M S 2
ESI ion trap and ESI quadrupole MS are currently the most popular setups for the 
simultaneous analysis of large numbers of peptides derived from enzymatic digests of complex 
protein mixtures. This is mainly due to their ability to interface chromatographic peptide 
fractionation methods online with the ESI based instruments and the possibility to obtain not 
only mass but sequence information as well. The other main advantage of ESI over MALDI is 
the production of multiply charged ions, which allows the measurement of high molecular 
weight peptides, often neglected in MALDI-TOF analysis.
Nano-electrospray is a variant of electrospray ionisation that, due to the slow introduction of 
sample into the machine, allows for the analysis o f very small volumes of sample. This 
technique (in positive-ion mode) passes the sample, in 50% methanol, 0.5% acetic acid, 
through a very fine capillary while a high voltage is applied. This creates a spray of droplets, 
carrying the same net charge, which is passed through a heated capillary. While the mechanism 
of ionisation is not completely understood, it is thought that evaporation of the solvent causes 
the droplets to shrink and the charge density to increase. This brings the positive ions closer 
together, and eventually the force of repulsion between them is strong enough to cause the 
ions to leave the droplet. These ions can then be “trapped” by an electric field. By varying the 
voltage of this field, ions of a given mass can be ejected from the trap without other masses, 
allowing the isolation of peaks for fragmentation, or scanned across the range to produce a full 
spectrum of masses up to 2000 m /z  (Figure 2). The machine measures m /z  (mass-to-charge 
ratio), as opposed to simply mass, so production of ions carrying multiple charges allows for 
the analysis of masses greater than 2000 Daltons.
CID (Collision-Induced Dissociation) is the method by which a chosen peak can be 
sequenced. Ions o f a particular mass are selected from the ion trap, and collided with atoms of
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an inert gas. This can cause amino acids to be broken off the main chain of a peptide, 
producing a series o f fragments (Figure 3). Adjusting the energy with which collisions take 
place varies the degree of fragmentation. Thus a single peptide can be examined at several 
collision energies, yielding a wide range of fragment sizes. A number of masses can be seen for 
each of these fragments. Groups such as —OH and —N H, can be lost, as well as post- 
translational modifications like phosphate. The detector measures m /z  so if a doubly charged 
ion is produced, a peak will appear at half the peptide mass, and so on. This gives rise to ions 
termed for example “a2 — NH 3” (a2 that has lost ammonia) or “a2+2” (a2 carrying a double 
charge — this ion has an m /z  of M+2H+/2) and permutations of these. The sequence infor­
mation containing MS/MS spectra are compared against comprehensive protein sequence 
databases using one of several different algorithms (Eng et al. 1994; Mann et al. 1994; Perkins 
et al. 1999). This strategy is very similar to peptide mass fingerprinting and, in analogy, is called 
peptide fragmentation mass fingerprinting.
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MS/MS
Figure 2. E SI/Ion-T rap  Mass Spectrometry
After ionisation, the full range of ions can be displayed (MS), or an ion of interest (shown in 
red), can be isolated. Collision energy is then applied and the spectrum of the fragments 
produced is analysed (MS/MS).
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Figure 3. Peptide fragmentation by ESI M S/M S
(A) Collision-Induced Dissociation (CID). When collided with atoms of inert gas, the starting 
peptide is fragmented. When the spectrometer is used in “positive-ion mode”, the sample is 
introduced in an acidic solution, so ionisation involves the addition of H + to all fragments, “y” 
and “b” ions are ions generated from pieces of peptide sequence containing either the N- 
terminus (y) or the C-terminus (b). These ions are most useful for sequencing peptides. Other 
ions including one of the termini are known as “a”, “x”, “c” and “z” ions. (B) Ions can also be 
generated which include neither terminus. These are known as “internal fragments”. An 
example would be an ion comprising AA2 and AA3 CID ion nomenclature, “y”, “a” and “b” 
ions are the most useful for sequencing peptides. The nomenclature for these ions is related to 
where in the amino acid the dissociation occurs. How it corresponds to the peptide structure is 
illustrated above, “y” and “b” ions are reciprocals, as are “a” and “x” ions. All include either 
the C-terminus or the N-terminus.
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Characterisation of post-translational modifications by mass 
spectrometry
Post-translational modifications (PTMs) are processing events that change the properties of a 
protein by proteolytic cleavage or by covalent addition of a modifying group to one or more 
amino acids. Delineation of protein function solely on the basis of changes in abundance 
provides a very limited view of the proteome since numerous protein activities are modulated 
by PTMs that may not be accurately reflected by changes in protein abundance. This is the 
reason for the application of many of the mass spectrometry driven techniques used to 
characterise proteins and peptides to the characterisation of post-translationally modified 
proteins.
A protein that has experienced some form of post-translational modification exhibits a mass 
increase or decrease relative to the molecular weight calculated from its amino acid sequence. 
Phosphorylation of a tyrosine residue, e.g., leads to a mass increment o f 80Da, which could, in 
principle, be detected by a very accurate mass determination by mass spectrometry of the 
intact protein. Usually, modified proteins are further characterised by enzymatic digestion and 
subsequent peptide mass mapping. In case the mass of the modified peptide is not sufficient to 
determine the nature of the modification and its location, the respective peptides are analysed 
by tandem mass spectrometry usually achieved by ESI MS.
These masses can be used to determine the sequence of a peptide. If a peptide is carrying a 
post-translational modification, its location can be pinpointed by observing the loss of that 
group from a series of backbone ions. Usually the mass of the ion with and without 
modification can be seen, but this is not always the case. The practical application of this 
technique is more clearly illustrated later in the results chapters by the sequencing of 
phosphopeptides of interest.
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This procedure is very often the last experimental step in the characterisation of a modified 
protein or peptide. Problems may arise from the complexity of the post-translationally 
modified protein sample and the characteristics of the modified peptides (Stannard et al. 
2003a; Stannard et al. 2003b). The size and the physicochemical properties of the peptides 
influence their ionisation and detection efficiency and consequently make them difficult to find 
in a high background of other ions. In addition, determination of the modified amino acid is 
sometimes not possible due to incomplete ion series in the tandem MS experiment.
Many of the currently used procedures to identify and characterise post-translationally 
modified proteins on a global scale employ some form of specific enrichment of the molecules 
to be identified prior to microcharacterisation by MS. This enrichment step can take place on 
the intact protein level as well as on the peptide level, as will be explained further in the next 
chapter.
Application of proteomics strategies in signalling studies
The bottom-up and top-down approaches in proteomics
Proteomics experiments most often invoke the simultaneous analysis of several thousands of 
protein from complex biological samples. The separation of peptides and proteins is therefore 
a key element in proteomics analysis providing a method to simplify complex mixtures and 
deliver molecules to the ionisation source. Most of the existing separation methods (including 
gel electrophoresis and liquid chromatography based methods) are currently in use and have 
been recently reviewed (Kleiner et al. 2005; Stannard et al. 2004; Wang et al. 2004; Yates 2004).
The final choice o f the mass spectrometer and of the separation method to couple to it 
depends on the purpose of the study. This is the branching point of two main proteomics 
approaches, the bottom-up and the top-down approach.
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In the bottom-up approach, complex protein mixtures are enzymatically digested into very 
complex peptide mixtures, which are then fractionated by multi-dimensional chromatography 
steps before they are subjected to tandem mass spectrometry. MS/MS spectra are recorded for 
as many peptides as possible, and the results used to search databases to identify the proteins 
in the original mixture. Such approaches are suitable for automation and high sample 
throughput can be achieved (Link 2002). These procedures typically identify a very limited 
number o f peptides per protein, often just one, but still enough to identify the gene from 
which the protein was transcribed. They work well in the study of microorganisms where the 
assumption that one gene codes for only one protein species is often true. However when 
higher eukaryotes are investigated, processes including alternative splicing, RNA editing and 
post-translational modification can lead to several different protein species from a single gene. 
Peptide-based identification strategies enable the identification o f the genes from which these 
proteins are derived but do not adequately identify the different functionally important protein 
isoforms (Godovac-Zimmermann et al. 2005; Link 2002).
In the top-down approach, intact proteins are displayed and different isoforms can be isolated 
before MS identification and characterisation. This is especially useful to unravel complex 
patterns of splice variations or post-translational modifications (Bogdanov et al. 2004; Kjeldsen 
et al. 2003; Reid et al. 2002; Sze et al. 2002). Difficulties in presenting intact proteins to the 
mass spectrometer, the complexity of the spectra and the lack o f automation still restrict this 
application to time-consuming “one protein after the other” studies. A more common top- 
down approach is to fractionate and display intact proteins, but to analyse them on the peptide 
level. FT-ICR-MS broadens the applications of top-down proteomics, thanks to its capability 
to fragment intact protein in situ and to sequence them directly.
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Phosphoproteomics: the subproteome for signalling studies
Cell signalling is often regulated by alteration of protein modifications. Proteins can have, 
amongst others, a modification in the shape of phosphate group, sulphate group, 
carbohydrates and lipids. Many post-translational modifications are reversible and can regulate 
the function of a protein. These modifications can not be predicted from gene sequence and 
are therefore subject to analysis of proteomics.
Protein phosphorylation is a major conduit o f signal transduction within the cell. It has been 
intensively studied over the last decade since kinases regulate most of the signals originating at 
the cell surface by phosphorylation. Serine and threonine phosphorylation of proteins is more 
common, occurring in about 99% of cases, whereas tyrosine phosphorylation occurs in less 
than 1% of cases (Hunter 1998). This is also reflected in the genomic organisation of several 
organisms in which serine/threonine kinases far outnumber tyrosine kinases (Adams et al.
2000). In spite of the fact that a large number of kinases and phosphatases have been 
identified, very few physiological substrates have been described.
Cellular signalling appears to be more complex than previously speculated. The concept of one 
receptor for each signalling pathway is overtaken by many evidences proving that pathways 
from different receptors are interconnected and form a network of interacting proteins (Daub 
et al. 1997). In this network some proteins transfer the signals themselves by phosphorylation 
and dephosphorylation. Other proteins have no catalytic function but instead bring together 
components that are supposed to interact with each other. This theory of cell signalling where 
molecules are not dynamically moving around the cell, but rather form molecular assemblies 
through which signals are propagated is relatively new (Hur et al. 2002). In this way new 
groups of proteins, “scaffold” and “anchor” proteins, are introduced into the “club” of cell 
signalling members. Last year quite a few proteomics studies of protein interactions were
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published. These experiments were designed to analyse protein complexes and they consist of 
affinity (bait) purification of the desired protein complex and identification of the bound 
proteins (Gavin et al. 2002; Ho et al. 2002).
Phosphorylation o f signalling molecules can modulate their activities by changing their 3D 
structure, as has been noted in several kinases. Src homology 2 (SH2) and phosphotyrosine 
binding (PTB) domains specifically bind to phosphorylated tyrosine residues, whereas WW and 
Forkhead-associated (FHA) domains bind to phosphorylated serine and/or threonine residues 
(Pawson et al. 1997; Yaffe et al. 2001). The substrates known to date were mainly discovered 
using strategies that rely on in vitro phosphorylation activities of the kinase in question. 
Prediction of putative phosphorylation sites from so-called consensus sites generally yields a 
large number of false positives, making it necessary to confirm phosphorylation of residues in 
vivo.
In addition, there is emerging evidence of phosphorylation as a cmcial determinant of 
functional partitioning of signalling components: the same molecule differently modified can 
play different roles in the cell (Stannard et al. 2003b).
Phosphoproteomics tools
Phosphoproteomics is a comprehensive analysis of protein phosphorylation that involves 
identification of phosphoproteins and phosphopeptides, localisation of the exact residues that 
are phosphorylated and quantification of phosphorylation. However, the analysis of 
phosphoproteins is relatively complex. Firsdy, the stoichiometry o f phosphorylation is 
generally relatively low as only a small fraction of the available intracellular pool of a protein is 
phosphorylated at any given time as a result of a stimulus. Secondly, the phosphorylated sites 
on proteins might vary, implying that any given phosphoprotein is heterogeneous (i.e. it exists
28
in several different phosphorylated forms). Thirdly, many of the signalling molecules are 
present at low abundance within cells and, in these cases; enrichment is a prerequisite before 
analysis. Fourthly, most analytical techniques used for studying protein phosphorylation have a 
limited dynamic range, which means that although major phosphorylation sites might be 
located easily, minor sites might be difficult to identify. Finally, phosphatases could 
dephosphorylate residues unless precautions are taken to inhibit their activity during 
preparation and purification steps o f cell lysates.
Amongst the different methods used to target the phosphoproteome, anti-phosphotyrosine 
antibodies have widely used for immunopredpitation of intact phosphoproteins in mass 
spectrometry driven proteomic studies of cell signalling (Blagoev et al. 2004; Soskic et al. 1999; 
Stannard et al. 2003a). However less spedfic, anti-phosphoserine and anti-phosphothreonine 
antibodies are used for the same purpose (Gronborg et al. 2002). A popular affinity- 
enrichment strategy for phosphopeptides in bottom- up proteomics approach is immobilised 
metal affinity chromatography (IMAC). Phosphate groups of phosphopeptides show a strong 
affinity towards immobilised Fe3+- and Ga3+-ions and this method is therefore used to enrich 
phosphopeptides from cmde peptide mixtures prior to LC-MS/MS analysis in large scale 
phosphoproteomics experiments (Ficarro et al. 2002; Nuhse et al. 2003).
The application of this strategy into a top-down approach would require the isolation of the 
phosphoproteome using techniques like IMAC, but to date no publications describe an 
effective protocol to enrich phosphoproteins. In this study, focus has been given to the 
development of such procedure with the aim of separating the obtained phosphoproteins in a 
differential 2D display and identifying them. It is possible to sequence phosphopeptides in the 
mass spectrometer and unambiguously determine the site of phosphorylation (Papac et al.
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1993; Roos et al. 1998), so some samples have been further analysed using ESI MS/MS, to 
obtain exact localisation of the phosphate in the protein sequence.
Quantitative mass spectrometry
In addition to the initial identification and protein characterisation, a key parameter in 
proteomics analysis, is the ability to quantitate proteins of interest. Quantitation is a vital tool 
towards an understanding of transcriptional, translational and post-translational effects that 
affect protein production and function.
At this stage of knowledge in signalling, the quantification o f every single phosphorylation site 
identified becomes the key and conclusive step. No such quantitative method applied to wide 
biological systems has been published to date.
There are several reasons why quantification of phosphorylation would be particularly 
important. A given protein might be in more than one signalling pathway (as is usually the 
case) with different stimuli inducing overlapping patterns of phosphorylation. That means a 
given site might not be phosphorylated at all, phosphorylated in a minority of molecules or, in 
an extreme case, on all the molecules of that protein. When a population of molecules from 
unsynchronised cells is analysed, this situation corresponds to detection of unphosphorylated, 
weakly phosphorylated or highly phosphorylated peptides containing the residue. Similarly, the 
ratio of phosphorylation of a protein on multiple residues might be cmcial for its function.
In recent years quantitative proteomics by mass spectrometry has mainly focused on the 
differential quantitative determination of protein expression rather then absolute 
measurements, as many proteomic applications to drug target discovery or to track signalling 
events are concerned with relative rather than absolute abundances of proteins.
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The techniques that have traditionally been used for quantification of phosphoproteins are 
based on 32P labelling of the cells, although MS-based techniques are rapidly evolving. 
Recently, stable isotope methods from small-molecule mass spectrometry have been 
introduced into MS-based proteomics and now allow relative changes to be determined. The 
principle of these methods is the incorporation of a stable isotope derivative in one of the two 
states to be compared. Stable isotope incorporation shifts the mass of the peptides by a 
predictable amount. The ratio of analyte between the two states can then be determined 
accurately by the measured peak ratio between the underivatised and the derivatised sample.
In mass spectrometry the amount of analyte in the sample does not correlate directly with the 
ion-current intensity of its mass spectrometric signal. Additional techniques have to be 
implemented to enable differential quantification of proteins with mass spectrometry. In 
proteomics almost all of these additional methods involve the labelling of peptides with stable 
isotopes by either biosynthetic or chemical methods. Peptides can then not only be identified 
but isotope labelling also allows the measurement of differential amounts of the same peptide 
(I ill 2003; Mason et al. 2003).
Metabolic isotopic labelling
Metabolic labelling of proteins exploits the incorporation of isotopic labels during the process 
of cellular metabolism and protein synthesis. A simple and universal method for protein 
quantification by mass spectrometry is whole cell stable isotope labelling.
In the original approach, one experimental cell population is grown in an isotopically depleted 
medium enriched in l3N, and the other in standard 14N-rich medium. After extraction, the two 
protein samples are pooled and proteins/peptides are then analysed using classic proteomics 
methods (Oda et al. 1999; Pasa-Tolic et al. 1999; Washburn et al. 2002).The MS measurement
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readily differentiates between peptides originating from the two pools because incorporation 
of a high abundance of l3N shifts the mass of any given peptide upwards, which leads to a pair 
of peaks from each peptide. The ratios between the intensities or areas of the lower and upper 
mass components of these pairs of peaks directly reflect the difference in the amount of a 
given protein in the two different cell pools. Accurate relative quantification is possible 
because the MS intensity response to a given peptide is independent of the isotopic 
composition of the nitrogen atoms (De Leenheer et al. 1992). An additional advantage of this 
approach is the availability of multiple peptide pairs per protein allowing a good estimation of 
the error associated with the quantification.
An increasingly popular method for protein quantification by MS is the labelling of proteins by 
incorporation of isotopically modified amino acids. This technique was recently named SILAC, 
for stable isotope labelling by amino acids in cell culture (Ong et al. 2002). In this approach, 
one population of cells is grown in medium containing the normal form of an essential amino 
acid while another population o f cells is grown in medium supplemented with a stable isotope- 
labelled analogue. The two resulting protein samples are pooled and analysed essentially as 
described above. Different amino acids are suitable for SILAC, among others leucine (Leu-dO) 
and deuterated leucine (Leu-d3) (Ong et al. 2003), arginine (12C6-Arg) and fully substituted 13C 
labelled arginine (13C6-Arg) (Ong et al. 2002), tyrosine (12C9-Tyr) and fully substituted 13C 
labelled tyrosine (13C9-Tyr) (Ibarrola et al. 2004) have been used.
So far, metabolic isotope labelling has been used to compare two cellular states, such as 
diseased cells versus normal cells. Very recently the SILAC method has been extended to allow 
simultaneous quantification o f proteins originating from three cellular states (Blagoev et al. 
2004). Three different populations of cells were grown in media containing different versions 
of arginine, 12C614N 4-Arg, 13C614N 4-Arg and 13C61;>N4-Arg. After protein extraction and pooling
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of the samples, arginine-containing peptides generated by proteolytic cleavage occur as triplets 
in the mass spectra showing a mass separation by 6 or lODa. Again, the intensity of each peak 
direcdy indicates the relative amount of the respective protein from the corresponding cell 
pool.
Until very recendy, the use of metabolic labelling was limited to samples derived from cell 
culture. The appliance of this method has now been extended to quantitative l3N metabolic 
labelling of the multi-cellular organisms Caenorhabditis elegans and Drosophila melanogaster 
(Kjeldsen et al. 2003). Organisms can be labelled by feeding them on l3N -labelled E.coli and 
yeast, respectively, and the relative abundance of individual proteins was determined by mass 
spectrometry.
The Phospho-SILAC strategy
In this introduction the main mass spectrometric tools available have been explained together 
with their applications in the investigation of signal pathways. Noticeably, most of the 
strategies used in proteomics to study signalling have been created to suit mainly bottom-up 
approaches. For instance, the study of phosphorylation has been mosdy achieved by isolating 
phosphopeptides from mixtures of total proteins from one organism. As well, differential 
quantification has been largely developed to be applied to mixture of peptides rather than 
individual proteins.
Although the validity of results obtained using this approaches is not in dispute, one must be 
aware that these methods leave a whole level of information obscured. Analysing the peptide 
mixtures from the whole proteome is analysing peptides as protein surrogates. This allows 
identification of many of the proteins contained in the mixture and, occasionally, of one
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possible phosphorylation site. No information is obtained on the number and the nature of 
proteins isoforms and their PTMs.
A more comprehensive, although not yet exhaustive, picture of the complicated signalling 
cascades can be only obtained by applying the newest technologies in a top-down approach. 
Indeed, in this thesis different methods were combined into a novel top-down tactic called the 
Phospho-SILAC strategy. First, a new phosphoprotein enrichment protocol was developed to 
isolate intact phosphoproteins rather then phosphopeptides. Second, an innovative application 
of the SILAC quantification method was developed. This focused on the quantification of 
changes of single phosphorylation at specific sites during EG F treatment of NRK49F cells. 
EG F signalling is described in the detail in the next sections.
Previous phospho-quantitative methods (32P labelling, immunodetection) only profile the total 
level of phosphorylation of one given protein. In summary, the Phospho-SILAC method 
allows quantitative and simultaneous profiling of single phosphorylation sites within the same 
protein, which has not been achieved before. It also allows description of different isoforms 
of the same protein, and their difference in terms of phosphorylation sites and 
phosphorylation kinetics of each of these sites. When this strategy is applied to a large number 
of proteins, behaviour of some classes of proteins can be identified.
EGF signalling
Signal transduction is essentially a mode of cell communication, and its mechanism is 
manifested through a chemical change, that directly or indirectly results in alterations in the 
activity or location o f multiple proteins within a cell. In the past signal transduction pathways 
have been studied using a number of approaches including genetic, biochemical, and 
functional strategies. Most of the achievements have been based on the study of single
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molecules to build up different networks. However, biochemical approaches to identify 
signalling molecules have in the past been hampered by the fact that large amounts of pure 
protein were generally required for identification by Edman degradation.
Proteomics makes use of classical methods but takes the study of cellular signalling a step 
further by employing 2D PAGE and/or various types of mass spectrometry, as described 
above. The major advantage of proteomics over classical methods is its ability to follow 
fluctuations o f multiple proteins in parallel, rather then limiting itself to changes in individual 
proteins.
The study presented in this thesis is focused on the development and applications of the 
Phospho-SILAC proteomics approach to study EGF signal pathways. This work overcomes 
some of the limitations associated with classical biochemical approaches, such as focusing on 
one protein at a time. It also tries to surpass the restrictions of widespread proteomics 
approaches, which are often limited for the large amounts of data obtained and the lack of the 
necessary functional connections. EGF has been chosen as a signalling model because it is 
known to be very complex and therefore provided the challenge of contributing with 
quantitative and qualitative information to the established pathways and models.
EGF
Epidermal growth factor (EGF) was discovered in the 1960s. A protein isolated from 
submaxillary glands of male mice was found to cause tooth eruption and premature eyelid 
opening in neonatal mice (Cohen 1962), and it was subsequendy called epidermal growth 
factor based upon growth of epidermis in mouse tissues treated with it. For this work Stanley 
Cohen was awarded a Nobel Prize in Medicine together with Rita Levi-Montalcini in 1986.
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EGF is a globular protein of 6.4 kDa consisting of 53 amino acids. It contains three 
intramolecular disulfide bonds essential for proper tertiary structure and therefore biological 
activity. EGF is found in varying concentrations in milk, saliva, urine (9-100 ng/mL), plasma 
(1 ng/mL) and most other body fluids. EGF proteins are evolutionary closely conserved; 
human EGF and murine EG F have 37 amino acids in common. Approximately 70 percent 
identity is found between human EGF and EGF isolated from other species, and the relative 
positions of the cysteine residues are conserved. Human EG F is synthesised as a very long 
prepro-protein o f 1207 amino acids from which the factor (position 970-1023) is released by 
proteolytic cleavage (Ullrich et al. 1984). The EGF precursor is N-glycosylated and contains a 
hydrophobic domain which allows it to be anchored in the plasma membrane.
There is a whole family o f EGF-like proteins, whose members are defined by high affinity 
binding to EGF receptor (EGFR), by structural homology and by production of mitogenic 
response in EGF-sensitive cells without being agonists o f EGF. They contain so called EGF- 
like repeats, consisting of approximately 40 amino acids and characterised by a conserved 
arrangement of six cysteine residues (found in EGF itself) which are involved in the formation 
of three disulphide bonds. Betacellulin, heparin-binding EGF and transforming growth factor 
alpha (TGFa) belong to this family.
EGF has been found to have many biological activities, the response to the stimulation 
depending on cell type and physiological circumstances. One of the most dramatic biological 
effects of EGF is the regulation of cell growth and differentiation. Other responses to EGF 
include: inhibition of the secretion of gastric acids (Gregory 1975), stimulation of 
vasoconstriction (Berk et al. 1985) and inhibition o f differentiation (Kim et al. 1987).
EGF and EGFR have a critical role in multiple biological processes and detailed understanding
of the signal transduction pathways and their crosstalks are of considerable interest. In
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particular, the importance of this receptor is also due to the high levels of EGFR that have 
been observed in a variety of tumours and that have been correlated with disease progression, 
poor survival and poor response to therapy (Mendelsohn et al. 2000). A number of EGFR 
mutants have been observed in tumours where gene amplification has occurred (Kuan et al.
2001). One of the current EGFR-targeted strategies against tumours sees the use of mono­
clonal antibodies against the extracellular ligand-binding domain, in order to prevent ligand 
binding (Baselga 2002). A better understanding of the regulation of the downstream EGF 
signal pathway could suggest new anti cancer approaches.
EGF receptor
EGF exerts its effects in the target cells by binding to the plasma membrane located EGFR. 
The latter belongs to the tyrosine kinases receptors (RTKs) family, a large class of proteins 
characterised by a single membrane-spanning domain and an intracellular tyrosine kinase 
catalytic domain. The extracellular chains are the least conserved, and vary considerably from 
one receptor to the other.
EGF receptors (EGFR) recognise six different structurally related ligands with high affinity 
and are expressed in almost all types of tissues at receptor densities of 20000-50000 
copies/cell. The EGFR is synthesised from a 1210-residue polypeptide precursor; after 
cleavage of the N-terminal sequence, an 1186-residue protein is inserted into the cell 
membrane. The EGFR extracellular receptor domain (or ectodomain) has a length of 621 
amino acids, including 11 glycosylated asparagine residues and 51 cysteine residues. This 
extracellular portion consists of four domains called LI, CR1, L2, and CR2 domains. Ligand 
binds between the LI and L2 domains of the EGFR (Garrett et al. 2002; Ogiso et al. 2002). 
The CR1 and CR2 domains consist of a number of small modules, each held together by one 
or two disulfide bonds, and are responsible for dimer formation as a large loop protrudes from
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the back of the CR1 domain and makes contact with the CR1 domain of the other receptor in 
the dimer.
The intracellular receptor domain has a length of 542 amino acids and encodes an intrinsic 
tyrosine-specific protein kinase activity (Ullrich et al. 1984). This kinase catalyses the transfer 
of the gamma-phosphate of ATP to a tyrosine residue of the receptor itself and to those of 
other intracellular proteins.
EGFR oligomerization and activation
The EGFR can form homodimers or interact with its three known homologues: ErbB2 (also 
called Neu or HER2), ErbB3 (HER3), and ErbB4 (HER4), in a ligand-dependent fashion to 
form heterodimers (Graus-Porta et al. 1997). Binding of EGF to the extracellular receptor 
domain activates the intracellular kinase domain of the EGFR. Each receptor molecule then 
phosphorylates the linked receptor on tyrosine, resulting in a interphosphorylation of the 
dimer in the C-terminal domain, leading to the activation of the dimer (Hubbard et al. 1998) 
(Figure 4). Recent studies have shown that the dimerisation is induced by the ligand, but 
mediated uniquely by the receptor-receptor contact (Ferguson et al. 2003). Differences in the 
C-terminal domains o f the four different EGFR proteins result in changes to the repertoire of 
signalling molecules that interact with the heterodimers, thus leading to an expansion in the 
number of possible signalling pathways stimulated by a single ligand. The stoichiometry of the 
complex EGF-EGFR is 2:2 (Schlessinger 2000).
It has been suggested that the receptor monomers are in dynamic equilibrium with the 
receptor dimers, and only a limited population of receptor would exist dimeric. The ligand 
binding to the extracellular domain stabilises the formation of the active dimers. This model
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would justify the enhanced activation of the protein kinase domain by receptor overexpression 
in the absence of ligand binding (Domagala et al. 2000).
The binding of ligand to the ectodomain releases the extracellular restraints on the formation 
of an active kinase dimer configuration. The monomeric EGFR has much reduced kinase 
activity compared to that of the dimerised receptor (Boni-Schnetzler et al. 1987; Sherrill 1997); 
it is assumed that in the absence o f dimerisation, the kinase is in a relatively inactive 
conformation.
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Figure 4. Activation of EGF receptor
Upon occupation of EGF, the EGF receptor forms a dimer and this induces a conformational 
change of the cytoplasmic domain that uncovers its latent tyrosine kinase activity. This 
phosphorylates the tyrosine residues of the bound receptor (interphosphorylation). The 
dimerised and phosphorylated receptors constitute the active molecule.
EGFR transactivation
EGFR and its relative HER2 are rapidly tyrosine phosphorylated after stimulation with the 
GPCR agonists endothelin-1 (ET-1), lysophosphatidic acid (LPA) or thrombin. This 
transactivation of a receptor tyrosine kinase leads to extracellular signal regulated kinase (ERK) 
activation, induction of fos gene expression and DNA synthesis which are abrogated either by
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selective EGFR inhibition or by expression of a dominant-negative EGFR mutant (Daub et al. 
1997; Eguchi et al. 1998).
Different experimental data led to the novel theory of the triple membrane-passing signal 
(TMPS) mechanism of EGFR transactivation (Prenzel et al. 1999). GPCR stimulation induces 
a metalloprotease activity which cleaves the HB-EGF precursor and allows the released growth 
factor to bind to the extracellular receptor domain thereby transactivating the EGFR signalling 
potential. This process also allows the transactivation of EGFRs on neighbouring cells but 
only over short distances and under participation of the heparin sulphate proteoglycan matrix.
Signal pathways activated by the EGFR
The EGFR exerts its function in the cellular environment mainly, if not exclusively, via its 
tyrosine kinase activity. Tyrosine phosphorylation of cellular substrates is thus the first and 
cmcial step in transducing EGFR-mediated signals. It is often difficult to determine whether a 
protein, phosphorylated in response to cellular stimulation with EGF, is a direct substrate of 
the EGFR kinase or has been phosphorylated following EGFR-dependent activation of other 
cellular kinases. There are some well-known domains that mediate the physical association 
between EGFR and signalling proteins. Phosphorylation of the EGFR's C-terminus, be it 
autophosphorylation or trans-phosphorylation by other kinases such as Src and Jak-2 (Tice et 
al. 1999; Yamauchi et al. 1997), provides specific docking sites for the SH2, SH3 or PTB 
domains of intracellular signal transducers and adaptors, leading to their colocalization and to 
the assembly of signalling complexes. SH2 and PTB domain-mediated association of 
intracellular proteins with the EGFR are inducible and determined by the phosphorylation 
state of key tyrosine residues on the receptor. However, there are some proteins that are 
associated with the EGFR in its resting state, only to be activated or translocated to other 
cellular locations when the ligand binds (Xia et al. 2002).
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Given the functional diversity of proteins that complex with, or are phosphorylated by, the 
EGFR, it is hardly surprising that EGF stimulation of a cell results in the simultaneous 
activation of multiple pathways often functionally interlinked. A scheme of some of the main 
pathways activated by EGFR is reported in Figure 5. More details on some of these pathways 
will be given in the next paragraphs.
EGFR plasma membrane
G rb2/Sos PLC PI 3-Kinase PLC 
Ras DAG PI 3,4,5 P IPs
Raf-1 —  PKC PKB Ca2+
MEK
ERK
ERK
GDK3p
STATs
STAT2
CaMKII/MLCK PP2B
nuclear membran
cJun STAT;
g e n e  activation
Figure 5. Branching of the signal transduction pathways.
Following activation of EGFR, several signal transduction pathways can be activated. Five of 
these are indicated, and they are further explained in the text.
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Phospholipids metabolism: PLD, PLC, and P/3-K
EGF stimulation of a cell has marked effects on its phospholipid metabolism. O f the enzymes 
involved in these pathways, at least three can be activated directly by the EGFR, phospholipase 
C-gamma (PLC), phosphatidylinositol-3-kinase (PI3-K), and phospholipase D (PLD), while 
others are regulated indirectly by EGF-mediated activation of other pathways.
Until recently the stimulation was thought to be indirect and mediated by cofactors such as 
PKC, Rho, and phosphotidylinositol biphosphate (PIP2). The mechanism of activation, while 
still obscure, appears to require the physical association of PLD with EGFR but not 
necessarily tyrosine phosphorylation: activation of PLD may require a conformational change 
that is stabilised, but not induced, by tyrosine phosphorylation. A similar mode of activation 
has been proposed for PLC (Hernandez-Sotomayor et al. 1993), suggesting a common 
mechanism of activation for this class of molecules. Once activated, PLC catalyzes the 
hydrolysis of phosphatidylinositol-4,5-biphosphate [Ptdlns(4,5)-P2] to yield the important 
second messengers 1,2-diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). IP3 
mediates calcium release from intracellular stores, affecting a host of Ca2+-dependent enzymes, 
while DAG is a cofactor for the activation of the serine/threonine kinase PKC. One of the 
first substrates of PKC is EG F receptor itself. This becomes phosphorylated on a serine very 
close to the transmembrane domain and has the effect of inactivating the receptor.
Thus, through IP3, EGFR can activate Ca2+-dependent pathways (Hofer et al. 1998; Sun et al. 
1998), and through PKC multiple signalling components, including the MAPK and JNK  
pathways (Marais et al. 1998) and possibly the Na+/H +  exchanger (Liaw et al. 1998).
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Phosphoinositide-3-kinases are major players in cellular functions, where they contribute to a 
variety of cellular processes including proliferation, survival, adhesion, and migration (Cantley 
2002).
PI3-K generates phosphatidylinositol-3,4,5-trisphosphate (PIP3). One of the best characterised 
targets of this second messenger is the Ser/Thr kinase PKB (Jones et al. 1991), which binds to 
the lipid and is translocated to the plasma membrane where it is phosphorylated and activated 
by phosphoinositide-dependent kinase-1 (PDK-1). PKB is a major mediator of PI3-K action 
in survival and proliferation, and may well be the major mediator of the antiapoptotic effects 
of EGFR activation.
MAPK (Mitogen activated protein kinase) pathway
G rb2/ Ras pathway
The cascade of biochemical events that leads from the EGFR to the activation of the proto­
oncogene Ras and, eventually, the serine/threonine kinase MAPK has been analysed 
extensively. The key player in EGF-dependent Ras activation is the adaptor protein Grb2 
(Growth factor Receptor Binding protein) (Lowenstein et al. 1992), which is constitutively 
bound to the Ras exchange factor Sos (son of sevenless) and is normally localised to the 
cytosol. Following activation of the EGFR kinase and autophosphorylation, the SH2 domain 
of Grb2 can bind to the EGFR. It must be noted that Grb2 can associate with the receptor 
either directly via Tyrl068 and Tyrl086 (Sorokin et al. 1994), or indirectly, by binding to 
EGFR-associated, tyrosine phosphorylated She (Sasaoka et al. 1994). It has been suggested 
that association of She to EGFR via its PTB domain, leading to its tyrosine phosphorylation 
and to the recruitment of Grb2, is the main step in EGF-dependent induction of the 
Ras/MAPK pathway (Sakaguchi et al. 1998). Activated Ras in turn activates the
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serine/threonine kinase Raf-1 (Hallberg et al. 1994). Raf-1 activation, through a series of 
intermediate kinases, such as MEK (MAPK-ERK Kinase), leads to the phosphorylation, 
activation, and nuclear translocation of Erk-1 and Erk-2 (Extracellular signal Regulated protein 
Kinase), which catalyse the phosphorylation o f nuclear transcription factors (Johnson et al. 
1994). Activation of the MAP kinases also provides a negative feedback loop for this pathway 
since the Grb2-Sos complex is dissociated following MAPK phosphorylation of Sos (Langlois 
et al. 1995).
Both Grb2 and She play important roles in the activation of other EGFR-dependent pathways. 
They are a beautiful example of “modular” construction. Grb2 contains two SH2 domains and 
one SH3 domain, which enables it to interact with tyrosine-phosphorylated motifs as well as 
with proline-rich regions of other proteins (Meisner et al. 1995). She can associate with specific 
tyrosine-phosphorylated sequences via its SH2 and PTB domain, and, being itself 
phosphorylated on tyrosine by activated receptors and cytosolic tyrosine kinases, serves in mm 
as a binding partner for SH2-containing proteins. The presence of such common domains sets 
the primary structure analysis of novel proteins as a valuable tool to attribute them an 
involvement in the signalling network.
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Figure 6. Regulation of Ras/M APK pathway by EGFR
The adaptor protein Grb2, in association with the guanine exchange factor Sos, attached to the 
tyrosine phosphorylated receptor through its SH2 domain. This brings the Grb2/Sos complex 
into the vicinity of the membrane where it catalyses the guanine exchange GTP/G DP 
exchange on Ras. Activated Ras associate with serine/threonine kinase Raf-1. Its localisation at 
the membrane results in activation and phosphorylation of MEK, which phosphorylates ERK 
on both tyrosine and threonine residues. Dimerisation exposes a signal peptide that allows 
translocation to the nucleus.
The fam ily of M A P K  related proteins
ERK is a member of a substantial family of proteins, referred to as MAP kinases. The function 
and regulation of these protein kinases has been conserved during evolution. MAPKs 
phosphorylate specific serines and threonines of target protein substrates and regulate cellular 
activities ranging from gene expression, mitosis, movement, metabolism, and programmed cell 
death. Substrates include other kinases, structural proteins and transcription factors. 
Modulation of the activities of these proteins alters the behaviour of the cells as they respond 
to changes in their environment. MAPKs are part of a phosphorylation system composed of 
three sequentially activated kinases and like their substrates MAPKs are also regulated by 
phosphorylation (Cowan et al. 2003).
MAPKs can be classified in at least three main functional groups, each operating in three 
different pathways, as schematised in Figure 7:
•  The ERK pathway. There are seven members of the ERK family (1-7). ERK1/2 are 
widely expressed and well known to regulate mitosis and meiosis and can be activated 
by many different stimuli, apart from EGF. The other members of the family do not 
seem to be involved in the same functions.
•  The JNK /SA PK  pathway. SAPK stands for Stress Activated Proteins Kinase. The 
JN K  1-3 (Jun N-Terminal kinase) are mainly involved in response to stress and 
inflammatory cytokines. They are known to bind and phosphorylate c-Jun, a DNA 
binding protein, and to enhance its transcriptional activity that indirectly regulates the 
expression of many cytokines.
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• The p38 pathway. P38MAPK (a,(3,y,8) regulate the expression of many cytokines, and 
is involved in immune response. P38a is the first MAPK that breaks the paradigm 
according to which the MAPKs are activated by MKK (Map Kinase Kinase). Recent 
work show that P38a is activated by TAB1, a scaffolding protein with no enzymatic 
activity (Ohkusu-Tsukada et al. 2004; Tanno et al. 2003).
The role of scaffolding protein in signal transduction is becoming clearer and clearer, as I will 
describe in the following section: Chaperones involvement in EG F signalling.
Stimulus EGF Integrin HjOj IL-1
i 1 1 1
A ctivator Ras-GTP Rac-1 Src Traf-6
1 i 1 i 1
MKKK c-Raf1 MEKK-1 MEKK-2 TAK-1
1 i 1 1 1
MKK MKK-1 MKK-4 MKK-5 MKK-6
i 1 i 1 1
MAPK ERK-1 JNK-1 ERK-5 p38
i i I 1 1
S u b stra te p90RSK c-jun MEF-2 MNK-1
Figure 7. MAPK phosphorylation systems
The modules shown in pink are representative of pathway connections for each MAPK family, 
whilst the module in light blue represents the general pathway. P90RSK: 90 kDa ribosomal 
protein S6 kinase. Src: an oncogenic tyrosine kinase. MEF-2: myocyte enhancer factor. IL-1: 
interleukin 1. TRAF-6: tumour necrosis factor-receptor associated factor 6. TAK1: 
transforming growth factor (3- activated protein kinase 1. MNK-1: MAPK-1 interacting kinase 
1.
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The JAK and STATpathways
EGF-mediated regulation o f transcription can be effected, at least in part, by STAT-1, 3, and 5. 
STAT proteins are inactive transcription factors, which are activated and translocated to the 
nucleus upon specific receptor stimulation.
Classically, STATs are recruited to the intracellular domain of the cytokine receptors through 
specific binding between STAT SH2 domains and receptor phosphotyrosine residues and are 
activated by JAK kinase (Kloth et al. 2003). The mode of activation by EGFR appears to be 
significantly different from that used by cytokine receptors. Firstly, the ligand-dependent 
phosphorylation o f STATs by EGFR does not require JAK kinases (David et al. 1996); 
secondly, STATs do not bind to the C-terminal phosphotyrosines of the EGFR; indeed it 
appears that STATs are constitutively associated with the EGFR in its inactive state (Xia et al.
2002). However, as in JAK kinase signalling, activation of STAT transcriptional activity is 
strictly dependent upon the EGFR tyrosine kinase activity (David et al. 1996). More recent 
reports have also implicated the Src kinase in EGF-dependent STAT activation (Kloth et al. 
2003; Olayioye et al. 1999).
GTPases in signalling
GTP-binding proteins (G-proteins) are important molecular switches that regulate a multitude 
of biological processes induced by extracellular signals by changing their status from inactive 
GDP-bound to active GTP-bound forms. Control of this transition is assisted by several 
different classes of proteins. The regulators for the Rab and Rho/Rac subfamilies include the 
guanidine nucleotide dissociation inhibitors (GDIs), which inhibit the dissociation of the 
nucleotide bound to these G-proteins. GDIs are known to extract the membrane-associated 
GDP-bound proteins from the membrane by binding to its prenylated C-terminus, keeping the 
Rho protein inactive in the cytosol by protecting the hydrophobic tail from aqueous solvent
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(Isomura et al. 1991). Three RhoGDIs have been reported to act on proteins in the Rho/Rac 
family, RhoGDI-1, which is ubiquitously expressed and binds to a broad range of Rho/Rac 
proteins, RhoGDI-2, which is specifically expressed in haematopoietic tissues and associates 
with still uncharacterised Rho proteins, and RhoGDI-3, which is expressed in brain, lung and 
testis, and preferentially binds RhoB (Olofsson 1999).
Rho proteins and their regulatory proteins are involved in EG F signalling. In human lens 
epithelial cells, stimulation with EGF for 10-60 minutes leads to Rho-GTPase and Rac- 
GTPase activation of 45% and 65% respectively (Maddala et al. 2003). In gastrointestinal 
epithelial cells, microinjected RhoGDI can inhibit EGF dependent cell migration (Santos et al.
1997). The full molecular mechanisms for regulation of RhoGDI-1 are not yet clear, although 
several studies suggest that the binding affinity of different RhoGDIs for Rho-GTPase is 
regulated by selective phosphorylation of the GDIs (Bourmeyster et al. 1996; Gorvel et al.
1998). More recent studies suggest that RhoGDI-1 phosphorylation and Rho activation require 
PK C a activation (Mehta et al. 2001).
Rabs act as molecular switches as well, cycling between “inactive” GDP-bound and “active” 
GTP-bound states (Seabra et al. 2004) (Figure 8). Importandy, these changes in activity are 
coupled to reversible association with their target membranes. Whilst the G D P/G TP switch is 
a well-recognised molecular mechanism for controlling the activity of small GTPases, the 
membrane association/dissociation cycle, which could be described as a membrane in /out 
switch, is just as critical for the proper functioning of Rab proteins; to be in a truly activated 
state, a protein must be both GTP-bound and membrane-associated. Rab proteins associate to 
the membrane by virtue of the double prenylation on their C termini. This cycle of events 
allows both spatial and temporal control of Rab activity and is coordinated by several factors.
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Geranyl-geranylated Rabs are delivered to their target membranes by a Rab escort protein 
(REP) or a Rab GDP dissociation inhibitor (RabGDI).
Rab proteins form the largest branch of the Ras superfamily of GTPases, with 63 different 
mammalian Rab proteins, many of which are restricted to specialised cell types (Seabra et al. 
2004). They are localised to the cytoplasmic face o f organelles and vesicles involved in the 
biosynthetic/secretory and endocytic pathways in eukaryotic cells. It is now well established 
that Rab proteins play an essential role in the processes that underlie the targeting and fusion 
of transport vesicles with their appropriate acceptor membranes. Rabl controls transport 
events through early Golgi compartments and recent work suggests a role for Rab6 in intra- 
Golgi transport (Martinez et al. 1998). Trafficking of epidermal growth factor receptor 
(EGFR) involves small GTPases of the Rab families and Rab5 in particular has been shown to 
have a clear link with internalisation of the EGFR (Lanzetti et al. 2000). Subsequent studies 
have also indicated that Rab5 and the Raf/Erk signal transduction pathway play essential and 
selective roles in EGF-induced cell proliferation, and highlight a new function for Rab5 in 
EGF signalling (Barbieri et al. 2004).
Other aspects of EGFR trafficking are better established. Unoccupied EGFRs are mostly 
localised in caveolae, which represent a minimal part of the plasma membrane. These 
microdomains are characterised by a high concentration of gangliosides, sphingomyelin, 
cholesterol and caveolin (Smart et al. 1999). Following the addition of EGF and receptor 
activation, EGFR-EGF complexes move out of caveolae into clathrin-coated pits. These 
microdomains are constituted by clathrin triskelions, the assembly of which seems to be 
stimulated by phosphorylation of the heavy chain of the protein (Connolly et al. 1984). There 
is some evidence that Src might be involved in clathrin phosphorylation (Ware et al. 1997). 
Coated intracellular vesicles are then formed and subsequendy the clathrin coat is removed to
produce early endosomes. This compartment then matures to form multivesicular bodies, 
where together with the early endosomes, the EGFRs can be either sent to the lysosome for 
degradation or they are dismanded into monomers and recycled to the membrane (Sorkina et 
al. 1999).
RhoRho
Rho
signal response
Figure 8. GTPases cycle
Rho GTPases cycle between an inactive GDP-bound form and an active GTP-bound form. 
The cycle is tightly regulated mainly by guanine exchange factors (GEFs), GTPase activating 
proteins (GAPs) and guanine dissociation inhibitors (GDIs). In their active form, Rho 
GTPases can bind to signalling molecules such as kinases and scaffold proteins and trigger the 
signal response.
Chaperones involvement in EGF signalling
Chaperone molecules bind proteins in non-native states, preventing their aggregation and 
assisting them to reach a functional conformation in stressed cells. They also play important 
roles in cells under normal conditions, in folding newly synthesised and translocated proteins, 
disassembling oligomeric protein structures, facilitating proteolytic degradation and controlling 
the biological activity of folded regulatory proteins (Townsend et al. 2003).
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The 70-kDa heat shock proteins constitute one of the best characterised families of molecular 
chaperones (Mayer et al. 2001). Although 70-kDa heat shock proteins have long been known 
to be involved in protein folding, they have been recently recognised as having important roles 
in cellular nucleo-cytoplasmic transport and in signal transduction. There are four major 
mammalian 70-kDa heat shock proteins, Hsc70 and Hsp70 which reside in the nucleus and 
cytoplasm, mHsp70 is found in the mitochondrial matrix and BiP (also called GRP78 or Hsp5) 
in the endoplasmic reticulum. Whereas Hsc70, mHsp70 and BiP are constitutively expressed, 
Hsp70 is induced by cellular stress. The sequences of Hsc70 and Hsp70 share 99% identity.
The role of heat shock protein 70 in protein folding, transport and complex formation has 
been studied extensively (Bukau et al. 1998) but its roles in signal transduction have been only 
recently established from observations that Hsp90 and Hsp70 are associated with a number of 
signalling molecules, including v-Src, Raf-1, PKB and steroid receptors (Dittmar et al. 1998; 
Sato et al. 2000). In some cases, these interactions have been shown to be regulated by EGF 
(see below for more details).
Hsp70/Hsc70 is composed of three main domains: an ATPase domain at the N-terminal, a 
peptide binding domain in the centre, and a tetratico-peptide repeat (TPR) binding motif at its 
C-terminal (Brive et al. 2002). Interactions with co-chaperones happen via Hsp70 N-terminal, 
while it binds to substrates via its C-terminal. Binding of exposed stretches of hydrophobic 
residues in unfolded proteins is regulated by ATP-hydrolysis induced conformational changes 
in the ATPase domain: release of substrate requires the binding of ATP to Hsp70, after which 
the substrate either is folded correctly or enters a new cycle of binding and release. Co­
chaperones can influence the cycle of binding and release of Hsp70 with its substrate, by 
stabilising the ADP state and therefore increasing its chaperone activity, like Hip, (Hohfeld et 
al. 1995) or by accelerating the nucleotide exchange and consequent release of non mature
substrates, like Bagl (Bimston et al. 1998; Brive et al. 2002). The ATPase domain is bi-lobed 
with a B-terminal lobe (residues 1-189) and a C-terminal lobe (residues 190-373) each 
consisting of separately folded units and the nucleotide binding crevice is between the lobes, 
and the nucleotide exchange happens in this crevice. It has been shown that the C-terminal 
lobe of the ATPase domain is enough to guarantee the binding with Bag domain (Briknarova 
et al. 2001; Brive et al. 2002; Song et al. 2001). In addition, Hip protein seems to bind regions 
240-260 and 280-290 (Velten et al. 2000), in the C-terminal region of the ATPase domain of 
Hsp70.
Both Hip and Bagl bind on the same site of the ATPase domain, and compete to influence 
Hsp70 activity (Nollen et al. 2001). Bag-1 and Hip also interact with other proteins in the cell. 
Bagl, for example, interacts with and influences the function of many key components of cell 
death and signal transduction pathways, including the anti-apoptotic protein Bcl-2 and the 
growth regulator Raf-1 (Takayama et al. 2001; Wang et al. 1996). It has been proposed that the 
regulation of Bagl function by Hsp70 serves as a checkpoint to regulate growth and death 
when the levels o f Hsp70 in the cell rise in response to stress (Song et al. 2001). Bagl, a co­
chaperone for Hsp70, coordinates signals for cell growth in response to cell stress, by 
downregulating the activity of Raf-1 kinase. Raf-1 and Hsp70 compete for binding to Bagl, 
such that Bagl binds to and activates Raf-1, subsequently activating the downstream ERK1/2. 
When levels of Hsp70 are elevated after heat shock, or in cells conditionally overexpressing 
Hsp70, Bagl—Raf-1 is displaced by Bagl—Hsp70, and DNA synthesis is arrested. Bagl 
mutants which can not bind Hsp70 constitutively activate Raf-1/ERK kinases but are 
unaffected by Hsp70; consequently neither B agl—Raf-1 nor DNA synthesis is negatively 
affected during heat shock. Likewise, Hsp70 mutants which retain chaperone activity but do 
not bind to Bagl, fail to repress Bagl activation of Raf-1/ERK kinase. Bagl functions in the 
heat-shock response to coordinate cell growth signals and mitogenesis, and that Hsp70
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functions as a sensor in stress signalling. It must be added though, that this might only be one 
of the many mechanisms of regulation, because the levels of Hip and Bagl are only 1% of 
that of Hsp70 (Figure 9, A).
Connections between Hsp70 family of proteins and PLC pathways have also been reported. 
BAG3 forms an EGF-regulated ternary complex with Hsc70 and PLC. Phosphorylated BAG3 
binds to Hsc70 in intact cells and BAG3. PLC binds to BAG3 in a separate region in 
unstimulated cells, generating a ternary complex. Upon stimulation with EGF, PLC dissociates 
from the complex, whilst Hsc70 remains attached to BAG3. It is thought that Hsc70 modifies 
the 3D structure of PLC (kept in the vicinity by Bag3) and then releases the activated PLC 
upon BAG3 phosphorylation on tyrosine (Doong et al. 2000). This phosphorylation requires 
PKC, since it is abolished in the presence of PKC inhibitors (Figure 9, B).
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Figure 9. Scheme of Hsc70 involvement in R af-l/E R K  pathway and in PLC pathway
(A) Hsp70 and Raf-1 have overlapping binding sites on BAGl. In case of stress, high 
abundant Hsp70 displaces Raf-1. Upon EGF stimulation, Raf-1 preferably binds to BAG1 and 
becomes activated (in a Ras-independent pathway). (B) Hsp70 and PLC have distinct binding 
sites on BAG3. Within 1 minute of EGF stimulation, PLC is activated and dissociates, whilst 
Hsp70 remains associated to BAG3.
Signalling crosstalk
Although the EGFR induced pathways modules mn in parallel (Figure 5), there is a 
considerable degree of cross-talk between them, which creates multiple opportunities for 
modulating or fine-tuning responses to different signals. MAPK cascades can influence other 
signalling pathways and vice versa; there are several known examples of MAPK influences the
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other signalling pathways. For example, ERKs can activate the JAK-STAT pathways (Marshall 
1995). MAPKs can also converge on the same substrates, like ERK and p38 which both 
activate MNK1 (Fukunaga et al. 1997), the MAPK signalling-integrating kinase 1, which is 
responsible for the activation of the eukaryotic translation initiation factor 4E, as well as 
MSK1.
Signalling pathways linked to cAMP and calcium are also influenced MAPK signalling 
cascades. The MEKs that activate ERKs can be activated by specific Raf isoforms based on the 
type of cell stimulated and the level of cAMP generated. Calcium signalling also affects ERK 
modules; it has been shown in cardiomyocytes and neurons that calcium influx results in MEF- 
2 activation, a transcription factor that is a substrate for the calcium/calmodulin-dependent 
protein kinase IV (Lu et al. 2000; Mao et al. 1999). The activation of MEF-2 correlates with the 
activation of p38, which is responsible for the phosphorylation of MEF-2 on its activation site.
A summary including different pathways branching from EGFR and indicating some of the 
crosstalks between pathways is reported in Figure 10.
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Figure 10. Scheme of different pathways involved in EGF signalling
(Taken form http://www.grt.kyushu-u.ac.jp/spad/pathway/egf.html).
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CHAPTER 2
MATERIALS AND METHODS
M aterials
Normal Rat Kidney Fibroblasts (NRK49F) were kindly given by Dr. J.T. Norman. Trypsin- 
EDTA, antibiotic/antimycotic, Dulbecco’s modified Eagle medium nutrient mixture F12 
Ham, molecular weight marker, were from Invitrogen (Paisley, U.K.). Foetal Bovine Serum 
(FBS) was from HyClone (lot). Dulbecco’s modified Eagle medium (DMEM), nutrient mixture 
FI 2 Ham without arginine (custom preparation) and Foetal Bovine Serum (FBS) dialysed were 
from Invitrogen. L-arginine U-13C6 (13C6 Arg) was from Cambridge Isotope Laboratories 
(Andover, MA). Duracryl (30% acrylamide, 0.8% bis acrylamide) was from Genomic Solutions 
(Huntingdon, U.K.). Disposable NAP-10 columns, ECLplus detection kit and 13cm linear pH 
4-7 IPG strips were from Amersham Biosciences (Chalfont St.Giles, U.K.). Complete mini­
protease inhibitor cocktail was from Roche Diagnostics Ltd (Lewes, U.K.). Sequencing grade 
trypsin was from Promega (Southampton, U.K.). Prestained SDS-page standards low range, 
acrylamide, 11 cm linear pH 5-8 Immobiline DryStrips, Colloidal Gold total Protein Stain were 
from Bio-Rad Laboratories Ltd (Hemel Hempstead, U.K.). Ni-NTA agarose was from Qiagen 
Ltd (Crawley, U.K.), Ni-TED silica resin was from Active motif (Rixensart, Belgium), 
Fractogel EMD chelate (S) was form Merck (Darmstadt, Germany), immobilised iminodiacetic 
acid gel was from Perbio Science (Northumberland, UK.) and Toyopearl AF-Chelate-650M 
was from Tosoh Bioscience (Stuttgart, Germany). Phospho-tyrosine monoclonal antibody (P- 
Tyrl02), phospho-(Ser/Thr) PKA substrate antibody, Phospho-(Thr) M APK/CDK Substrate 
monoclonal Antibody, Phospho-(Ser) PKC Substrate Antibody, phospho-p44/42 MAPK 
(Thr202/Thr204) E10 monoclonal antibody and p44/42 MAPK antibody were from Cell 
Signaling Technology (distributed by New England Biolabs, Hitchin, U.K.). Goat anti-mouse
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or goat anti-rabbit Alexa-labelled secondary antibodies were from Molecular Probes, Oregon. 
All other chemicals were purchased from Sigma-Aldrich Company Ltd. (Poole, U.K.) and were 
of the best grade available.
Cell C u ltu re  
Culture of NRK49F
NRK49F cells were grown in p i00 dishes in DMEM Nutrient mixture F I2 Ham medium 
supplemented with 10% FBS plus antibiotics/antimycotic (100X solution contains 
10,000U/ml penidllin-G, lOmg/ml streptomycin and 251/ml amphotericin-B) at 37°C and 5% 
CO,. Cells were split when they were 70-80% confluent. Splitting involved washing the cells 
with 10ml PBS, trypsinising them with 1ml of Trypsin-EDTA and leaving them to incubate at 
37 °C for 2 minutes. Detachment of cells from the dishes could be seen by naked eye. After 
detaching, cells were resuspended in fresh medium and plated. For stable isotopic labelling of 
amino acids in cell culture (SILAC), L-arginine and L-arginine U-13C6 were added as to two 
separate lots of the arginine deficient media, to reach 147.5 mg/ml. NRK49F cell line was 
grown separately in the modified medium DMEM Nutrient mixture FI 2 Ham and normal 
media, supplemented with 10% dialysed FBS plus antibiotics at 37°C and 5% CO,. Cell lines 
were grown for at least eight splitting passages in media containing either 12C6 Arg or 13C6 Arg, 
before the preparation of cellular extracts.
Freezing of NRK49F cells
NRK49F cells were grown until 70-80% confluent. They were trypsinised as mentioned above, 
resuspended in a small volume of medium and spun at 4°C for 5 minutes at lOOOrpm. 
Supernatant was aspirated and cell pellet resuspended in freezing solution: 10% DMSO in
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FBS. Cells were first left for 1-2 days (maximum 7 days) at -80°C, and then transferred to a 
liquid nitrogen container.
EGF stimulation of NRK49F cells
Cells were grown until 70-80% confluence, and then the medium was replaced with the 
medium containing 0.5% FBS (starvation medium) and the cells were starved for 48h. On the 
day of the experiment, medium was replaced with fresh starvation medium 2 hours prior to 
stimulation. Cells were treated with EGF (200ng/ml) for 2, 5,10 and 20 minutes at 37°C. After 
incubation dishes were placed on ice, washed twice with 5ml of ice-cold PBS and lysed in lysis 
buffer (50mM NaMOPS pH 6.8, 4% Zwittergent 3-12, 2% Triton X-100, 5mM NaF, 5mM Na 
Glycerolphosphate, ImM Na3V 0 4, 5mM Na4 EDTA, ImM Na2P20 7, 1 tablet/lOml of 
complete mini protease inhibitor cocktail) .
Immunofluorescence Staining
Cells were fixed in 4% paraformaldehyde in PBS for 15 min, quenched, and permeabilised in a 
solution of 50mM ammonium chloride and 0.2% saponin in PBS for 15 min, incubated with 
primary antibody 1:1000 in PBS supplemented with 1% gelatin and 0.02% saponin for 1 h, and 
then incubated with Goat anti-mouse or goat anti-rabbit Alexa-labelled secondary antibodies at 
1:200 for 40 min. Confocal images were obtained using an MRC 1024 laser scanner (Bio-Rad, 
Hercules, CA) attached to an Optiphot 2 microscope (Nikon, Garden City, NY). Images were 
collated using Adobe Photoshop (Adobe Systems, Mountain View, CA).
In-vivo 32P cells labelling
NRK49F cells were incubated 14 hours in 0.25mCi/ml dissolved in phosphate free DMEM 
medium and 10% dialysed serum. Cells were washed with cold TBS containing orthovanadate 
lOOmM.
IMAC purification of phosphoproteins
Cell culture dishes were placed on ice, washed twice with 5ml of ice-cold PBS and lysed in 
50mM NaMOPS pH 6.8, 4% Zwittergent 3-12, 2% Triton-XlOO, ImM Na3V 0 4, 5mM NaF, 
5mM [3-glycerophosphate, 5mM EDTA and protease inhibitor. The cellular suspension was 
sonicated for 15 seconds three times and spun for 20 minutes at 13000rpm at 4°C. 8.0M LiCl 
was added to the supernatant to a final concentration of 2M LiCl. One part of bind mix (2M 
LiCl in lysis buffer containing 20% silica) was then mixed to 6 parts of protein solution and 
incubated on a rocking platform at room temperature for 5 minutes. The suspension was then 
centrifuged for 3 minutes at 13000 rpm and the supernatant was saved, the silica discarded. 
The protein solution was then rebuffered into binding buffer (50mM bis-(hydroxyethyl)- 
piperazine pH 3.4, 4% Zwittergent 3-12, 2% Triton X-100) using NAP-10 size exclusion 
columns according to manufacturer’s instructions. For each Fe3+ affinity column in the 1ml of 
50% slurry of Ni-NTA Agarose beads was pipetted into 2.5ml plastic columns. Ni2+ ions were 
removed from the resin by washing the column with 4ml of regeneration buffer (50mM Tris- 
HC1 pH 7.5, 2% Triton X-100, 0.1M EDTA, 0.5M NaCl). The column was then washed with 
4ml of ddH ,0  to remove any trace of EDTA and subsequendy activated with 2ml of freshly 
dissolved FeCl3x 6H20  (27mg/ml in water). The column was then washed with 4ml of water 
and equilibrated with 4ml of binding buffer. 1.5ml of protein solution containing usually 
between 1-3 mg of protein were loaded on the Fe3+ affinity column: at all times the column 
was run by gravity force alone. After loading the sample the columns were washed with 3ml of 
binding buffer and then with 1ml of 25mM Na2S 0 4 and 25mM imidazole in binding buffer. 
Phosphoproteins were eluted in 1ml of 50mM NaH2P 0 4x 1H20  in binding buffer. The 
columns, after extensive washing with binding buffer and water, can be recycled starting with 
the regeneration buffer step. Phosphoproteins were precipitated with 7.5% TCA and 0.02% 1, 
10 phenantroline on ice over night. They were then spun for 20 minutes at 13000 rpm at 4°C.
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Supernatant was aspirated and the protein pellets were washed once with ice-cold 5% TCA for 
10 minutes, and 4 times with ice-cold 80% acetone. Washing includes 5 minutes incubation on 
ice and subsequent 5 minutes spinning at 13000rpm at 4°C. After the last wash protein pellets 
were left on the bench to air-dry for a few minutes and then resuspended in isoelectric 
focusing buffer (8M urea, 2M thiourea, 4% CHAPS, 1% Triton X-100, 65mM DTT, lOmM 
Tris base, 0.8% ampholytes).
P ro te in  assays 
Bicinchoninic acid protein assay
This is a modification of a method originally proposed by (Smith et al. 1985). The principle of 
the method is that BCA reduces divalent copper ion to monovalent ion in alkaline conditions. 
A molybdenum/tungsten purple product is produced with an absorbance maximum at 
A,=562nm. The reagents used for the assay were Bicinchoninic acid solution and Copper (II) 
sulphate pentahydrate 4% solution. A standard curve was prepared with BSA. BSA 
concentrations were chosen in the range between 2pg to lOOpg, depending on the approximate 
estimation of the concentration of the unknown proteins.
BCA protein assays were performed in microtiter 96-well plates. The working BCA reagent so­
lution was prepared by mixing 1 part of Copper (II) sulphate pentahydrate 4% solution to 50 
parts Bicinchoninic acid solution. The working solution was added to the BSA and unknown 
protein sample in ratio 20:1. The plate was incubated for 30 minutes at 37°C. After incubation 
the plate was cooled to room temperature and absorbance measured at A,=595nm. Control for 
each set of samples was the corresponding buffer. The absorbance of the control was sub­
tracted from the absorbance of the samples to obtain the net absorbance of the proteins. A 
standard curve was plotted as the net absorbance at X =595nm vs. the known pg of BSA. This
curve was used to determine the amount of protein in unknown samples. This method is not 
compatible with reducing agents such as DTT.
Modified Bradford protein assay
This method is property of ProteoSys AG, Germany.
Electrophoresis of proteins 
One-dimensional SDS-polyacrylamide gel electrophoresis (SDS- 
PAGE) and Western blot
This electrophoresis was based on the protocol originally proposed by Laemmli (Laemmli 
1970). Acrylamide used for all gels was a mixture of 30% Acrylamide and 0.8% Bisacrylamide. 
Separating gels were prepared in the range from 10% - 12% depending on the size of proteins. 
Separating gel was prepared with different volumes of 30% Acrylamide and 0.8% Bisacryla­
mide, 0.375M Tris HC1 pH 8.8, 0.1% SDS and APS and TEMED were used for 
polymerisation. All stacking gels were of 5% acrylamide concentration and contained 0.125M 
Tris HC1 pH6.8, 0.1% SDS. Sizes of gels were either 15cm x 16cm (Hoefer SE600 system, 
Amersham Pharmacia) or 8.3cm x 7.3cm (Mini-Protean 3 system, Bio-Rad). Samples were 
prepared in SDS-PAGE sample buffer (5X solution: TrisHCl pH 6.8 0.225M, glycerol 
50%, SDS 5%, bromophenol blue 0.05%, DTT 0.25M), vortexed and heated for 5 minutes at 
95°C.
Proteins from cellular extracts and proteins obtained after phosphoprotein enrichment were
separated on 10% SDS-PAGE gels, and then transferred onto nitrocellulose membranes by
semi-dry blotting. Transfer was performed at 21V for 90minutes. Membranes were blocked
with 7% non-fat dry milk or 5% BSA in TBS/Tween buffer (20mM Tris-HCl, pH 7.4 ,150mM
NaCl, 0.1% Tween 20) for minimum 1 hour at room temperature (or overnight at 4°C). After
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blocking, membranes were washed quickly with TBS /Tween and incubated with the primary 
antibodies for a minimum of 1 hour at room temperature (or overnight at 4°C). Primary 
antibodies were diluted in TBS/Tween according to the manufacturer's instructions. 
Membranes were then washed 3 times with 150ml TBS/Tween for 10 minutes and incubated 
with secondary antibodies for 1 hour at room temperature. Horseradish peroxidase-conjugated 
secondary antibodies were used at a 1:10000 dilution in TBS/Tween. After incubation 
membranes were washed 3 times for 10 minutes with TBS/Tween and then once with TBS for 
5 minutes. Detection was done using the ECLplus detection kit.
Antibodies were stripped off membranes by incubating in stripping buffer (62.5mM Tris-HCl, 
pH 6.8, lOOmM (3-mercaptoethanol and 2% SDS) for 30 minutes at 60 C under agitation. 
Membranes were then washed with TBS/Tween for 3 times for 10 minutes and reblocked as 
described above.
After a maximum of 5 different antibodies were tested the membrane was washed with 100ml 
of TBS/Tween 3 times for 20 minutes, rinsed with 100ml of ddH20 for 3 times for 5 minutes, 
and incubated in the minimal amount or colloidal gold to cover the surface until the staining 
was satisfactory (4-5 hours). The membrane was then drained and let dry overnight to increase 
the signal to noise ratio.
Western blot films were scanned using ImageScanner (Amersham Pharmacia Biotech) and the 
image analysed with ImageQuant software (Amersham Biosciences).
Two-dimensional- polyacrylamide gel electrophoresis (2D-PAGE)
13cm linear pH 4-7 IPG strips were loaded with 150pg of proteins by passive rehydration 
overnight. Isoelectric focusing was performed on an IPGphor device (Pharmacia Biotech) and 
was carried out up to a total of 66000 Volt-hours. The IPG strips were rinsed thoroughly with
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distilled water, quickly dried on filter paper and focused proteins were reduced (50mM 
Tris/HCl, pH 6.8, 6M urea, 2% w /v  SDS, 30 % v /v  glycerol, 2% w /v  DTT) and alkylated 
(50mM Tris/HCl, pH 6.8, 6M urea, 2% w /v SDS, 30 % v /v  glycerol, 4.5% w /v iododaceta- 
mide) for 20 minutes each. IPG strips were rinsed thoroughly with distilled water, and the 
excess water was drained onto a piece of filter paper. Gels (15cm x 16cm x 1mm) of varied 
acrylamide concentration 10% - 12% were used, depending on the size of the proteins being 
separated.
Molecular weight markers were loaded onto a piece of filter paper and placed close to the 
acidic part of the IPG strip onto the polyacrylamide gel. The strip and the markers were 
overlayed with 0.5% boiling agarose prepared in stacking gel buffer with a trace of 
bromophenol blue. Electrophoresis ran at a constant voltage of 200V for approximately 5 
hours at 11 C. When the bromophenol blue dye reached the end of the gel the run was 
stopped and the gel was further stained with either silver (Shevchenko et al. 1996) or Comassie 
brilliant blue R250.
Silver stain ing of polyacrylamide gels
This procedure was adopted from Shevchenko (1996). Gels were placed in fixing solution 
(12% CHjCOOH and 50% methanol) and agitated for a minimum of 2 hours. They were then 
washed 3 times for 20 minutes with 50% ethanol. The gels were then pre-treated for 1 minute 
with 0.02% Na2S20 3 and rinsed well with distilled water 3 times for 20 seconds each time. The 
staining step was performed in 0.1% AgNOs for 20 minutes. Excess silver nitrate was washed 
off twice with water, and the proteins spots were detected with a solution containing 
3%Na2C 0 3, 0.0002% Na2S20 3 and 0.009% formaldehyde. When the spots became a dark 
brown colour, the gels were rinsed twice for 2 minutes in distilled water. Staining was stopped 
by immersing the gels in the fixing solution for 10 minutes. After this the gels were washed in
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50% methanol, and finally in 5% methanol. Gels were then packed in plastic wraps with a 
small amount of 5% methanol, to stop them from drying and they were stored at 4°C until the 
proteins were cut and analysed by mass spectrometry.
In-gel tryp tic  pro tein  digestion
Protein spots of interest were excised from the SDS gels and chopped into small pieces 
(1mm3). The gel spots were automatically processed using Genetic Solution Processor or 
manually as described here. Gel pieces were treated with 25mM N H 4H C 0 3 for 15 minutes. 
This step was repeated until the pH of the solution was alkaline. Protein spots were then 
washed three times with acetonitrile and dried in the speed-vacuum concentrator for 30 
minutes. The dry gel clump was rehydrated in lOmM DTT, lOOmM NH 4H C 0 3 for 30 minutes 
then spun down and the supernatant removed. The gel was washed again in acetonitrile and 
dried in the speed-vacuum concentrator for 5 minutes. Trypsin solution was prepared by 
dissolving 20pg of trypsin in 500pl of 25mM N H 4H C 0 3 in ice. 5pl of this solution was added 
to each sample, left to rehydrate for a while at 4°C, and then if necessary more trypsin solution 
was added just to cover the gel, without letting it dry. The final concentration was kept 
between 6-30 n g /p i These samples were then incubated overnight at 30°C.
Mass Spectrom etric Analysis 
MALDI-TOF Mass Spectrometry
For MALDI-TOF mass spectrometry aliquots of 0.5pl o f the digest solution were applied to a 
target plate and allowed to air-dry. Subsequently, 0.5pl of matrix solution (1% w /v  a-cyano-4- 
hydroxycinamic acid in 33% acetonitrile and 0.1% v /v  trifluoroacetic acid) was applied to the 
dried sample and the sample was again allowed to dry. Spectra were obtained using Bruker Bi­
flex III (Bremen, Germany) spectrometer in reflector mode. The spectrometer was calibrated
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using a mixture of 5 known peptides ranging in mass between 842 and 3495 Daltons. Obtained 
spectra were processed manually using Bruker's DataAnalysis software, version 1.6.
Mass Fingerprinting (MFP)
Trypsin is known to cleave proteins after a lysine or arginine residue. Therefore if the sequence 
of a protein is known, it is possible to predict what masses would be produced if that protein 
were cleaved by trypsin. Several internet-based databases now exist in which the theoretical 
digests of known proteins are stored. By matching the spectrum of masses obtained by mass 
spectrometry with these databases it is possible to identify the starting protein from a tryptic 
digest sample. This technique is known as “mass fingerprinting” (see introduction). Searching 
the database provides a list of possible matches and a score for each indicating the probability 
that that protein is the correct match. The larger the number of peptides compared, and the 
more accurate the mass measurements made, the more likely it is that this method of protein 
identification will be successful. However, possible matches may have similar probabilities, and 
factors such as post-translational modification may interfere with database matching. If a clear 
match can not be found, or the location of a post-translational modification is to be 
pinpointed, the remaining sample can be sequenced using an ESI-Ion Trap mass spectrometer.
Protein fragments were identified using PROFOUND programme available at Prowl website 
(http://prowl.rockefeller.edu/profound_bin/WebProFound.exe). Mass finger printing of 
SILAC sample were all conducted allowing a partial modification on arginine of +6 Dalton.
ESI-lon Trap Mass Spectrometry
Tryptic digest samples were almost completely dried and resuspended in 50% methanol and 
5% formic acid. Nanospray mass spectrometry was performed using a Finningan-Matt LCQ 
(San Jose, CA, USA), in a positive ion mode. Collision energy changed between 28 and 35%.
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Peaks previously identified using MALDI-TOF MS were chosen for sequencing, both to 
confirm the identity o f the protein, and the phosphorylation status of the tryptic peptides. 
Mass values corresponding to high probability phosphorylated peptides were also analysed. 
The probability of the modification on specific residues was determined using scansite 
(http://scansite.mit.edu/motifscan) and prosite (http://ca.expasy.org/prosite/). Sequences 
were scanned for specific motifs using pattinprot software (available on www.expacy.org). 
Fragmentation spectra were compared to theoretical fragmentations of the likely sequences 
obtained from MS-Product (http://jspl.ludwig.edu.au), and the location of post-translational 
modifications ascertained where possible.
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CHAPTER 3
PHOSPHOPROTEIN ENRICHMENT 
INTRODUCTION
Protein phosphorylation is a fundamental process for regulation of the activity of proteins in 
signal transduction and in a variety of cellular functions including metabolism and apoptosis 
(Hunter 1995; Pawson et al. 2003). One third of the proteins expressed in mammalian cells are 
phosphorylated at serine, threonine and, less commonly, tyrosine residues (Krebs 1994), hence 
protein phosphorylation is considered to be one of the most important posttranslational 
modifications (Annan et al. 1996; Neubauer et al. 1999). This justifies an intense development 
of methods to detect, analyse and quantify phosphoproteins.
On one hand, focus has been given to staining procedures specific for phosphoprotein (Ge et 
al. 2004; Patton 2002; Schulenberg et al. 2004). On the other hand, phosphoproteins separated 
on gels have be followed by either radiography after 32P radiolabelling (Immler et al. 1998; 
Kang et al. 1997), or western blotting with phospho specific antibodies (Soskic et al. 1999; 
Stannard et al. 2003a; Steen et al. 2002). Detection of 32P-labelled phosphoproteins is very 
sensitive, but it is only applicable to cells in culture. Since it is much more sensitive than silver 
staining, low yields in subsequent protein identifications have been a limitation of the overall 
procedure (Adam et al. 2002). In any case, one of the most powerful techniques for separation 
of phosphoproteins continues to be gel electrophoresis.
Identification of the proteins and assignment of the phosphorylation sites is generally achieved 
by MS, although phosphopeptides are often of low abundance and difficult to ionise. This 
complicates their analysis in very complex peptide mixtures and it has initially led to the
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development of procedures for extraction and enrichment of phosphopeptides based 
immobilised metal ion affinity chromatography (IMAC).
This separation technique uses solid chromatographic supports with covalently bound 
chelating compounds that complex metal ions and serve as affinity ligands for nucleophilic 
groups in peptides/proteins. Metal ions can be divided into three categories based on their 
reactivity towards nucleophiles, namely hard, intermediate and soft. Hard metal ions like Fe3+, 
Ca2+, and Al3+ show a preference for oxygen, soft metal ions such as Cu+, Hg2+, and Ag+ prefer 
sulfur and intermediate metal ions (Cu2+, Ni2+, Zn2+, Co2+) coordinate nitrogen, oxygen and 
sulfur. High affinity o f Fe(III) for the oxygen atoms in the phosphorylated side chains of 
serine, threonine and tyrosine, as well as carboxylic acids, has been exploited to isolate 
phosphopeptides under acidic conditions (Chaga 2001). Substantial progress has been made 
with this approach and its application as a reliable method for high-throughput analysis of 
phosphorylated peptides by mass spectrometry (Jin et al. 2004; Liu et al. 2005; Nuhse et al. 
2003). One of the main problems encountered was protein solubility under the acidic 
conditions required in the isolation procedures.
Previous studies have underlined difficulties in separating phosphoproteins from proteins with 
surface exposed clusters of carboxylic groups using IMAC. The affinity of phosphate groups 
to immobilised Fe(III) and its use in isolating phosphoproteins was first described by Porath 
and colleagues in 1986 (Andersson et al. 1986; Muszynska et al. 1992). In these early studies, all 
20 naturally occurring amino acids plus the phosphorylated forms of serine, threonine and 
tyrosine were tested for affinity to Fe(III) immobilised on IDA-sepharose under different pH 
conditions. The phosphoamino acids showed tight binding at pH 3.1 and 5.0, but no affinity at 
pH 7.2 and 8.5. L-aspartic acid and L-glutamic acid were the only other amino acids that 
showed some affinity, although very weak. In a later study the same group demonstrated that,
although the interaction between carboxyl groups and chelated Fe(III) ions is very weak 
compared with the phosphate-Fe(III) interactions, when there are clusters of carboxylic and 
phenolic groups, the chelating effect is increased, becoming almost comparable to that for 
phosphate groups.
Current knowledge about cellular biology suggests that a more comprehensive analysis of the 
role of phosphorylation in signalling can be obtained by isolation and analysis of 
phosphoproteins rather than phosphopeptides (Godovac-Zimmermann et al. 2003). The 
majority of genes in the human genome encode for polypeptides that become co- and 
posttranslationally modified. Many different isoforms of a single protein are produced during 
different cellular responses, at different times and in different cell types. In a single cell, a single 
protein can have many different isoforms which are involved in different functional processes. 
The roles and partitioning of these isoforms between different functions are extremely difficult 
to study with phosphopeptide methods since protein fragmentation by tryptic hydrolysis 
irretrievably destroys and superimposes the functionally crucial information on isoform 
distributions (Stannard et al. 2004). Furthermore, efficiencies and patterns of tryptic 
fragmentation of proteins are known to be changed by post-translational modifications such as 
phosphorylation and this complicates determination of accurate, quantitative relationships 
between phosphorylation and cellular function. The interest has therefore been in monitoring 
phosphoproteins separately and in identifying the roles of specific phosphorylation isoforms in 
different cellular states or tissues (Godovac-Zimmermann et al. 2003).
In this chapter the development of an efficient protocol to strongly enrich phosphoproteins 
from complex mixtures based on home made, recyclable Fe(III)-affinity columns and 
inexpensive buffers is described. In the following chapters different applications of this 
optimised method to study EGF signalling are exposed.
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RESULTS 
Development of phosphoprotein enrichment procedure
A scheme of the phosphoprotein extraction protocol is shown in Figure 11. Cells were lysed in 
the presence of protease and phosphatase inhibitors under high detergent concentration in a 3- 
(N-Morpholino) propane-sulfonic acid buffer at pH 6.8. As the solubility of phosphoproteins 
is strongly dependent on pH, a key feature of this procedure was the use of different pHs for 
recovery of total proteins from cell lysates (pH 6.8) and for subsequent capture of 
phosphorylated proteins (pH 3.4). In the course of the method development the ability of 
many different combinations of detergents and detergent concentrations to retain proteins in 
solution at pH 6.8 and at pH 3.4 was tested. Zwittergent detergents (Zwittergent 3-8, 3-10, 3- 
12 and 3-14) were preferred because, unlike other amphoteric surfactants, they retain their 
zwitterionic character over a wide pH range. Their ionic balance prevents irreversible binding 
of the detergent to either anionic or cationic compounds. The most effective combination 
proved to be 4% Zwittergent 3-12 together with 2% Triton X-100.
The following step is a simple DNA removal which exploits the affinity of DNA for silica in 
the presence of high ionic strength. This DNA removal step is strictly necessary since the 
DNA was otherwise absorbed to the affinity matrix via its phosphate backbone. For the 
amounts of cell lysates typically processed, a minimum of 0.2 m g/ml of silica was necessary to 
ensure complete DNA removal in the presence of 2M LiCl (data not shown).
A low pH value (pH 3.4) is expected to maximise the affinity and specificity of the 
immobilised Fe(III) for phosphate groups. The protein lysate was therefore exchanged with a 
N,N’-Bis(2-hydroxyethyl)piperazine buffer containing the same detergents (binding buffer). 
The Fe(III) affinity columns were prepared just prior to use by treating the chelating resin with 
a FeCl3 solution and then equilibrating the affinity column with the low pH binding buffer.
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A variety of different immobilised Fe(III) media have also been tested (see discussion). 
Amongst these media, the use of NTA-agarose was preferred due to its good performance 
with the general conditions used here, its reported superiority over IDA-agarose in the 
isolation of phosphopeptides (Zhou et al. 2000) and potential advantages in the mode of 
binding of phosphate groups to Fe(III) as compared to carboxylate groups (Muszynska et al. 
1986; Muszynska et al. 1992) (see discussion).
Following absorption of the phosphoproteins, the columns were washed to reduce non­
specific binding. A first general wash was performed with binding buffer and subsequently the 
columns were washed with binding buffer containing 25mM Na2S 0 4 and 25mM imidazole 
(pH 3.4) to minimise interaction o f histidine groups with the immobilised Fe(III). For 0.5ml 
columns, loading of increasing amounts of protein lysates (1.5 - 12 mg) gave a constant 
proportion between protein loaded and protein eluted up to 3 mg (data not shown). This 
capacity is consistent with capacities reported for commercially available columns.
The absorbed phosphoproteins were eluted using 50mM sodium phosphate in binding buffer 
(pH 3.4). The elution efficiency was checked by varying the phosphate concentration and the 
pH value of the buffer (data not shown). The elution of the phosphoproteins was primarily 
dependent on increasing phosphate concentration rather that on increasing pH value, as has 
been found by others for phosphopeptides (Hart et al. 2002). Yields of phosphoproteins 
relative to total proteins were typically between 10-13% for NRK49F cells, 17-23% for Hela 
cells, and 20-25% for rat liver tissue.
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Figure 11. Schematic representation of the protocol used for IMAC extraction of 
phosphoproteins
Cells were lysed and the LiCl was added. The lysate was then treated with silica for DNA 
removal. The total proteins were rebuffered in a high detergent buffer at pH 3.4. The proteins 
were then loaded on IMAC column and, after one non-specific and one specific wash, the 
phosphoproteins were eluted with a phosphate buffer at the same pH. Proteins were then 
TCA precipitated and resuspended in IEF buffer for 2D electrophoresis. 2D gel is of 
phosphoproteins extracted from NRK49F cells over pi 5-8.
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The phosphoproteome of NRK49F cells
NRK49F fibroblast cells were radiolabelled with 32P, and representative silver stained 2D gels 
of total, flow through, wash and enriched phosphoproteins and the corresponding 
radiographic images are shown in Figure 12.
Many abundant cellular proteins such as vimentin, annexins, etc., exist in multiple isoforms. 
Figure 12 shows prominent “ladders” of proteins showing the same molecular weight, but a 
series of different pi values. The present extraction protocol has enriched many such ladders, 
including some which were not observable in the total protein gel. Figure 13 compares the 
enlargements of the boxed region c and d from the gel in Figure 12 in each fraction. Evidence 
for highly differential selection of proteins is apparent in the expansions shown for regions a 
and b of the 2D gels (Figure 13, ab). Substantial changes in protein intensities between the 
total protein and phosphoprotein fraction were apparent - some proteins were strongly or 
completely suppressed (spots pointed with a minus), while others were only observed in the 
extracted material (spots pointed with a plus) (Figure 13, regions a, b). This can be particularly 
helpful in identifying ladders which are obscured in the total protein gels. Conversely, as 
expected, a substantial number of non radioactive proteins were observed in the flow-through 
and wash from the IMAC column, but not in the extracted material (Figure 13, region d). 
Investigations with 32P labelling indicated that 32P labelled proteins are efficiendy captured by 
this procedure and that selectively enriched protein spots contain phosphate (Figure 13, region 
c and d).
Although complete removal of other proteins was not obtained for all proteins without 32P 
labelling (Figure 12), phosphoproteins could be reliably identified on the silver-stained gels by 
their selective enrichment in the extracted material.
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Figure 12. Silver stained 2D gels for total proteins, flow through, wash and 
phosphoproteins extracted from 32P radio labelled NRK49F cells
Equal amount o f total proteins, flow through, wash and phosphoprotein fractions were 
separated on 2D gels, using 13m pi 4-7 strips on 12% acrylamide gels, and the gels silver 
stained. For each gel the corresponding 32P image is reported.
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Figure 13. Phosphoprotein enrichments specificity
Enlargements refer to gels in Figure 12. In a and b, - indicates spots lost in the 
chromatography and + spots o f phosphoprotein enriched.
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Specificity of phosphoprotein capture
108 protein spots enriched in the phosphoproteins gel were randomly chosen from a 13 cm, pi 
4-7 2D gel and the proteins subjected to MS mass fingerprinting (Figure 14) (data obtained in 
collaboration with Jelena Predic-Atkinson). The identified proteins are listed in Table 1. With 
the recent rapid progress in characterisation of the rat genome, almost all proteins could be 
assigned to rat proteins and most to specific genes.
Amongst the 108 spots which were analysed, 94 were identified (most of the rest corresponded 
to superposition of different proteins in the low resolution gels used here). They matched 60 
different proteins. All of these proteins are predicted to have phosphorylation sites, and 
previous experimental demonstrations of phosphorylation are available for about 80% of them 
(Table 1, the PubMed ID numbers of relevant publications are reported on the last column). 
For many of the 51 proteins that have previously been reported to be phosphorylated the sites 
of phosphorylation are not known in detail and only some have previously been reported to 
have multiple phosphorylation isoforms. Between 2 and 5 different isoforms were identified 
for 16 of these proteins on the 2D gels.
While this is not yet exhaustive (examples of detailed analysis of the phosphorylation 
sites/isoforms for some individual proteins is reported in the following chapters), these results 
strongly suggest that phosphorylated proteins are highly predominant in the extracted 
phosphoprotein fraction.
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Figure 14. Phosphoprotein fraction separated on 2D electrophoresis gel
The phosphoprotein fraction was separated on 2D PA GE using a 13cm pi 4-7 strip, on a 
13% acrylamide gel. The spots labelled have been cut and identified using MALDI-TOF MS.
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Proteins that act as chaperones/mediators o f protein folding GI Accession Gene PMID Reference
Mixture: similar to dnaK-type molecular chaperone hsp72-psl 56385 CAA49670.1 none 10843916
Similar to chaperonin containing TCP-1 beta subunit 34864883 XP 216891 LOC299809
dnaK-type molecular chaperone hsp72-psl 347019 S31716 none 10843914
dnaK-type molecular chaperone hsp72-psl 347019 S31716 none 10843914
dnaK-type molecular chaperone hsp72-psl 347019 S31716 none 10843914
dnaK-type molecular chaperone hsp72-psl 347019 S31716 none 10843914
Endoplasmic oxidoreductase 1 19744821 AAL96669.1 none
FK506 binding protein 10 34873708 XP_340902.1 FkbplO 7493967
FK506 binding protein 10 34873708 XP_340902.1 FkbplO 7493968
FK506 binding protein 10 34873708 XP_340902.1 FkbplO 7493969
FK506 binding protein 10 34873708 XP 340902 1 FKBP10 7493969
Glucose regulated protein, 58 kDa 8393322 NP_059015.1 Grp58 10870974
Glucose regulated protein, 58 kDa 8393322 NP_059015.1 Grp58 10870975
Glucose regulated protein, 58 kDa 8393322 NP_059015.1 Grp58 10870976
26.2 Heat shock 70kD protein 5 25742763 NP_037215.1 Hspa5 7517674; 3141786
25 Heat shock 70kD protein 5 25742763 NP_037215.1 Hspa5 7517674; 3141786
38 Heat shock protein 8 38181549 AAH61547.1 HSPA8 12080070; 10600240
155 Heat shock protein 60 (liver) 11560024 NP_071565.1 Hsp60 9724719; 15252132
156 Heat shock protein 60 (liver) 11560024 NP_071565.1 Hsp60 9724719; 15252132
22 Procollagen lysine, 2-oxoglutarate 5-dioxygenase 2 28400783 CAD23630.1 Plod2
23 Procollagen lysine, 2-oxoglutarate 5-dioxygenase 2 28400783 CAD23630.1 Plod2
24 Procollagen lysine, 2-oxoglutarate 5-dioxygenase 2 28400783 CAD23630.1 Plod2
26.1 Protein disulfide isomerase related protein (calcium- binding protein, intestinal-related) 16758712 NP_446301.1 Erp70 8631326; 10079081
63 Similar to chaperonin containing TCP-1 beta subunit 34864883 XP_216891 LOC299809
70 Stress-induced-phosphoprotein 1 (Hsp70/Hsp90- organising protein) 20302113 NP_620266.1 Sti.pl
By similarity 14754904; 
11154072
157 T-complex protein 1, theta subunit (TCP-1-theta) (CCT-theta) 34867525 XP_213673.2 Cct8 by similarity to HSP60
Spot Protein that act as metabolic enzymes Gi Accession Gene PMID Reference
15 Alpha glucosidase 2 34861580 XP_215144.2 Ganab 8094613; 246728931; 59730
16 Alpha glucosidase 2 34861580 XP_215144.2 Ganab 8094613; 246728931; 59730
ooK>
66 Enolase-1, alpha 6978809 NP_036686.1 Enol 8578591; 1956339; 6330085
67 Enolase-1, alpha 6978809 NP_036686.1 Enol 8578591; 1956339; 6330086
69 Enolase-1, alpha 6978809 NP_036686.1 Enol 8578591;1956339; 6330087
103 Enolase-1, alpha 6978809 NP_036686.1 Enol 8578591;1956339 6330085
83 Enolase-2, gamma 26023949 NP_647541.1 Eno2 8578591;1956339; 6330087
62 Glucose-6-phosphate dehydrogenase 8393381 NP_058702.1 G6pdx 3122660
61 Glucose-6-phosphate dehydrogenase 8393381 NP_058702.1 G6pdx 3122660
173 Glycerol-3-phosphate dehydrogenase 2 6980978 NP_036868.1 Gpd2 3030270
52 P4ha2 protein 34870735 XP_340799.1 P4ha2
53 P4ha2 protein 34870735 XP_340799.1 P4ha2
59 P4ha2 protein 34870735 XP_340799.1 P4ha2
46 Prolyl 4-hydroxylase alpha subunit 51036657 NP_742059.2 P4hal
49 Prolyl 4-hydroxylase alpha subunit 51036657 NP_742059.2 P4hal
48 Prolyl 4-hydroxylase alpha subunit 51036657 NP_742059.2 P4hal
95 Transaldolase 12002054 AAG43169.1 none 11390181
00U)
Spot
142
84
87
101
179
86
89
146
75.2
11
12
13
51
43.2
Proteins that function in cell motility or structure Gi Accession Gene PMID Reference
Tubulin, beta 5 38014544 AAH60540.1 Tubb5 12631274;3920212
Cytoplasmic beta-actin 13592133 NP 112406.1 Actb 9067634; 7835422; 12043959
Beta-actin. 55575 CAA24528.1 none 9067634; 7835422; 12043959
Gamma-actin 178045 AAA51580.1 ACTG1 9067634; 7835422; 12043959
Myosin regulatory light chain 2-A, smooth muscle isoform 
(Myosin RLC-A)____________________________________ 127170 P I3832 R1c-£ 6313687; 7715706
put. Beta-actin (aa 27-375). 71620 ATRTC none 9067634; 12043959; 7835422
put. Beta-actin (aa 27-375) 71620 ATRTC none 9067634; 12043959; 7835422
Similar to Cappal protein 34859736 XP 227551.2 LOC310758 4044559
Similar to tubulin alpha-1 chain — Chinese hamster 27664758 XP 217040.1 LOC300217 by similarity 3036806
Similar to Vinculin (Metavinculin) 27673645 XP 223781.1 LOC305679 8797806; 6225775; 6417142
Similar to Vinculin (Metavinculin) 34868946 XP 223781.2 LOC305679 8797806; 6225775; 6417142
Similar to Vinculin (Metavinculin) 34868946 XP 223781.2 LOC305679 8797806; 6225775; 6417142
Similar to Vinculin (Metavinculin) 27673645 XP 223781.1 LOC305679 8797806; 6225775; 6417142
T-plastin 48734834 AAH72523.1 none 9881671
41 T-plastin 2493465 Q63598 PLS3 9881671
76.2 Tubulin alpha 223556 0812252A none 3036806
77 Vimentin 14389299 NP_112402.1 Vim 1850997; 8373419; 7983050; 8718673; 7832980; 2500966
78 Vimentin 14389299 NP_112402.1 Vim 1850997; 8373419; 7983050; 8718673; 7832980; 2500966
131 Vimentin 38197662 AAH61847.1 none 1850997; 8373419; 7983050; 8718673; 7832980; 2500966
75.1 Vimentin 14389299 NP_112402.1 Vim 1850997; 8373419; 7983050; 8718673; 7832980; 2500966
76.1 Vimentin 14389299 NP_112402.1 Vim 1850997; 8373419; 7983050; 8718673; 7832980; 2500966
Spot Proteins involved in protein degradation Gi Accession Gene PMID Reference
133 Cathepsin B 203648 AAA40993.1 None 10876156
138 Huntington interacting protein 2 27695307 XP_214043.1 HIP2 15117950
17 Protease, serine, 15 19173766 NP_596895.1 Prssl5
134 Proteasome (prosome, macropain) subunit, alpha type 3 8394066 NP_058976.1 Psma3 14583091
150 Serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 6 38014574 AAH60594.1 Serpinb6
154
Similar to serine (or cysteine) proteinase inhibitor, clade B, 
member lb; serine (or cysteine) proteinase inhibitor, clade B 
(ovalbumin), member lb
34875374 XP_214459.2 LOC291091
Spot Proteins involved in protein synthesis Gi Accession Gene PMID Reference
97 Acidic ribosomal phosphoprotein PO 57708 CAA33199.1 none 10706406; 8620032
98 Acidic ribosomal protein P0 11693176 NP_071797.1 Arbp 10706406; 8620032
44 Heterogeneous nuclear ribonucleoprotein K 38197650 AAH61867.1 Hnrpk 10329716; 10506147; 11231586; 12052863
80 Heterogeneous nuclear ribonucleoprotein K 38197650 AAH61867.1 Hnrpk 10329716; 10506147; 11231586; 12052863
79 Hnrpk protein 38197650 AAH61867.1 Hnrpk 10329716;10506147; 11231586; 12052863
107 Translation initiation factor 1240053 CAA58316.1 none 7590282; 7665584; 778232; 8505316; 3112145
Spot Proteins that act as signalling molecules Gi Accession Gene PMID Reference
99 Annexin A4 55742832 NP_077069.3 Anxa4 2956093
115 ADP-ribosylation factor 3 18266716 NP_543180.1 Arf3
96 Annexin 1 6978501 NP_037036.1 Anxal 1832554
169 Annexin A4 55742832 NP_077069.3 Anxa4 2956093
40 Annexin A6 13994159 NP 077070.1 Anxa6 1420329
42 Annexin A6 13994159 NP_077070.1 Anxa6 1420329
43.3 Annexin A6 13994159 NP_077070.1 Anxa6 1420329
160 Annexin III — rat 71766 LURT3 none 1692066; 2550491
82 cAMP-dependent protein kinase type I-alpha regulatory subunit 6981396 P09456 Prkarla 10422841
81 Dynactin 2 34865747 XP_216906 Dctn2 12119357; 9126359
147 G-protein beta 2 subunit 41351301 AAH65579.1 none 8809067
132 Lipocortin V 2981437 AAC06290.1 none 10329451
108 Ras-related protein 44890248 AAH66662.1 Rabl 1902553
139 Similar to Ras-related protein Rab-IB 27709432 XP_229035.1 LOC317550 19025532
176 TNF receptor-associated protein 1 55741837 XP_213218 Trapl 8051124
Spot Other proteins Gi Accession Gene PMID Reference
114 Dismutase 818029 CAA29121.1 none
141 Reticulocalbin 1 34856626 XP_342482.1 Rcnl 11886868
174 TUC-4b 21666559 AAM73758.1 none
Table 1. Proteins contained in the phosphoprotein fraction
Each protein is accompanied by its spot number, referred to Figure 14. The Accession number identifies the protein sequence and is often 
accompanied by the version number, which tracks changes to the sequence itself (Accession.Version); the GI number (genlnfo identifier) is the 
unique integer which identifies a particular sequence and it changes every time the sequence is changed in the database. The name of the 
correspondent gene is reported when known. The PubMed ID (PMID) references of the papers containing evidence for their phosphorylations 
are listed.
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Comparison of IMAC-extracted proteins with the rat genome
Adsorption of acidic peptides to the affinity matrix has been a limitation in the extraction of 
phosphopeptides with IMAC (see discussion). It is difficult to prove that none of the extracted 
proteins result from affinity for the IMAC columns of proteins with a high content of acidic 
residues. To provide further evidence that the IMAC extraction protocol does not 
systematically extract such proteins, properties of the extracted proteins with properties of the 
set of proteins with pi 4-7 in the rat genome were compared (analysis done in collaboration 
with Dr Larry Brown). In particular, proteins in the rat genome that contain potential acidic 
binding regions for the IMAC affinity matrix were identified. For this purpose, an acidic 
pattern was defined as a tetra peptide in which at least 3 of 4 residues are Asp or Glu (Figure 
15). An isolated acidic motif was defined as a tetra peptide or penta peptide containing 3 acidic 
residues in acidic patterns, and which could not be extended under either strict or relaxed 
conditions (see below). There are three types of sequences that qualify as isolated acidic motifs. 
A peptide sequence containing sequential, overlapping tetra peptide acidic patterns and which 
contains at least 4 acidic residues has been defined as an acidic cluster (Figure 15). The acidic 
clusters are classified as either strict clusters (every adjacent tetra peptide along the sequence 
contains an acidic pattern) or as relaxed clusters (tetra peptides containing acidic patterns 
overlap, but are not necessarily adjacent along the sequence). The simplest strict and relaxed 
acidic clusters are shown in Figure 15. In an individual protein, there may be many isolated 
acidic motifs, strict clusters and relaxed clusters, as indicated in Figure 15 for the protein 
complexin 2.
The draft of the rat genome (Jan. 2005) contains a total of 8734 proteins with pi 4-7. To 
provide a protein set for comparison with the experimentally identified proteins, proteins with 
more than 1300 residues were excluded since the 2D gels used in the present experiments do
not monitor proteins of very high molecular weight. This left 7971 rat proteins for which all 
acidic motifs and clusters were identified. A summary of the distribution of motifs and clusters 
amongst these rat proteins is given in Table 2. Only 15.9% of the rat genome proteins contain 
neither an isolated motif nor a cluster (Table 2). A further 20.1% contain only a single instance 
of one or the other of these elements. Although there is an average of about 2 isolated acidic 
motifs and 1 acidic cluster per rat protein, these are very unevenly distributed in individual 
proteins with a maximum of 26 isolated acidic motifs (in Gi: 34869308, similar to DnaJ 
(Hsp40) homologue, subfamily B, member 11) and a maximum of 18 acidic clusters (in Gi: 
34858373, similar to ribosome biogenesis protein BMS1 homologue - a handful of proteins 
with > 1300 residues have still more clusters). Similarly, the size of the acidic clusters varies 
enormously, with a maximum strict cluster size of 51 residues (in Gi: 19173798, splicing factor 
YT521-B). Thus, in general isolated acidic motifs and acidic clusters are common in proteins 
with pi 4-7, with 84.1% of the 7971 proteins containing one or more of these elements.
About half (49.7%) of the rat proteins contain one or more acidic clusters. However, on 
average those proteins containing acidic clusters have only a slighdy greater total content of 
acidic amino acid residues (Figure 16, A). Acidic clusters are found in proteins with as litde as 
4.4% total acidic residues and amongst the 166 rat proteins with greater than 21% acidic 
residues, less than half have acidic clusters. Similarly, proteins containing acidic clusters have 
on average only slighdy lower pi values than the full set of proteins (Figure 16, B) and for both 
the total proteins and the proteins with acidic clusters, more than half the proteins have pi > 
5.5.
Given the ubiquity and diversity of proteins with acidic motifs and clusters, it is no surprise 
that the proteins experimentally enriched by IMAC contain many such motifs and clusters. 
Three types of comparisons of the experimentally identified proteins with the rat genome pi 4-
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7 protein set were made. First, the distributions of cluster sizes in the two sets of proteins were 
compared. As shown in Figure 17, A, there is no indication that the IMAC protocol favours 
extraction of proteins with large acidic clusters. Second, in principle the 3 acidic residues 
contained in isolated acidic motifs might also constitute sites for binding to the IMAC columns 
and therefore the distribution of isolated acidic motifs for the two sets of proteins was 
compared. There is no indication that the IMAC protocol favours extraction of proteins with 
large numbers of isolated acidic motifs (Figure 17, B). Finally, the distribution of the total 
number of residues in acidic clusters per protein was compared between the two protein sets. 
Again there is no indication that high numbers of residues in acidic clusters favours extraction 
of proteins (Figure 17, C). Indeed, there is a weak indication that large numbers of residues in 
acidic clusters might be negatively correlated with IMAC extraction. This might reflect 
negative correlation of phosphorylation with high content of acidic clusters. However, since 
this is only an average property over all proteins and confirmation would require much more 
work, this has not been further investigated. In summary, these comparisons provide good 
evidence that the IMAC extraction protocol is not systematically enhancing extraction of 
proteins with high contents of acidic motifs or clusters and strongly suggest that in proteins 
where both acidic clusters and phosphorylation exist (Table 2), affinity for the phosphate 
group is the dominant process under the conditions of this extraction protocol.
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Figure 15. Schematic description of the definitions used to classify acidic regions in 
protein sequences
(A) The primary condition is an acidic pattern in which 3 of 4 residues along the polypeptide 
sequence are Asp or Glu (patterns in italics under isolated motifs). Strict sequential overlap 
of the tetra peptide patterns can give rise to strict acidic clusters (every successive tetra 
peptide along the sequence contains an acidic pattern). In relaxed acidic clusters, the 
tetrapeptide acidic patterns overlap, but are not necessarily sequential. Relaxed clusters 
contain tetra peptides that are not acidic patterns and may include sequences that are strict 
acidic clusters (see the underlined residues). The three types of isolated motifs (bold) are 
sequences containing 3 acidic residues that can not be extended under either strict or relaxed 
conditions. (B) Acidic motifs and clusters in the sequence of the protein complexin 2. 
Isolated acidic motifs are underlined. Strict acidic clusters are shown as bold capitals and 
relaxed acidic clusters as underlined.
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Property genomeset experimental set
total proteins 7971 62
0 motifs, 0 clusters 1266 5
1 motif, 0 clusters 1180 5
0 motifs, 1 cluster 426 0
> 1 motif, 0 clusters 2747 31
0 motifs, > 1 cluster 652 3
total clusters 8342 42
strict clusters 6799 33
relaxed clusters 1543 9
isolated motifs 16394 169
Table 2. Distribution of proteins with acidic motifs and clusters
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Figure 16. Distribution of proteins of the rat genome
(A) Distribution of proteins over their content of acidic amino acid residues. (B) Distribution 
of proteins over their pi value.
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Figure 17. Comparison of the properties of isolated acidic motifs and acidic clusters for the experimentally identified proteins 
(black circles) with proteins in the rat genome (empty circles)
(A) Proportion o f clusters (strict plus relaxed) containing the indicted number of amino acid residues. (B) Proportion o f proteins 
containing the indicated number of amino acid residues in isolated acidic motifs. (C) Proportion of proteins containing the indicted 
number of amino acid residues in acidic clusters (strict plus relaxed). The number of clusters/proteins in the rat genome which fall outside 
the plotted regions is indicated.
DISCUSSION
Effective protocols for isolation of phosphoproteins must satisfy several stringent conditions 
and an optimal choice of absorbent and elution conditions was probably reached in the 
described procedure. First, since many lower abundance proteins are regulated by 
phosphorylation, high rejection of non-selective absorption o f high abundance proteins is 
crucial. Second, if these procedures are to be used in analyses o f cellular function under 
different conditions, extraction of the phosphoproteins must be of high yield and 
reproducible. The reported experiments provide good evidence for effective extraction of 
phosphoproteins and utility in signalling study will be further confirmed in the next chapters, 
in conjunction with kinetic studies of the phosphoproteome response of kidney fibroblasts to 
stimulation with EGF.
The nature of the chelator, the stationary phase and the buffer systems are all potentially 
important in obtaining selectivity. For this reason, a discussion of some of the background 
theory and previous work in this field is probably essential to understand some important 
considerations in the development of this method. Several support matrices were tested, 
including more recent innovations such as Toyopearl® AF-Chelate-650M (Tosoh Bioscience) 
(IDA coupled to synthetic polymer-based particles to give high mechanical strength and 
chemical resistance) and Fractogel® EMD Chelate (Merck) (IDA coupled to a tentacle gel to 
give higher functional group density, better steric accessibility and higher protein capacity) 
(Gaberc-Porekar et al. 2001). No major influences of the stationary phase was noticed, which 
has also been concluded by other groups (Chaga 2001). Amongst polysaccharide-based 
matrices, IDA-agarose (Perbio Science), NTA-agarose (Qiagen) and TED-agarose 
(ActiveMotif) were tested. The chelating ligands tris-carboxymethyl ethylene diamine (TED), 
nitrilotriacetic acid (NTA) and iminodiacetic acid (IDA) offer a maximum of tri- (IDA), tetra-
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(NTA) and penta-dentate (TED) coordination sites to the metal ion. In general, tetra-dentate 
chelating ligands have higher affinities for metal ions than tri-dentate chelators, but they have 
lower binding capacity due to the loss of one coordination site on the metal ion. This is even 
more pronounced in a penta-dentate chelating ligand, where only one coordination site on the 
metal ion is left for protein binding. No significant phosphoprotein enrichment was found 
with TED as the chelating ligand. This would be consistent with a proposed model of the 
binding of phosphate groups to Fe(III) in which two unoccupied Fe(III) coordination sites 
form a four-membered chelating ring that is necessary for high affinity binding (Muszynska et 
al. 1986; Muszynska et al. 1992). This can not be the case for a penta-dentate chelating ligand 
like TED. For extraction of phosphoproteins, both the IDA and NTA groups provided strong 
enrichment and only small differences in performance between the two were observed.
In contrast, the interaction of carboxyl groups with immobilised Fe(III) is promoted by the 
presence of several carboxyl groups, which very likely are involved in the formation of a multi­
point attachment (Chaga 2001; Muszynska et al. 1986; Muszynska et al. 1992; Porath 1990). 
The different proposed modes of interaction of phosphate and carboxyl groups with 
immobilised Fe(III) suggest NTA could have better discrimination against acidic proteins than 
IDA. In particular, provision of additional coordination sites beyond what is necessary for 
optimal binding of phosphate groups can only favour proteins with acidic clusters at the 
expense of phosphoproteins. An additional potential advantage of NTA is that Fe(III) chelate 
adsorbents can function as pseudo-cation- and pseudo-anion-exchangers under specific low- 
ionic strength buffer conditions. The interaction between proteins and immobilised Fe(III) can 
involve both coordination and electrostatic contributions under some conditions. Fe(III) ions 
bound to chelating ligands form hexahedral coordination sphere complexes in water and, in 
acidic solution, the Fe(III) complexes have a net charge of 0 (NTA and TED) or +1 (IDA).
This means that Fe(III) bound to IDA can assume a pseudo-anion-exchange character with
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proteins. Shifting pH in the alkaline direction converts the Fe(III) affinity matrix into a 
pseudo-cation-exchanger, irrespective of the number of carboxylic groups present in the ligand 
(Porath 1990; Zachariou et al. 2000). Fe(III) bound to NTA-agarose is not capable of acting as 
an ion-exchanger under acidic conditions and acidic conditions were therefore chosen in 
combination with the use of NTA over IDA for investigation of optimal buffer conditions for 
capture and elution of phosphoproteins.
For purification of phosphopeptides using the IDA-Fe(III) system, it has been demonstrated 
that lowering the pH value leads to co-elution of fewer acidic peptides with the 
phosphorylated peptides (Posewitz et al. 1999). Below pH 2.0 the affinity for phosphopeptides 
is decreased, probably due to protonation of the IDA resin. The critical pH above which an 
increasing number of non-phosphorylated acidic peptides were retained by the Fe(III) IMAC 
column seemed to be 3.5. This is one reason why a pH value of 3.4 was chosen for binding. 
Another reason has to do with the distribution o f the isolelectric points of proteins. Proteins 
are generally poorly soluble near their pi (Arakawa et al. 1985) and proteins from eukaryotes 
show a bimodular distribution in pi values with maxima around pH 5.5 and 9.5 (Weiller et al. 
2004). Less than 1% of proteins have a pi value below pH 4. A binding pH of 3.4 should 
therefore help to retain as many proteins as possible in a soluble state. Finally, a low binding 
pH should strongly minimise the binding of proteins rich in surface exposed histidine residues. 
Under the chosen conditions surface histidines should not be able to undergo any significant n 
— d orbital electron donation via the imidazole moiety as both nitrogens should be protonated. 
Imidazole itself has a low affinity for hard Lewis metal ions and was therefore incorporated 
into the washing buffer to quench any residual affinity that histidine residues within individual 
proteins might have for the immobilised Fe(III).
96
In conclusion, a new method for enriching phosphoprotein has been optimised, and problems 
previously reported of protein solubility at low pHs and acidic proteins interference were 
overcome. Information about the specificity and the recovery of phosphoproteins is also given 
by comparing the silver stained gels with their autoradiography. Although this procedure does 
not allow full isolation, but rather enrichment of phosphorylated protein, it is still of high 
importance in the study of different phospho-isoforms participating in the signalling networks, 
as I show in the next chapters.
The results presented in this chapter are currendy in press (Guerrera et al. 2005b).
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CHAPTER 4
FISHING FOR KINASE SUBSTRATES IN EGF 
SIGNALLING PATHWAYS 
INTRODUCTION
In eukaryotes, phosphorylation on serine/threonine is much more frequent than 
phosphorylation on tyrosine, as mentioned in chapter 1. Phosphorylation on tyrosine has been 
studied intensively, mainly due to the longstanding availability of specific antibodies against 
phosphorylated tyrosine. However, efficient antibodies recognising phosphorylated serine and 
threonine have only become available recently. These include antibodies against phospho- 
serine/threonine in specific consensus sequences recognised in vivo by specific kinases. The 
optimal amino acid sequences phosphorylated by protein serine/threonine kinases can be 
experimentally analysed by screening peptide libraries for modified peptides after treatment 
with a specific kinase. The protein kinase substrate motif can be defined by enrichment and 
sequencing of phosphorylated peptides. There are many records of using anti phospho- 
serine/threonine antibodies in chasing and identifying substrates of different kinases 
(Gronborg et al. 2002; Kohn et al. 2003; Marinissen et al. 2001; Matter et al. 2002). Though 
there are some inherent problems with the use of antibodies, such as specificity and 
reproducibility of immuno-detection in western blots, these newly introduced antibodies were 
used in the present study.
Antibodies against phosphorylated substrates of MAPK, PKC and PKA were used for a partial 
screen of the fibroblast proteome. In detail, the antibodies mainly used and adopted for the 
following experiments were: (i) against M APK/CDK substrates, which recognise
phosphorylated threonine when followed by Pro (TP); (ii) against PKC substrates, which
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recognise phosphorylated serine surrounded by Arg or Lys in the -2 and +2 position, and a 
hydrophobic residue at + 1 position ([RK]XS[Hyd][RK]); (iii) against PKA substrates, which 
recognise phosphorylated Ser/Thr with Arg in -3 position (RXXS/ RXXT). For simplicity 
they are referred to (i) as TP, (ii) as RXS and (iii) as RXXS/T.
All these kinases are known to be involved in the EGF signal cascade (see chapter 1). In an 
attempt to investigate some of the downstream players in different activated pathways, the 
immuno response of enriched phosphoproteomes from NRK49F cells stimulated with EGF 
was compared with the corresponding phosphoproteome from unstimulated cells. This 
investigation was complemented by densitometric analysis for an indication of the 
phosphorylation kinetics of the proteins identified.
Three main factors suggest that this analysis must be considered as a proof-of-concept study. 
First, intrinsic limitations of the techniques and materials used in this approach exclude the 
possibility of obtaining a wide and exhaustive screening of kinase substrates. Second, the 
antibodies used cover only a subset of the potential substrates for the kinases selected. Third, a 
scan of the SwissProt database for the consensus sequence [RK]XS[Hyd] [RK] using Pattinprot 
software revealed that out of the 193 proteins containing this consensus sequence, only 59% 
would fall in the pi and MW range used in this work. These factors limit the outcome of this 
screening to be less than exhaustive. Some practical limitations that have been found during 
this analysis are discussed in details at the end of this chapter.
The EGF-induced phosphorylation changes of the subset of proteins identified as potential 
MAPK, PKC and PKA substrates were analysed in a semi-quantitative way. These proteins 
were identified using MALDI-TOF MS. Along with the identification, MALDI-TOF spectra 
often provide information about the coverage, which is the percentage of primary structure 
matched by the tryptic peptides experimentally obtained. The distribution of these peptides
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along the sequence can also be indicative of possible splice variants. Finally, leads were 
obtained for potentially phosphorylated peptides, which correspond to peaks associated with a 
tryptic peptide of the protein plus 80Da or multiples of 80Da (Guerrera et al. 2005a). 
However, observations on phosphorylation sites were not exhaustive because 
phosphopeptides are more reluctant to ionise in MALDI-TOF MS. An additional limitation of 
the overall analysis is that only proteins from the control could be analysed. For these reasons 
the focus in this chapter is on substrate identification and not on potential phosphorylation 
sites.
The following chapter describes a more sophisticated mass spectrometric analysis of some 
proteins identified here. Application of this analysis yielded further details of peptide 
phosphorylation site and quantitative information on the kinetics that characterise these 
regulatory events.
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RESULTS 
Effects of EGF stimulation in NRK49F cells
Phosphoproteins were isolated from normal rat kidney fibroblast cells (NRK49F) as described 
in chapter 3 after stimulation with EGF for 0, 2 and 5 minutes.
Selected signalling proteins specifically phosphorylated in response to EGF were followed in 
order to verify the efficiency of the stimulation. Equal amounts of phosphoproteins and total 
proteins were separated by 1D-SDS PAGE and then electroblotted onto a membrane. 
Proteins blotted were probed with antibodies specific for p44 and p42 mitogen-activated 
protein kinase (MAPK) proteins and with antibodies specific for a phosphorylated form of the 
same proteins. P44/p42 are activated through a double phosphorylation, and the activation by 
phosphorylation, marker of transmission of the signal, was found to be maximal at 2 minutes 
(data not shown). Phosphorylated p44/p42 was fully recovered during the purification, while 
total p44/p42 was present in the same amount in both the whole cell lysate and in the 
phosphoprotein fraction (Figure 18, A). Similar results were obtained with phospho Map38 
(data not shown). Furthermore, the phosphorylated p44/p42 signal after stimulation is much 
stronger in the phosphoprotein fraction than in the total protein, whilst the signal in the 
unstimulated cell was not improved, confirming the efficiency of the phosphoprotein 
enrichment. Total MAPK (modified and unmodified) was followed as well to demonstrate that 
the same amount of protein has been loaded. Interestingly no endogenous MAPK is found in 
the flow through, suggesting that the protein is lost in the washing steps performed before the 
elution.
Considerably stronger signals in the phosphoprotein fraction compared to the total protein 
fraction were observed on blots probed with anti-phospho-tyrosine antibodies and anti- 
phospho-(Ser/Thr) PKA substrate (Figure 18, B-C).
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When total protein and phosphoprotein fractions were stained with comassie, different 
patterns were obtained on 1D gel. However, pattern changes of the phosphoprotein fraction at 
different times could hardly be observed, both on ID  and 2D PAGE separation (Figure 19). 
For this reason, a different experimental route was employed, namely a combination of 
western blotting and phospho motif specific antibodies. The yield of the phosphoprotein 
enrichment was 12% and ca. 800 spots were detected by the software in each 2D gel shown 
here.
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Figure 18. Analysis of enrichment of phosphoproteins after IMAC columns
Quiescent NRK49F cells were treated with or without EGF for the indicated time periods 
and protein extracts subjected to enrichments using IMAC columns. Same amounts of total 
cellular extracts (T), IMAC column flow through (-P) and IMAC column eluate (+P) were 
separated on SDS-PAGE and subjected to immunoblot analysis. (A) Blot was probed with 
and-phospho-p44/42 MAPK (lower panel) and reprobed with anti-p44/42 MAPK (upper 
panel) antibodies. (B) Blot was probed with anti-phospho tyrosine antibody. (C)Blot was 
probed with anti-phospho threonine/serine antibody.
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Figure 19. Phosphoprotein fractions separated on 2D gel
The total proteins (T) and the phosphoproteins (+P) at described time points stimulation 
with EGF were separated on ID  SDS-PAGE using 13% acrylamide gels, and stained with 
blue comassie. Phosphoprotein fractions from the same experiment were separated on 2D- 
PAGE using 7cm pi 5-8 strips on 11.5% acrylamide gels, and stained with silver.
Effects of EGF stimulation on specific substrates of MAPK, PKC 
and PKA
In order to identify some of the proteins involved in proteome changes associated with the 
stimulation, phosphoproteins were resolved on 2D-SDS PAGE and western blotted using 
antibodies against phosphorylated protein kinase C (PKC), protein kinase A (PKA) and 
mitogen activating protein kinase (MAPK) substrates.
Three different sets of immunoblots of the NRK49F phosphoproteome at 0, 2 and 5 minutes 
were obtained. As the same amount of phosphoproteins was loaded at each time point,
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different intensities suggest different grade of phosphorylation and/or number of copies of 
phosphorylated proteins.
Figure 20 represents the silver stained gel used for identification and the labelled spots that 
were cut and processed. Each panel presents the western blot (WB) performed with the 
indicated antibody of the corresponding area on the preparative silver stained gel (dotted 
areas). Alignments between blots and the preparative silver stained gel were facilitated by 
staining the total proteins on the membranes with colloidal gold after immunodetection. In 
this way the protein patterns on the membranes were matched with the ones obtained by silver 
staining (using Photoshop software). As a result, the proteins of interest visualised by western 
blotting could be properly allocated on the preparative gel.
The gel containing the phosphoproteins obtained from the control cells (0 minute stimulation) 
was used for the analysis and for the identification of the proteins targeted by the antibodies. 
Significant protein spots were excised from the gel, washed and digested in situ with trypsin. 
The resulting peptides were analysed using MALDI-TOF MS and the proteins identified are 
listed in Table 3. Despite the fact that a broad range of high and low abundance proteins was 
observed when the membranes were stained with colloidal gold (data not shown), the protein 
pattern in western blots matched mostly high abundance proteins. This suggests that high 
phosphorylation level on these spots might obscure the signal of very low abundant proteins. 
This issue was not followed further because the detection of low abundance substrates by WB 
probably could have not been complemented with satisfactory identification.
In summary 21 spots out of 33 analysed could be identified; these spots contained a total of 9
different proteins. The discrepancy is due to the presence of different isoforms of the same
protein (the same protein found in more than one spot). As commented before, the variation
in isoelectric point is usually associated with different degrees of post translational
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modifications (PTMs), which may or may not cause a significant shift in molecular weight. In 
this experiment, as all isoforms were detected with antibodies against phosphorylation, at least 
one of the PTM in question must be phosphorylation. In the opposite case, some spots 
contained more that one protein, therefore mixtures of more than 2 proteins have not been 
considered because no reliable connection with the phosphorylation kinetics could be made. 
90% of the identifications are characterised by a minimum of 15% coverage. In few cases the 
coverage was lower, but the protein identifications were still considered valid by the software 
performing the search. This is probably due to the low number of peptides submitted to the 
search and to the high accuracy of the match.
Some proteins could not be identified due to their very low abundance in the cell, (therefore 
low intensity on the gel). Amongst these, spots 35, 36 and 38 showed an interesting behaviour 
as MAPK/CDK substrates (Figure 20). Spot 16 and 17, which are substrates of MAPK/CDK 
and PKC could not be identified either, as they were not even detectable on the silver stained 
gel. Interestingly, there are two spots in the in PKA substrate blots in the area were 16 and 17 
are found in the other western blots, but they are strongly shifted toward the alkaline region 
and have lower molecular weight. These could possibly be the same proteins, but no 
speculation could be made as they have not been identified. For this reason these spots are not 
labelled as 16 and 17.
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Figure 20. M apping of kinase substrates on 2D gel
The central panel represents the silver stained gel of the phosphoprotein fraction of 
unstimulated cells. This gel was used for the cutting and the analysis o f the spots o f interest. 
The phosphoprotein fractions obtained from cells EG F stimulated for 0, 2 and 5 minutes were 
separated on 2D PAGE using a 13cm pi 4-7 strip, on a 13% acrylamide gel. The 
phosphoproteins were transferred to membranes and probed with the indicated phospho 
substrates antibody. The dotted areas on the gel correspond to the zooms on the relevant areas 
of the different western blots.
1 0 6
s gene Accessionnum ber Gi Protein Cov. PM Ppm
1 Hspa8 NP_077327 13242237 Heat shock protein 8 32% 19 32
2 Hspa8 NP_077327 13242237 Heat shock protein 8 39% 37 36
3 Hspa8 NP_077327 13242237 Heat shock protein 8 19% 9 50
4 Hspa8 NP_077327 13242237 Heat shock protein 8 22% 11 15
Hypertension-related protein; 
mitochondrial transmembrane
7 NM_130894 NP_570964 29501815 GTPase 12% 7 71
8 Hspa8 NP_077327 13242237 Heat shock protein 8 36% 21 26
13 Stipl NP_620266 20302113
Stress-induced-phosphoprotein 1 
(Hsp70/Hsp90-organising protein) 21% 15 94
14 Stipl NP_620266 20302113
Stress-induced-phosphoprotein 1 
(Hsp70/Hsp90-organising protein) 17% 9 83
Protein disulflde-isomerase A3
15 Pdia3 P11598 1352384 precursor 22% 11 25
Vim NP 112402 14389299 Vimentin 49% 21 14
18 Tubal NP_071634 11560133 similar to Tubulin alpha-1 chain 25% 10 23
Vim NP_112402 14389299 Vimentin 52% 23 19
19 Tubal NP_071634 11560133 similar to Tubulin alpha-1 chain 26% 10 31
Vim NP 112402 14389299 Vimentin 50% 23 55
20 Tubal NP_071634 11560133 similar to Tubulin alpha-1 chain 23% 9 63
Vimentin
Vim NP_112402 14389299 Protein disulfide isomerase precursor 60% 34 27
27 P4hb P04785 129731 (PDI) 28% 13 35
Vimentin
Vim NP_112402 14389299 Protein disulfide isomerase precursor 58% 32 29
28 P4hb P04785 129731 (PDI) 21% 10 38
31 Hspa5 P06761 121574
78 kDa glucose-regulated protein 
precursor (GRP 78) (BiP) 15% 8 37
40 Hspa8 NP_077327 13242237 Heat shock protein 8 10% 5 15
46 Enol NP_036686.1 6978809 Enolase-1, alpha 34% 13 55
49 Enol NP_036686.1 6978809 Enolase-1, alpha 40% 17 48
60 AAB19888 8248819
Phosphoglycerate mutase type B 
subunit 15% 5 23
61 Gstpl P04906 121749 Glutathione S-transferase P (Chain 7) 34% 5 37
68 Hspa8 NP_077327 13242237 Heat shock protein 8 21% 9 177
Table 3. List of proteins identified
S is the number of the spot; the Accession number identifies the protein sequence and is often 
accompanied by the version number, which tracks changes to the sequence itself 
(Accession.Version); the GI number (genlnfo identifier) is the unique integer which identifies a 
particular sequence and it changes every time the sequence is changed in the database; Cov is 
the % of the protein found as tryptic peptides; PM is the number of peptides matched, ppm is 
the maximum error in part per million.
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Phosphorylation kinetics
When same amounts of proteins are used, the intensity of the signal obtained by WB using 
antibodies against phosphorylated residues is very likely correlated with the degree of protein 
phosphorylation. In order to describe the EGF related phospho-kinetics of the proteins 
identified, changes in intensities of the proteins spots from the exposed films were quantified 
using ImageQuant software. Each spot was calibrated against a large area in the background of 
the blot, and equal areas were taken when spots were compared from one blot to the other. 
Comparisons were only performed for spots belonging to the same set of western blots, 
immunostained with the same antibody and developed for the same length of time. Finally, the 
intensities of the spots were normalised to the protein loading, by comparing the intensities of 
the spots from the corresponding membranes stained with colloidal gold.
The proteins analysed were grouped according to their role in the cell, and a detailed analysis 
of their phosphorylation kinetics is reported below.
Structural proteins
Vimentin isoforms
All identified vimentin isoforms were recognised by all antibodies used, and a similar 
phosphorylation kinetic characterised the spots from the same set of blot (Figure 21). Spots 18, 
19 and 20 contained Vimentin together with alpha tubulin, and spots 27 and 28 contained 
vimentin together with Protein Disulfide Isomerase (PDI) precursor. Although the mixture 
was dominated by vimentin (according to the respective coverage of the two proteins in the 
same spot) these kinetics could not be considered a reliable quantification of the phospho- 
kinetics of vimentin.
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Figure 21. Phospho-kinetics of Vimentin
Each curve represents one protein isoform of Vimentin, called with the name of the 
corresponding spot on the western blots in Figure 20. The diagrams report the ODI (optical 
density intensity) of each isoform, which corresponds to their behaviour as substrates of the 
indicated kinases (y axis) versus the minutes of stimulation with EGF (x axis).
Proteins involved in chaperone regulated redox network
H eat Shock Protein 8 isoforms
For Heat Shock Protein 8 (Hsp8) different isoforms were observed, and they behaved as 
distinct substrates of M APK/CDK and PKC. Indeed, whilst the isoforms contained in spots 
2, 3 and 4 were recognised by both antibodies, spots 1, 8 and 40 were specifically recognised 
by the MAPK/CDK substrate antibody and spot 68 was recognised only by the PKC substrate 
antibody. More proteins were present in this area of the anti PKC substrate blots (Figure 20) 
but only spots visible on the silver stained gel and successfully identified are reported in these 
graphics.
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As readily noticeable from the positions o f the different isoforms on the gel (Figure 20) 
although they all had slightly different isoelectric points, isoforms 8 and 40 differed 
substantially in molecular weight (MW) from the theoretical values. Isoform 8 was 10 kDa 
lighter whilst isoform 40 was smaller by 30 kDa. Interestingly, the distribution of tryptic 
peptides along the amino acid sequence o f the protein changed considerably only for isoforms 
40 (Figure 22): the peptides matched only the N-terminal portion of the sequence and this was 
in agreement with the difference in MW observed on the gel.
Kinetics o f differential phosphorylation are reported in Figure 23; interestingly all isoforms 
underwent dephosphorylation on T P  with different rates, except 40, which became strongly 
phosphorylated. Phosphorylation on potential sites recognised by anti phospho PKC 
substrates did not seem to be overall influenced by EG F treatment.
Quantitation o f differential phosphorylation on different sites o f Hsp8 is described in the next 
chapter.
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Figure 22. D istribution of tryptic peptides in different isoforms of Hsp8
The x axes represent the aminoacidic sequence o f Hsp8; the segments in the graphic 
represent the tryptic peptides matched to the sequence; modified stands for peptides 
containing oxidised methionine and /o r cysteine alkylated.
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Figure 23. Phospho-kinetics of Hsp8
Each curve represents one protein isoform of Hsp8, called with the name o f the 
corresponding spot on the western blots in Figure 20. The diagrams report the O D I (optical 
density intensity) o f each isoform, which corresponds to their behaviour as substrates o f the 
indicated kinases (y axis) versus the minutes o f stimulation with EG F (x axis).
Stress-induced-phosphoprotein 1 (Hsp70/Hp90-organising protein) isoforms
Hsp70/Hsp90-organising protein (corresponding to human Hop) was found in spot 13 and 
14. The predicted molecular weight and p i for this protein are 63 kDa and pi 6.4. Spots 13 
and 14 showed the same molecular weight (around 65kDa), but a difference in 0.2 p i units (pi 
6.9 and pi 7.1 respectively). The isoform contained in spot 13 did not change its 
phosphorylation state, whilst phospho-isoform 14 seemed to increase phosphorylation on TP, 
but to decrease it on RXS (Figure 24). The sequence contains Thr332 and Thr398 which are 
followed by proline (TP).
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Figure 24. Phospho-kinetics of Stress induced phosphoprotein 1
Each curve represents one protein isoform of stress induced phosphoprotein 1, called with 
the name of the corresponding spot on the western blots in Figure 20. The diagrams report 
the O D I (optical density intensity) o f each isoform, which corresponds to their behaviour as 
substrates o f the indicated kinases (y axis) versus the minutes o f stimulation with EG F (x 
axis).
78 kDa glucose-regulated protein precursor (GRP 78) (BiP)
BiP is also known as Heat shock protein 5; it was found in spot 31, but presented quite a lower 
molecular weight (55kDa) than predicted (72kDa) and a higher pi (pi 5.7 rather that pi 5.1). 
This protein underwent strong and clear EGF-dependent phosphorylation on RXXS/T 
(Figure 25). Ser300 could be a potential site because it lies within a typical PKA consensus 
motif.
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Figure 25. Phospho-kinetics of BiP
This curve represents BiP, called spot 31 according to the western blots in Figure 20. The 
diagram reports its O D I (optical density intensity), which corresponds to the behaviour as 
substrates o f PKA (y axis) versus the minutes o f stimulation with EG F (x axis).
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Protein disuljide-isomerase precursor proteins
PDI precursor was present in spot 15 and it was also found in mixtures with Vimentin in spots 
27 and 28. The protein contained in spot 15 and the protein contained in spots 27 and 28 were 
first thought to be identical (Boado et al. 1988), and later been shown to be very different on 
primary structure level (Schoenmakers et al. 1989). This agrees with the observed isoelectric 
points but not for molecular weights of these proteins. The isoform in spot 15 presented a 
remarkably higher MW (ca 15 kDa heavier than predicted), and it was quickly 
dephosphorylated upon stimulation with EGF (Figure 26). PDI contains a TP motif at 
Thr462, and Seri50 in [RK]XS[Hyd][RK] (but with K in -3 rather than in -2).
ODI ^  ODI
7000 8000
70002 6000
S \  6000
^  3000
j y  sooo2
£ 4000
3000
3000
1000
0 2 5 minuteso 2 s minutes
Figure 26. Phospho-kinetics of PDI
Both curves represent the protein PDI, called with the name of the corresponding spot on 
the western blots in Figure 20. The diagrams report the ODI (optical density intensity) of 
this protein, which corresponds to their behaviour as substrates of the indicated kinases (y 
axis) versus the minutes of stimulation with EGF (x axis).
Glutathione S-transferase P (Chain 7)
Glutathione S-transferase P was found in spot 61, in agreement with the theoretical MW and 
pi. It was only recognised by PKC substrate antibody, and seemed to undergo light 
dephosphorylation after 2 minutes (Figure 27). Despite the fact that no phosphopeptide was 
observed in the spectrum, a sequence analysis reveals Seri 85 as potential phosphorylation site 
for PKC.
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Figure 27. Phospho-kinetics of Glutathione S-transferase P
This curve represents Glutathione S-transferase P, corresponding to spot 61 in the western 
blots in Figure 20. The diagram reports its ODI (optical density intensity), which 
corresponds to the behaviour as substrates of PKC (y axis) versus the minutes of stimulation 
with EGF (x axis).
Mitochondrial transmembrane GTPase
Mitochondrial transmembrane GTPase was present in spot 7, in good agreement with the 
theoretical values of MW and pi. The potential site falling in the TP motif is Thr484, while the 
candidate residues for [RK]XS[Hyd][RK] are Serl49 and Ser466.
This protein appeared to be phosphorylated only on TP (the scale of the second graph is 
strongly expanded) (Figure 28).
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Figure 28. Phospho-kinetics of mitochondrial transm em brane GTPase
Both curves represent the protein mitochondrial transmembrane GTPase, called with the 
name of the corresponding spot on the western blots in Figure 20. The diagrams report the 
ODI (optical density intensity) of this protein, which corresponds to their behaviour as 
substrates of the indicated kinases (y axis) versus the minutes of stimulation with EGF (x 
axis).
Metabolic enzymes
HLnolase-1 isoforms
Enolase-1 showed a similar conduct for both isoforms contained in spots 46 and 49 as 
substrates of MAPK/CDK. Interestingly, a spot adjacent to spot 46 contained Enolase-1 (in 
mixture) which is not recognised by the antibodies used, but that is likely to be phosphorylated 
because enriched with IMAC columns. The coverage obtained for the different isoforms was 
high, and the distribution on the sequence very similar. This agreed with the observation that 
the three iso forms migrate at similar molecular weight, although this was lOkDa higher than 
predicted; as for the different isoelectropoint, the isoforms showed similar general behaviour 
(Figure 29).
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Figure 29. Phospho-kinetics of Enolase-1
Each curve represents one protein isoform of Enolase-1, called with the name of the 
corresponding spot on the western blots in Figure 20. The diagrams report the ODI (optical 
density intensity) of each isoform, which corresponds to their behaviour as substrates of 
MAPK/CDK (y axis) versus the minutes of stimulation with EGF (x axis).
Phosphogfycerate mutase type B
Phosphoglycerate mutase type B was found only in spot 60; its observed isoelectric point was 
0.6 pi units lower than the theoretical, while its MW was in good agreement. This protein is 
recognised as being phosphorylated on [RK]XS[Hyd][RK] at time 0, which could be Seri 18 
(although with only 76% similarity with the strict recognised sequence) (Figure 30).
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Figure 30. Phospho-kinetics of Phosphoglycerate mutase
This curve represents Phosphoglycerate mutase, corresponding to spot 61 in the western 
blots in Figure 20. The diagram reports its ODI (optical density intensity), which 
corresponds to the behaviour as substrates of PKC (y axis) versus the minutes of stimulation 
with EGF (x axis).
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DISCUSSION 
EGF activates ERK1/2 in NRK49F cells
In fibroblasts, EGF induces ERK2 phosphorylation through alternative pathways in a cell type 
specific manner (Burgering et al. 1993). In the past MAPK has been shown to be activated in 
this cell line, with maximum activation reached after 4 minutes of stimulation with EGF 
(Lahaye et al. 1998).
Similar amounts of total cellular proteins (proteome) and total phosphoproteins 
(phosphoproteome) were loaded on lD-gels and changes of ERK1/2 and p38MAPK were 
followed in both protein fractions. IMAC proved to enrich the phosphoprotein fraction; after 
2 minutes of stimulation with EGF the phospho E rk l/2  signals were much stronger in the 
phosphoprotein fraction than in the total protein fraction, whilst the signal from the 
unstimulated cells was not enhanced (Figure 18, A). The results obtained suggest that EGF 
activates ERK1/2 and p38MAPK in NRK49F cells within the first 2 minutes of cell 
stimulation (Figure 18, A). This effect decreased later, at 5 minutes, but was still present even 
after 10 minutes (data not shown).
Some conclusions could be drawn about the specificity and efficiency of the phosphoprotein 
enrichment. None of the phosphorylated ERK1/2 forms were lost during the purification, 
while the mixture of both unphosphorylated and phosphorylated ERK1/2 was present in the 
same amount in the whole cell lysate and in the phosphoprotein fraction.
In summary, the results obtained so far in this study show that ERK1/2 are activated as a 
response of the NRK49F cells to EGF stimulation under the conditions used and that the 
IMAC based methodology developed is appropriate for further studies of signalling related 
phosphorylation events.
117
Phosphoproteome changes upon EGF stimulation
No visible changes could be seen in the proteome and in the phosphoproteome of NRK49F 
after stimulation with EGF when proteins were separated on ID  SDS-PAGE (Figure 19). The 
NRK49F phosphoproteins after 0, 2 and 5 minutes of stimulation with EGF were therefore 
separated on 2D gels, but in spite of the high resolution of the gels obtained the analyses and 
comparisons of the gels appeared too laborious and complex with the software available 
(Figure 19). This seems to be recognised as a common problem, and in spite of the advances in 
gel electrophoresis and software performance it is quite unlikely that 2D gels can be exploitable 
to compare and analyse complex samples with high accuracy (Mann et al. 2001).
However, classical proteomics approaches have historically relied on 2D PAGE separation, 
although this approach encounters the above mentioned limitation as well as others, such as 
poor reproducibility and failure to resolve proteins above 200 kDa, proteins with very acidic 
and alkaline pi and membrane proteins. In spite of these restrictions, 2D-PAGE is still the 
most powerful method for separating proteins with high resolution, and was chosen in this 
study in combination with a higher level of partition.
Kinase substrates immunodetection and identification
The largest group of enzymes that catalyse regulatory posttranslational modifications is the 
family of protein kinases. These enzymes transfer phosphate groups from ATP to specific 
hydroxyl groups on substrate proteins.
To obtain additional information concerning the EGF-dependent phosphorylation on some 
proteins, the phosphoproteome was screened for phosphorylated residues contained in 
consensus sequences known to be recognised by certain families of kinases. The choice of 
antibodies was based on previous work describing the role of EGF in activating the MAPK
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pathway (see chapter 1). Phosphospecific antibodies have recendy been introduced as tool in a 
new approach to protein kinase substrate identification (described in the introduction to this 
chapter). In this study these antibodies have been used for a general screen of 
phosphoproteomes. Subclasses of serine/threonine phosphorylated proteins that could 
potentially behave as protein kinase substrates have been identified. After stimulating cells with 
EGF for 0, 2 and 5 minutes, phosphorylation changes in multiple proteins were followed using 
antibodies specific for phosphorylated threonine followed by proline (TP) (MAPK/CDK 
phosphorylated substrates), phosphorylated serine in RXS consensus (PKC phosphorylated 
substrates), and both serine and threonine in RXXS/T consensus (PKA phosphorylated 
substrates). However, it must be added that, even assuming the antibody specificity is very 
high, this approach would not capture atypically phosphorylated proteins, proteins out of the 
pi/M W  range used and low abundant proteins.
Phosphoprotein fractions for cells treated with EG F were separated on 2D gels and 
specifically immunostained (Figure 20). Blot images showed significant changes in the pattern 
of protein spots after stimulation with EG F for 2 and 5 minutes. This confirms that EGF 
causes a boost in phosphorylation events in the cell. Upon stimulation, some proteins become 
more phosphorylated, others become dephosphorylated while some remain unchanged. This is 
consistent with previous work showing that EG F activates phosphatases as well as kinases 
(Cunnick et al. 2002; Ren et al. 2003). Some of the proteins appeared in more than one blot, 
justifiable by the fact that proteins are frequently phosphorylated on more than one type of 
amino acid and therefore also by different kinases.
These images were compared to the silver stained gel images and proteins of interest were pin­
pointed and identified (listed in Table 3).
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Limitations
As mentioned in the introduction to this chapter, there are some drawbacks to this method. 
Antibodies can occasionally give non-specific signals, making accurate interpretation of the 
results difficult. There is a possibility that these antibodies recognise the same phosphorylation 
site on one protein, suggesting that the same protein has two distinct phosphorylation sites. 
Although more interference was expected between the RXS and RXXS/T antibodies, the 
blots of TP and RXS have more spots in common.
Antibodies can be highly specific and superimposition of the colloidal gold stained membranes 
with the blots and the analytical gels accurate (Liberatori et al. 2004). Even when this is 
achieved, it must be considered that the sensitivity of silver staining is lower than the sensitivity 
obtained by immuno staining. As a result low abundance proteins recognised by the antibodies 
can not be identified by MALDI-TOF MS because they are hardly visible on the silver stained 
analytical gels or overlap with more abundant proteins. An example of such a problem has 
been encountered with the spots 27, 28 and 18, 19 and 20. Although the signal from the 
immuno-blot is very clear and perfectly matched with the spots on the preparative gel, a 
mixture of two proteins was found in the same spots, making it impossible to determine which 
protein is binding to the antibody.
A different problem was encountered for spots 35, 36 and 38: although the immuno signal was 
strong and seemed very specific, after superimposition to pinpoint the corresponding protein 
on the analytical gel, the amount of these proteins was found to be below the sensitivity of the 
silver staining.
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Nevertheless, in most other cases a unique match and identification was possible, and the 
proteins obtained were analysed. The sequence of each protein was also screened to find the 
phospho-motifs recognised by the antibodies.
Substrates identified are involved in chaperone-redox network
One of the limitations o f this experiment is that only a small subset, mainly constituted by 
abundant proteins, could be identified with confidence, leaving out the low abundant signalling 
proteins. However, as this problem is widely encountered, a wealth of proteomics data on such 
proteins has been generated. This is a good starting point to further understand the role of 
high abundance proteins, which also appear the most versatile. The subset of potential kinases 
substrates is too limited to unveil possible connections within signalling cascades. However, 
some correlations with chaperone-regulated redox networks and its possible cross-talk to 
signalling are discussed in this chapter.
Excluding Vimentin
Vimentin was a common substrate for the three kinases. This protein followed the same 
phosphorylation behaviour as substrate of the three kinases, although it does not have RXS 
and TP consensus motifs in its sequence. Furthermore, Vimentin is the only substrate that 
PKA has in common with the other kinases. Combined with the fact that Vimentin is always 
found in mixture with other proteins this strongly suggests that is a false positive. In addition, 
Vimentin would be an ideal target for non-specific binding as it is abundant in the cell and is 
highly phosphorylated.
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Chaperones and co-chaperones as a kinase substrate
The general behaviour observed for Hsp8 is dephosphorylation on TP with exceptions for the 
isoform contained in spot 40. The isoforms which become immediately dephosphorylated 
before two minutes of EG F stimulation are the most acidic isoforms and therefore likely the 
most phosphorylated. The proteins at higher p i follow the same process at a slower rate. As 
for the isoform in spot 40, the peptide distribution strongly suggests that this could be a 
truncated form, possibly a degradation product. It is not possible to judge if it was a non­
specific degradation that occurred during sample preparation, or a more specific product of a 
regulated proteolytic process that occurred in the cells. Interestingly, if indeed this was a 
proteosomic event, the increased phosphorylation might have a role in controlling the process.
As for phosphorylation on RXS, the Hsp8 isoforms were comparably not influenced by the 
stimulation, and no changes were observed. The isoform in spot 40 was not recognised by this 
antibody, suggesting that RXS might be located in the C-terminal of the protein.
It has been shown that Hsc70 forms complexes with Hsc90 and Casein Kinase II in resting 
platelets (Gear et al. 1997). Upon treatment with thrombin, Hsc70 dephosphorylation and 
dissociation from the complex occur, in agreement with these results. Investigations into these 
phosphorylation events included a 2D display of the isoforms, showing that only a subset of 
Stress induced phosphoprotein 1 isoforms become phosphorylated after 10 minutes of heat 
stress (Lassie et al. 1997). This is also in agreement with the data presented here: only two 
isoforms were immunostained with antibodies against phosphorylated TP and RXS, and only 
the isoform in spot 14 (with lower level of phosphorylation than the isoform in spot 13) 
showed a phosphorylation increase on TP and a decrease on KXS upon EGF stimulation. 
Thrl98 is indeed in a TP consensus motif, confirming these findings. In addition to this, the 
consensus motif of MAPKAP kinase 2 is RXXS, which is the same as that recognised by the
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antibody against PKA substrates. The data presented confirmed that Stress induced 
phosphoprotein 1 is not phosphorylated on sites which lie in this consensus. PDI becomes 
dephosphorylated upon stimulation, and a potential phosphorylation site is Seri 50. An 
increasing phosphorylation of BiP upon EG F stimulation on possible RXXS/T consensus was 
also observed.
Redox-signalling crosstalk networks
Oxidative conditions, as well as growth factors stimulation, are known to stimulate tyrosine 
phosphorylation of EGFR, leading to activation of ERK1 /2  in a number of cell types (Droge 
2002). Recent works have shed some light on how the activity of the chaperones is 
coordinated and revealed links between the stress induced response and the thermal response 
(Jacob et al. 2004). The following paragraphs describe the relationships between the proteins 
identified in this study and redox networks.
Interestingly, at least four of the chaperones identified in this work, namely Hsp8, BiP, PDI 
and GST-P, are protagonists in redox networks regulated by chaperones (Sitia et al. 2004). 
Hsp8 and Stress induced phosphoprotein 1 are protagonists in protein folding in the cytosol 
and nucleus, whilst BiP, PDI and GST play a crucial role in the second protein folding 
compartment in the cell, the endoplasmic reticulum (ER). Two distinct redox networks in the 
cytosol and ER guarantee that protein folding is strictly regulated, both under physiological 
and stress conditions. Mechanistically, the cysteines are the main targets as their thiol groups 
can be modified according to the redox conditions. When a disulfide bond (SS) is created by 
two reduced SH groups, a strong structural constriction is imposed on the protein, which can 
regulate its function. Cysteines behave like real reversible molecular switches and their 
controlled oxidation modulates signalling pathways, in a similar manner to phosphorylation.
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Hsp8 and BiP are part of complexes (in the cytosol and in the ER respectively) and are able to 
fold polypeptides chains correctly and are sensitive to H20 ,  treatment (Baty et al. 2005).
Remarkably, Enolase-1 and phosphoglycerate mutase B (PGM), not previously connected with 
redox networks, have also recendy been found to be sensitive to H ,0 2 treatment (Baty et al. 
2005). Enolase-1 was also found to be glutathionylated under resting conditions, suggesting 
that this protein can also be important as a glutathione store (Fratelli et al. 2002). Another 
observation is that upon oxidative stress only one isoform of Enolase-1 was previously found 
(Baty et al. 2005). Three isoforms have been identified here, only two of which are 
phosphorylated following similar kinetics. PGM has been identified as a new substrate for 
histidine kinase activity in vitro (Engel et al. 2004), whilst in this work it is strongly 
dephosphorylated on serine/threonine upon stimulation with EGF.
The mitochondrial transmembrane GTPase is involved in mitochondrial fusion, and stimulates 
the mitochondrial oxidation o f substrates, cell respiration and mitochondrial membrane 
potential suggesting that this protein may play an important role in oxidation processes 
(Zorzano et al. 2004). Furthermore, mitochondrial transmembrane GTPase is a powerful 
regulator of cell proliferation via inhibition of ERK1/2 signal pathway (Chen et al. 2004). This 
protein is increasingly phosphorylated on TP, whilst the phosphorylation on RXS is not 
altered upon EG F treatment. Unfortunately, no further information on the exact 
phosphorylation sites could be obtained.
PDI creates disulfide bonds in the polypeptide chain, thereby reducing its own cysteines;
additionally, it functions as isomerase to rearrange the disulfide bonds created until the protein
is properly folded. When required, it can function as an unfoldase. PDI has long been known
to be a phosphoprotein capable of autophosphorylation, and the phosphorylated region was
shown to be within 146-306 (although the authors suggest that the phosphorylation does not
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influence the activity) (Quemeneur et al. 1994). In the presented study PDI was 
dephosphorylated upon stimulation; a predicted phosphorylation site for this is Seri 50.
As previously stated, BiP belongs to the family of Hsc70/Hsp70, but is found in the ER. The 
form found in this analysis showed a sensibly lower MW, due to degradation or different 
splicing. Early studies have shown this protein to be phosphorylated (but not 
autophosphorylated) on serine/threonine upon stress, with the phosphorylation causing 
dissociation from its substrates (Hendershot et al. 1988). Recent work has shown that during 
ER stress, malfolded proteins accumulate in the ER, and BiP is dissociated from different 
cytosolic kinase domains leading to their activation (Shen et al. 2002). The ATPase activity of 
BiP is also thought to be coupled to detachment of substrates from PDI. The results shown 
demonstrate that there is an increasing phosphorylation upon EGF stimulation on a possible 
RXXS/T consensus site.
GST-P has different functions: it is involved in oxidant metabolism and regulation by 
catalyzing the glutathionylation of peroxiredoxin (Manevich et al. 2004), and has also been 
shown to bind to JN K  and dissociate upon oxidative stress allowing JN K  phosphorylation and 
activation (Adler et al. 1999). N ot much has been published on GST-P phosphorylation, as the 
main regulatory mechanism for this protein is oxidation; the present results also suggest that 
no major changes in phosphorylation occur under the conditions for stimulation used here.
A more detailed and quantitative analysis of some of the potential substrates described in this 
chapter is offered in the following section.
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CHAPTER 5 
PHOSPHO-SILAC STRATEGY 
INTRODUCTION
A SILAC-based proteomics method for protein quantification was applied in the present EGF 
signalling study. In this approach, one population of cells was grown in medium containing the 
normal form of an essential amino acid and another was grown in medium supplemented with 
a stable isotope-labelled analogue (see chapter 1 for more details). The two resulting protein 
samples were then pooled and analysed. Fully labelled arginine containing six 13C atoms was 
chosen because it allows 6Da difference in weight between the labelled and the unlabelled 
peptide containing 1 arginine residue. This guarantees good separation of the corresponding 
peaks, and minimises the overlapping of the two isotopic patterns. The protease used for 
digesting the proteins was trypsin, which hydrolyses after arginine and lysine (equally abundant 
in proteins); this ensures that at least half o f the peptides obtained contain arginine and can be 
quantified.
In this chapter a new strategy based on the combination of a more innovative application of 
SILAC and the previously described methods for selective enrichment of phosphoproteins 
(chapter 3) (Guerrera et al. 2005b) is described. This strategy allows quantitative, time- 
dependent scanning for phosphorylation for a majority of peptides containing arginine in many 
proteins identified on 2D gels. This use of SILAC also enables detection of changes in post- 
translational modifications other than phosphorylation of a certain protein upon stimulation of 
kidney fibroblasts with EGF. This suggests that this method is useful in characterising the 
correlation between different post-translational modifications in the same proteins or in 
different isoforms of the same protein.
The principal aim of the study described in this chapter is to investigate more thoroughly some 
of the proteins identified as potential targets of selected protein kinase families, as described in 
chapter 4. The Phospho-SILAC labelling was applied to phosphoproteomes of NRK49F cells 
stimulated for 2 and 5 minutes with EGF. The proteins of interest were isolated and analysed 
in detail.
This method proved ideal in integrating the analysis of previously functionally characterised 
proteins, and is equally applicable in obtaining interesting leads when analysing the whole 
phosphoproteome, as demonstrated in the following chapter.
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Figure 31. Scheme of the Phospho-SILAC strategy
Cells were grown in labelled arginine containing media (pink and blue) and in ordinary media 
(green). After incorporation of labelled arginine the cells were treated with 200ng/ml EGF for 
2 (pink) and 5 (blue) minutes. The cell lysates obtained from the control and each of the 
stimulated cell lines were mixed 1:1. Phosphoprotein fractions were isolated from both 
mixtures and separated on 2D gels. Each spot on the gel contained quantitative information 
for the resolved protein. The same spot from the two gels enclosed the data of the specific 
protein before and after 2 and 5 minutes of stimulation with EGF.
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Normalisation of the MALDI-TOF spectra
Each spectrum was normalised to compensate for differential loading of the labelled 
/unlabelled cell lysates, due to inaccuracy of the protein concentration determination. In fact, 
as new synthesis is excluded within the time span chosen, the differences between the same 
peptide in the unlabelled protein (control) and labelled protein (stimulated) can only be 
attributed to PTMs, and in particular to phosphorylation as this fraction of the proteome has 
been enriched. Assuming that no protein expression changes occur in the first 5 minutes of 
EGF treatment, the same intensities of unmodified peptides belonging to the same protein 
before and after stimulation is expected. Ratios of peptides attributed to unmodified peptides 
in each protein identified were calculated. These values were averaged, and the same nor­
malisation factor was applied to all the proteins (0.53 for the proteins contained in 0-2 minutes 
gel and 1.45 for proteins contained in 0-5 gel). The standard deviation (weighed for number of 
pairs considered in each protein) was 0.088. On this basis, only abundance changes of more 
than 10% were considered to be significant.
Data analysis
The searches of the peptides obtained were performed using ProFound. This programme 
compares the experimental masses with the theoretical tryptic masses of all the proteins 
present in the database. In order to permit the recognition of 13C labelled peptides an 
additional partial modification of +6Da was allowed on arginine. Potential partial 
phosphorylations were allowed on serine, threonine and tyrosine and partial oxidation was 
allowed on methionine. Allowance o f a large number or partial modification is often associated 
to non-specific attribution of the peaks; therefore simple rules have been established with the 
purpose of limiting false interpretation:
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• Only peaks that could not be attributed to the sequence were considered for 
interpretation of peptides with potential modification. Often a peak could be attributed 
to two or three different peptides on the same protein, and this trend increased when a 
large number of potential modifications were allowed. As phosphorylated peptides are 
more difficult to visualise on MALDI-TOF MS than unmodified peptides, it was 
assumed that if the same peak can be attributed to either a phosphopeptide or another 
peptide not carrying any modification, there is a higher possibility that the latter is the 
correct interpretation.
•  When peaks were separated exacdy by 6Da the interpretation of these was always given 
to the peptide containing modified (hR) and unmodified arginine (R). Even when it 
was not possible to recognise the peptides generating the doublet, alternative 
association of one of the two peaks to a peptide with PTMs was excluded.
•  In most cases the attribution of 13C6 Arg containing peptides (especially for the ones 
carrying PTMs) was double checked to be not present on the MALDI-TOF spectrum 
of the same protein obtained from not labelled cells.
Although the application of these rules might have left out some potential modifications, it 
was necessary in order to exclude a large number of incorrect interpretations. A good example 
of the application of these criteria on a real search result is shown in Figure 32.
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gi|38181549|gh|AAH61547.1| Heat shock protein 8 IRattus norvcgicusl
Sample ID : 8
Measured peptides : 59
Matched peptides : 38
Min. sequence coverage: 4 4%
Measured Avg/ Computed Error Residues Missed
Mass(M) Mono Mass (ppm) Cut Peptide sequence
1196.649 M 1196.655
1202.709 M 1202.702
1198.671 M 1198.666
1204.739 M 1204.713
1204.73 9---M— 1204.519
1216.730
1252.663
1258.686
1302.660
1318.629
1449.729
1479.801
1491.833
1486.834 
1492.803 
1491.833 
1615.842 
1631.823 
1646.820 
1648.840 
1664.815
1658.928
1690.782
1696.803
1720.923
1744.859
1744.859
1787.006
1787.006 
1981.029 
1987.055
2259.128
2262.104
2321.070
2513.262
2773.232
2779.245
2996.296
3002.290
-5
6
4
21
459
459
160
160
469
469
171
171
-989--- 543--546-
0 FELTGIPPAPR 
0 FELTGIPPAPR(1)+H60R;
0 DAGTIAGLNVLR
0 DAGTIAGLNVLR(1)+H60R; *
-4 MVQEAEKYK1H -H PO30STY ;
1216.629
1252.608
1258.655
1302.591
1318.586
1449.797
1479.746
1491.840
1486.693
1492.740
1491.687
1615.780
1631.774
1646.626
1648.787
1664.782
1658 -928--- M— 1658 .871
83 551 561 1 ATVEDEKLQGK
4 4 302 311 0 FEELNADLFR
24 302 311 0 FEELNADLFR(1)+H60R;
53 540 550 0 NSLESYAFNMK
33 540 550 0 NSLESYAFNMK(1)+O0M;
-47 34 6 357 1 IQKLLQDFFNGK
37 300 311 1 ARFEELNADLFR
-5 300 311 1 ARFEELNADLFR(2)+H60R;
94 37 49 0 TTPSYVAFTDTER
42 37 49 0 TTPSYVAFTDTER(1)+H60R;
98 513 524 1 EDIERMVQEAEK(1)+O0M;
39 113 126 0 SFYPEEVSSMVLTK
30 113 126 0 SFYPEEVSSMVLTK(1)+O0M;
118 37 49 0 TTPSYVAFTDTER(2)+HPO30STY;
32 57 71 0 NQVAMNPTNTVFDAK
20 57 71 0 NQVAMNPTNTVFDAK(1)+O0M; 4
— 3-4----- 89--192---- 0--HWPFMWNDAGRPK (1)+H60R;
Excluded because 
assigned to part o f  
a doublet AND  
because the 
alternative is an 
unmodified 
peptide
1658.887
1690.718
1696.764
1720.698
1744.801
1744.748
1786.982
1786.837
1980.990
1987.037
1981.029---M— 1980.816
24 172 187 0 IINEPTAAAIAYGLDK
38 221 236 0 STAGDTHLGGEDFDNR
23 221 236 0 STAGDTHLGGEDFDNR(1)+H60R;
131 329 342 0 SQIHDIVLVGGSTR (3)+HPO30STY;
33 584 597 1 NQTAEKEEFEHQQK
63 57 71 0 NQVAMNPTNTVFDAK(1)+O0M;(1)+HPO30STY
13 172 188 1 IINEPTAAAIAYGLDKK
94 156 171 1 QATKDAGTIAGLNVLR(2)+HPO30STY;
20 138 155 0 T VTN A W T  V PAY FN DS QR
9 138 155 0 TVTNAWTVPAYFNDSQR (1) +H60R;
-988----- 52--- 22---- 1--NQVAMNPTNTVFDAKRlxO0M; (2) +HPO30STY;
Excluded because 
assigned to an 
unmodified peptide
Excluded 
because 
assigned to 
unmodified 
doublet
1987.055---M— 1986.863 -92- -5 9 - -9 2 -
9987,055---M— 1986.871 -93 - -9 9 3 -----9 2 8 -
■NQVAMNPTNTVFDAKR1xO@M;(2)+HPO30STY;(1)+H60R^T 
SFYPEEVSSMVLTKMK2xO0M;(1)+HPO30STY;
2259.137
2262.109
2321.058
2513.300
2773.318
2779.365
2996.449
3002.496
- 4
- 2
5
-15
-31
-43
-51
- 6 8
362 384 0 SINPDEAVAYGAAVQAAILSGDK
4 25 0 GPAVGIDLGTTYSCVGVFQHGK
37 56 1 TTPSYVAFTDTERLIGDAAK 2xHPO30STY;(1)+H60R;
470 493 0 GVPQIEVTFDIDANGILNVSAVDK
424 447 0 QTQTFTTYSDNQPGVLIQVYEGER
424 4 47 0 QTQTFTTYSDNQPGVLIQVYEGER (1)+H60R;
273 299 0 TLSSSTQASIEIDSLYEGIDFYTSITR
273 299 0 TLSSSTQASIEIDSLYEGIDFYTSITR (1)+H60R;
Unm atched M onoisotop ic M asses:
1211.726 1315.649 1457.875 1466.875 1537.927 1549.789 1554.775 1566.883 1568.849 1572.811 1601.790 1613.679 1753.719 1759.738 
1761.748 1974.100 2043.998 2050.020 2175.060 2230.159 2325.043
Figure 32. Exam ple of selection of relevant attributions of a M ALDI-TOF spectrum
This figure represents the typical result page of the search engine most commonly used in the 
analysis, PROFOUND. Some of the attributions are excluded and a small explanation is given. 
The modifications are highlighted in red: H6@R stands for 13C6 Arg label (hR) and 
HP03@STY stand for phosphorylation on serine, threonine or tyrosine.
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Quantitation
Strict rules were applied to quantification of the peptide doublets. First, special emphasis needs
to be put on the fact that only intensities of peaks corresponding to structurally identical
peptides can be compared. When one peptide appeared to be modified only in one of the 
analysed cellular states, no quantitative information could be obtained directly from this 
peptide, except on the on-off presence of such modification. When the corresponding 
unmodified peptide was detectable as a doublet some indirect conclusions could be drawn, 
because changes in the unmodified peptide must be complementary to changes in the 
corresponding modified peptide. A simple scheme is reported in Figure 33.
Some cases when the quantification within the same spectrum could not be obtained have 
been recognised:
• The peptide analysed did not contain any arginine;
• The peptide contained methionine both oxidised and unmodified and it was not
possible to calculate accurately the amount of that peptide at different cellular states;
• On rare occasions, one of the peaks of the doublets of the peptide to quantify 
overlapped with the isotopic pattern of another peak.
• Finally, the comparison of quantification results obtained from different spectra of the 
same isoform of the same protein to obtain the kinetics of a certain phosphorylation at 
0, 2 and 5 minutes were considered valid only when comparable coverage was obtained 
for the proteins analysed. For instance, this applies to results related to a spot from a 
gel containing a mixture of control and proteins from cells stimulated for 2 minutes 
with EGF (Arg 0-2 gel) and the same spot from a gel containing a mixture of control
and proteins from cells stimulated for 5 minutes with EGF (Arg 0-5 gel). The same 
rules applied when comparing the kinetics of different isoforms of the same protein.
o o & o o ®
6D a
6Da6Da
direct quantification
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Figure 33. Scheme of peptide quantification
Black circles indicate heavy arginine, light blue circles indicate unlabelled arginine, empty circle 
indicate all other amino acids. P indicates phosphorylation. In the upper spectrum an example 
of phosphorylated peptide present before and after stimulation is reported. In this case 
quantification can be easily obtained calculating the ratio between the heights of the two peaks. 
In the lower spectrum a different case is reported, where the phosphorylation occurs only after 
stimulation. The ratio of the unmodified peptide before and after stimulation indicates the 
fraction of protein that undergoes phosphorylation upon stimulation.
Protein kinase targets: Hsp8, Stress induced phosphoprotein 1 
and Enolase-1
The sequence of different isoforms of the most abundant proteins found as kinase targets (as 
described in chapter 4) was investigated to potentially associate the phosphorylation found 
with the differential phospho-kinetics shown. Only spots that could be uniquely overlapped
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with the gel reported in Figure 20 were included in the analysis. These spots, and the ones 
which were found to contain other isoforms of the same proteins, are shown in Figure 34.
O' EGF+2' EGF O' EGF+5' EGF
« 44 29
33 m m - 'ML*
Figure 34. Arg 0-2 and Arg 0-5 gels
Enlargements of the gel obtained by mixing phosphoproteins from quiescent cells and 
proteins from cells stimulated for two minutes (on the let) and five minutes (on the right) 
with EGF.
Heat Shock Protein 8 (Hsp8)
MALDI-TOF M S analysis
Spot 2, 3 and 4 corresponded to spots previously identified as Hsp8 (see chapter 4). Spots 1, 
68 and 40 were not cut due to low abundance for spot 1 and 68 and poor co-localisation of 
spot 40. The coverage of the protein sequence using MALDI-TOF MS ranged from 40 to 
65%, due to the abundance of the proteins contained in the spots. On one hand this 
constituted an advantage for this study, but on the other hand many potential 
phosphopeptides were excluded from the analysis as the above mentioned rules were followed, 
which implies that only the most probable sites are reported.
The results obtained are summarised in Figure 35; the isoform in spot 7 contained the peptide 
37-49 both unmodified and monophosphorylated in resting cells. Upon stimulation there was 
an additional phosphorylation after stimulating for two minutes and complete 
dephosphorylation after 5 minutes. This is in agreement with the data shown in chapter 4: one
of the potential sites in this peptide is Thr38, which is in a MAPK substrate consensus 
sequence (TP). Unique attribution of the phosphorylation site was obtained by ESI MS (see 
below). The other isoforms showed the same behaviour for this part of the protein, but show 
an additional phosphorylation event after five minutes treatment with EGF; this can only be 
allocated to Thrl63 (peptide 160-171hR-P, at 1285.7 m /z), which is not in any of the 
consensus sequences tested with antibody, therefore showed no signal on the western blot, but 
has been purified through the IMAC column.
Indirect quantification o f the phosphorylation on Thr38 was hardly possible. The peak at 
1493.7 m /z  corresponding to 37-49hR was overlapping with the isotopic pattern of the 
peptide 300-311 2hR (1492.8 m/z).
Phosphorylation on Thrl63 appeared to happen at different rates. According to the data 
obtained for the corresponding unmodified peptide 160-171, only 10% of the protein isoform 
8 present in the cells became phosphorylated after 5 minutes, whilst up to 30% of the protein 
isoform 9 underwent phosphorylation after the same treatment.
136
81 6 0 -1 7 1
( 10)37^ 49 3 7 - 4 9
j .2
1 6 0 -1 7 13T-49 3 7 -4 9
2'EGF
2'EGF
(10)
2
2
6 0 -1 7 1
(10)19 3 7 -5 6
2
(60 -171
(10)
3^ 9 37-56
5'EGF
5' EGF
3 7 -4 9 1 6 0 -1 7 1  1 6 0 -1 7 1  
(9)
3 7 -4 9 1 6 0 -1 7 1  1 5 0 -1 7 1  
(7)
Figure 35. Phospho-kinetics of Hsp8
Distribution phosphorylation upon stimulation with EGF in different Hsp8 isoforms. Each 
“worm” represents a peptide observed in the MALDI-TOF spectrum of the corresponding 
protein. Phosphorylation on different residues is indicated as —P. The name of the specific 
isoform analysed is indicated on the left.
E S I M S  analysis
In order to uniquely allocate the phosphorylation sites ESI MS-MS analysis was performed on 
peptides 37-49 and 37-56. Peptide 160-171 only has only one possible phosphorylation site on 
Thrl63, therefore it was not analysed.
Table 4 reports the ions that have been selected for tandem MS.
peptide Atg
13
Arg modifications parent ion charge
isolated
ion
A 37-56 X Diphosphorylation 2322.1 3+ 774.7
B 37-49 X Phosphorylation 1567.7 3+ 523.2
Table 4. Peptides selected for the ESI MS/MS analysis of Hsp8
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Figure 36. ESI MS analysis of peptide A (as described in Table 4)
The ions belonging to the peptide are annotated in the spectrum and they are listed in the 
table, with the theoretical values and the errors associated, expressed as difference in Da. 
On the top, a schematic representation of the peptide with the corresponding ions 
identified is reported. For convenience the charge and the N H 3/H 20  losses are not 
indicated on the spectrum and on the peptide scheme, but they can be found in the table. 
hR is 13C labelled Arg.
fragm ent exper. theor. A D a
aio 1215.10 1216.13 1.0
aio-H3P 0 4 1118.90 1118.13 -0.8
b3-H3P 0 4 282.80 282.32 -0.5
b5 710.20 710.55 0.3
b6-H20 792.30 791.67 -0.6
b6 809.40 809.69 0.3
b8-H20 1010.00 1009.93 -0.1
b9-H20 1110.90 1111.03 0.1
bio-H3P 04 1147.00 1146.14 -0.9
bio 1245.20 1244.14 -1.1
b 12 1474.50 1474.36 -0.1
b u 1747.80 1748.77 1.0
bi6-H20 1899.70 1900.97 1.3
y7-NH3 671.10 670.79 -0.3
y9-H20 +2 479.40 480.59 1.2
yio-NH3+2 880.80 880.77 0.0
yio-H20 1061.20 1061.27 0.1
yio 1078.20 1079.29 1.1
yn-NH3+2 589.40 589.18 -0.2
yn-H20 1176.00 1176.36 0.4
yi2-H20 1277.90 1277.47 -0.4
y n 1295.10 1295.49 0.4
y n 1443.80 1442.66 -1.1
yi4+2 756.30 757.38 1.1
yw 1512.20 1513.74 1.5
y is+2 1020.50 1020.62 0.1
yis-H20 +2 1011.20 1011.61 0.4
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Figure 37. ESI MS analysis of peptide B (as described in Table 4)
The ions belonging to the peptide are annotated in the spectrum and they are listed in the 
table, with the theoretical values and the errors associated, expressed as difference in Da. 
On the top, a schematic representation of the peptide with the corresponding ions 
identified is reported. For convenience the charge and the NH3/H 20  losses are not 
indicated on the spectrum and on the peptide scheme, but they can be found in the table.
fragm ent exper. theor. A D a
a3 352.6 352.31 -0.3
a4-H3PC>4 340.3 341.39 1.1
a5-H3PC>4 505.3 504.57 -0.7
as 602 602.56 0.6
an -H 3P 0 4 1140.4 1139.26 -1.1
b 2- H 20 265.2 265.18 0.0
b 2 282.5 283.2 0.7
b 3- H 20 362 362.3 0.3
b 4- H 20 448.9 449.38 0.5
b4 468.4 467.4 -1.0
b 5- H 20 613.7 612.56 -1.1
b 5 630.1 630.57 0.5
b 6- H 3P 0 4 632.2 631.71 -0.5
b 6- H 20 712.6 711.69 -0.9
b 9- H 20 1030.4 1031.05 0.6
y  2 303.5 304.33 0.8
ys 405.8 405.43 -0.4
y3+2 203.4 203.22 -0.2
y 4 521.6 520.52 -1.1
y5+2 311.3 311.32 0.0
y 6+2 384.8 384.91 0.1
ye 767.7 768.81 1.1
y i2-H 3 P 0 4 1370.5 1369.48 -1.0
A F 220.1 219.27 -0.8
SY V A F -28 540.4 540.64 0.2
tP S Y V A F -28 818.9 818.85 0.0
tP S Y V A F 846.1 846.86 0.8
Stress induced phosphoprotein 1
No potential phosphorylation complied with all the rules described in the introduction of this 
section. However, it must be pointed out that only 2 isoforms o f this protein were found as 
substrates of kinases, whilst and additional two isoforms at higher pi have been identified here, 
suggesting differential phosphorylation.
Enolase-1
Spots described as 46 and 44 were both found in this analysis. In the previous experiments 
(chapter 4) spot 44 could not be identified as Enolase-1. Spot 29, which did not correspond to 
any spot from the kinase fishing experiment, was also found to contain Enolase-1. In total four 
spots containing Enolase-1 were found (spots 46, 29, 44 in Figure 34 and spot 49 in Figure 
20): only spots 46 and 49 were recognised by the antibody against phosphorylated TP. Spot 46, 
recognised by the antibody and analysed in this SILAC experiment for time 0 and 2 minutes, 
showed phosphorylation on serine 177 (or Seri 76) upon stimulation, but no phosphorylations 
on TP were visible. Spot 44 and spot 29 have been analysed in this SILAC experiment, but 
were not recognised by any of the antibodies used, and showed phosphorylation on 
serine/threonine. In detail, spot 47 could only be analysed for the first two minutes of 
stimulation, because the spectrum from the gel containing proteins from control and cells 
stimulated for 5 minutes could not successfully be taken. Enolase-1 in spot 44 was analysed 
throughout the stimulation, although a small reserve must be expressed for the peak 
corresponding to the peptide 395-403, with two arginines labelled and no other modifications. 
The isotopic profile of this peptide overlapped to the one of a strong peak deriving from auto 
digestion of trypsin, therefore it is likely to be covered by it. Finally Enolase-1 in spot 29 
underwent phosphorylation on two different peptides, 395-403 which from 
monophosphorylated became biphosphorylated, and stayed so up to 5 minutes stimulation;
peptide 163-179 instead became transiently monophosphorylated at 2 minutes, only to lose it 
after 5 minutes of treatment with EGF. It would have been interesting to calculate the 
percentage of the protein that became phosphorylated, but this was not possible as no traces 
of phosphorylated peptide were present at 0 and 5 minutes. Indirect quantification was not 
possible because unmodified 163-179 was present as a mixture of peptides with different 
degrees of oxidised methionine. Spot 46 was not analysed.
The amino acids involved are not in a consensus sequence searched, consequently it is not 
surprising that they were not recognised by any of the antibodies. A scheme of the results 
obtained is shown in Figure 38.
The ratio between the peptide 163-179 before and after the stimulation of isoform 47 was near 
1:1, suggesting that the portion of protein that undergoes this phosphorylation is very small. 
However, in isoform 29 as much as 40% became phosphorylated after 2 minutes. Inexplicably, 
the ratio between the unmodified peptide after 5 minutes of EG F treatment and the control is 
3:2, suggesting that this peptide might be reversely modified in the control but such 
modifications could not be identified.
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Figute 38. Phospho-kinetics of Enolase-1
Distribution phosphorylation upon stimulation with EGF in different Enolase-1 isoforms. 
Each “worm” represents a peptide observed in the MALDI-TOF spectrum of the 
corresponding protein. Phosphorylation on different residues is indicated as —P. The name of 
the specific isoform analysed is indicated on the left.
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DISCUSSION
The focus of the work presented in this chapter was on Hsp8 and Enolase-1 analysis. A variety 
of their phospho-isoforms was covered in an attempt to understand the role that they play in 
response to EG F stimulation. The observations on the structures reported in the following 
paragraphs have been made in collaboration with Dr. Nicholas Keep.
Hsp8 phosphorylation
A large number o f heat shock proteins, which constitutes a major class o f proteins chaperones 
(described in chapter 1), were identified using the broader Phospho-SILAC approach. Due to 
the high sequence homology between Hsc70 and Hsp8 (more than 99%), considerations on 
function and structure reported for Hsp70/Hsc70 will be considered valid for Hsp8.
It has long been known that the family of Hsp70 undergoes autophosphorylation, and that the 
level of phosphorylation of some Hsp70 proteins in vivo is responsive to stress and other 
cellular conditions (Leustek et al. 1992). In some cases phosphorylation has been shown to 
increase the binding o f Hsp70 substrates (Sherman et al. 1993). Only recently Hsp70 proteins 
have been shown to be phosphorylated by PICA and that this provides an on /o ff switch for 
the regulation of protein phosphatase 2B signalling by Hsp70 (Lakshmikuttyamma et al. 2004). 
No records of exact phosphorylation sites are available.
Results presented in chapter 4 showed that Hsp8 is a potential target for MAPK and PKC 
kinase families. In this chapter the protein Hsp8 isoforms and their phosphorylation kinetics in 
different phosphorylation sites were analysed in more detail. All isoforms identified in this part 
of the analysis (the three most abundant) are phosphorylated on Thr38 (TP motif) in quiescent 
cells. In addition, a second site o f phosphorylation was found in the same domain. Ser40 only 
became phosphorylated within the first two minutes of stimulation, presumably to support the
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role of the phosphorylation o f Thr38. Both phosphorylations were removed after 5 minutes of 
EGF treatment. Unmodified proteins were present throughout the stimulation, suggesting that 
these changes only involved a fraction of the Hsp8 isoforms present in the cell. Unfortunately, 
it was not possible to quantify the fraction that became phosphorylated for each protein 
isoform, for two main reasons. First, identical phosphorylated peptides were not present in all 
Hsp8 spectra. Second, indirect quantification was not possible because the unmodified peptide 
peaks were overlapping with isotopic pattern of other peaks. Despite the limitations of the 
method encountered in this specific case, a high level of information was achieved: multiple 
Hsp8 isoforms were distinguished and different phosphorylation sites and relative kinetics 
were separately studied for each isoform.
An additional phosphorylation has been found on Thrl63, which is not in any of the substrate 
consensus screened in the previous experiment (see chapter 4). This residue became 
phosphorylated only after 5 minutes of stimulation with EGF. Interestingly, this activation 
seems isoform-dependent. Hsp8 isoform 2 did not become phosphorylated, one in ten 
molecules of Hsp8 isoform 3 became phosphorylated on Thrl63 after 5 minutes, and up to 
three in ten molecules of Hsp8 isoform 4 did the same. Different isoforms seemed to become 
phosphorylated in a wave, maybe to more finely modulate cellular processes.
In order to understand the functional meaning of these multiple phosphorylations the 
presented study should be completed with molecular and structural biology experiments. 
However, very good leads could be obtained by observing the Hsc70 structure. The 
commentary on this structure has been made in collaboration with Dr. Marialuisa Pellegrini- 
Calace.
All the modifications found in this study fall in the N-terminal of the ATPase domain (refer to
the introduction for more details on Hsc70/Hsp70 structure). Phosphorylations on Thr38 and
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Ser40 might influence the nucleotide exchange rate by stabilising the binding with ADP. As 
shown in Figure 39, the ADP is surrounded by two loops which stabilise the binding between 
ADP and the Hsp8 via H bonds between the NH of the backbone and the phosphates. 
Phosphorylation on both Ser40 and Thr38 might push the loop towards the ADP molecule, 
stabilising the binding and therefore favouring Hsp8 chaperoning activity. However, the 
accessibility o f these two peptides is very limited, and phosphorylation on these sites must 
imply a strong structural change (Figure 39). After five minutes of EGF treatment, these 
residues are dephosphorylated, possibly to allow the exchange of ADP for ATP, as the 
dephosphorylated form o f the protein seems to favour the ATP binding. Interestingly, only a 
portion of the protein is phosphorylated on Thr38 in resting cells, and the same portion 
probably becomes diphosphorylated within the first two minutes of stimulation. This is likely 
due to the fact that Hsc70s are highly expressed and play many roles in the cell; partial 
phosphorylation might define the portion available for short term stresses.
Thrl63 is on the surface of the ATPase domain, and its phosphorylation might influence 
binding with other proteins, or with the C-terminal part of the protein. It is not possible to 
analyse this further as a structure of the whole protein is not available.
In conclusion, the modifications on the N-terminal o f Hsp8 might influence its activity by 
regulation of the A D P/A TP exchange. In particular, when Hsp8 is phosphorylated the ADP 
bound form is favoured and the chaperoning activity is increased. This would result in 
activation of the signalling proteins previously found to be associated with Hsp8. After a few 
minutes of EG F treatment the ATP form is stabilised by removal of the phosphorylation on 
Hsp8 and the substrate released in its active form.
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Figure 39. Hsc70 structure lkax
The amino acids of interest have been highlighted. Top panels are an enlargement of the site 
of the protein binding ADP (left) and ATP (right). Bottom panel shows the whole ATPase 
domain of Hsc70 and T163 as a potential phosphorylation site and Ser381 which is the C- 
terminal of the structure.
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Enolase-1 involvement in EGF signalling
Enolase-1 is an enzyme of the glycolytic pathway, but has been long thought to have other 
roles, together with a few other glycolytic proteins. Twenty years ago it was shown that 
purified EG F receptor kinase phosphorylates Enolase-1 together with other key regulatory 
enzymes o f the glycolytic pathway, phosphofructokinase and glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), in an EGF-dependent manner (Reiss et al. 1986). A number of 
more recent works indicate that Enolase-1 (or MBP1, Myc-binding protein 1, an alternatively 
translated form of Enolase-1) is a transcriptional repressor of the oncogenic transcription 
factor Myc (Kim et al. 2004). MBP1 translocates into the nucleus and binds the regulatory 
region of the Myc gene and suppresses its expression (Ghosh et al. 1999) and Myc directly 
transactivates the gene encoding Enolase-1 (ENOl). However, the significance of 
phosphorylation in relation to the glycolytic or non-glycolytic functions of E N O l is unknown 
at present.
Enolase-1 was highly abundant and therefore could be analysed in depth. The three most 
abundant isoforms were analysed after Phospho-SILAC isolation. Three different 
phosphorylation sites were identified, though none o f them was in a consensus sequence TP, 
as expected. A transient phosphorylation on Seri 77 or Seri76 appeared after two minutes of 
EG F stimulation and was removed after five minutes of treatment. This phosphorylation 
seemed to be isoform specific, as it was found on two of the three isoforms. However, the 
portion of protein isoforms becoming phosphorylated was very different: less than 10% for 
one Enolase-1 isoform and up to 40% for the other. Another phosphopeptide identified was 
395-403; this peptide contained two phosphorylation sites, Thr395 and Ser401. Isoforms 47 
and 29 were monophosphorylated in untreated cells, and they became diphosphorylated within 
two minutes o f EGF treatment.
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It is very difficult to make hypotheses on the role of the phosphorylations found in this study 
because they do not fall in any of the functional sites, such as metal binding site or protein 
interaction sites. However, the residues of interests were located on the structure from a 
sequence with 83% identities and 90% positives This structure reports the whole protein as a 
homodimer (Chai et al. 2004) (Figure 40). Ser401 is pointing into the interface of the dimer, 
possibly regulating the affinity of the two subunits; in addition, overlapping the structures of 
the monomer and the homodimer shows that Ser401 is the amino acid that undergoes the 
strongest change. It is very difficult to determine the role of this residue during EGF 
stimulation; two isoforms out of three present a monophosphorylation in this region that 
could be attributed to either Ser401 or Thr395. Thr395 could easily accommodate a phosphate 
group, which could even stabilise the structure via a number o f favourable neighbours. 
Nevertheless, this amino acid is quite inaccessible, which suggests that the phosphorylation 
might be structural. Unfortunately, it is not possible to confirm that this phosphorylation is 
constitutive because the structures have been determined only from proteins expressed in 
bacteria. It seems that Thr395 phosphorylation is less likely to be functional compared to the 
Ser401 phosphorylation, and that the latter is probably connected to a signalling event. It could 
indeed cause dimer dissociation, and inactivation as glycolytic enzyme. However, it was not 
possible to quantify the changes, leaving most questions open.
Seri 77 (and not Seri 76) is conserved in the protein structure; this residue is engaged in 
stabilising the end of the helix and seems to be very accessible, although its function in 
destabilising this part of the structure under EGF induced phosphorylation (in an isoform 
specific way) is hard to predict. It becomes phosphorylated in two isoforms only at two 
different rates, but is already dephosphorylated after five minutes, suggesting that this 
phosphorylation is a rapid effect of the early stage of the stimulation. In Figure 40 the structure 
the three residues of interest discussed above is displayed.
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In conclusion, stimulation with EGF might cause dissociation of part of the Enolase-1 present 
in the cell, maybe in a negative regulation feedback, or as part of redox network regulation.
> Ser177i
Figure 40. Enolase-1 structure lte6
Top panel shows the whole structure with the amino acids of interest highlighted. Bottom 
panels are an enlargement of the site of the homodimer interface.
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CHAPTER 6
Phospho-SILAC strategy wider application in
signalling
INTRODUCTION
The aim of the work reported in this chapter was to screen the phosphoproteome for proteins 
that show changes in their PTMs in relation to the EGF signal and have not been highlighted 
by the use of antibodies. This study demonstrated that the Phospho-SILAC strategy can be 
independent from previous antibody based screenings and from the limitations associated with 
them.
A 2D gel obtained by mixing the phosphoprotein fractions from unstimulated and stimulated 
cell lysate was randomly analysed and protein spot were excised, processed and identified. This 
provided evidence of the value of the Phospho-SILAC strategy in signalling studies to find 
leads to key modifications.
Attention has been given to the signalling proteins. Considered the nature and the dynamics of 
its modifications, RhoGDI-1 was one of the most interesting signalling proteins found in the 
present SILAC screening. Two distinct Rab proteins were also identified, together with a 
typically neuronal signalling protein, collapsin response mediator protein (CRMP-2).
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RESULTS
Proteins from the whole phosphoproteome were analysed by SILAC/phospho-enrichment 
combination. Three hundreds spots were cut from a gel which contained phosphoproteins 
from control cells and phosphoproteins from stimulated labelled cells. The analysis was 
performed only for the first two minutes of stimulation with EG F as it has been shown that 
the activation of MAPK cascade lies within this time (chapter 4).
Forty proteins were selected and divided in different categories according to their role in the 
cell. The analysis of the data obtained is presented according to the class of proteins identified. 
Due to constant changes of accession numbers (Gi No) in the used non-redundant database 
(NCBI) each protein in the tables is accompanied by Gi No, the closest reference sequence 
(RefSeq) and the name of the corresponding gene, when known.
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Figure 41. Arg 0-2 gel
Enlargements of the gel obtained by mixing phosphoproteins from quiescent cells and 
proteins from cells stimulated for two minutes with EGF. Spots annotated were analysed.
Other chaperones
A whole section of these results is dedicated to chaperones proteins in the attempt of 
understanding a possible common behaviour between them and Hsp8, previously analysed. 14 
proteins belong to the class of chaperones proteins, and they are listed in Table 5. For spots 
26, 58, 127 and 134 no differences between the protein coming from the stimulated cells and 
the control were observed.
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spot
Proteins that act as
chaperones/mediators o f protein
folding
G iN o Refseq Gene Cov.
5 Heat shock protein 70kDa protein 4 24025637 NP_705893.1 Hspa4 28%
6 Heat shock protein 70kDa protein 4 24025637 NP_705893.1 Hspa4 15%
26 dnaK-type molecular chaperone grp75 precursor 2119726 156581 14%
58 Heat shock protein HSP90-beta (HSP84) 1346320 P34058 HSPCB 20%
59 Heat shock 70kD protein 5 (GRP78) 25742763 NP_037215 Hspa5 28%
60 Heat shock 70kD protein 5(GRP78) 25742763 NP_037215 Hspa5 43%
61 Heat shock 70kD protein 5(GRP78) 25742763 NP_037215 Hspa5 36%
62 Hscp70. Heat shock protein 8 13242237 NP_077327 Hspa8 21%
63 Hscp70. Heat shock protein 8 13242237 NP_077327 Hspa8 22%
64 Hscp70. Heat shock protein 8 13242237 NP_077327 Hspa8 28%
65 Hscp70. Heat shock protein 8 13242237 NP_077327 Hspa8 20%
127 T-complexl 6981642 NP_036802 Tcpl 25%
134 T-complexl 6981642 NP_036802 Tcpl 15%
Table 5. Proteins that act as chaperones/mediators of protein folding
Heat shock protein 4
Spots 5 and 6 contained the Heat shock protein 4 in different isoforms. Both spot 5 and spot 6 
contained a peak at 1492.9 m /z  corresponding to peptide 333-346 and a peak at 1498.9 m /z 
corresponding to the same peptide after stimulation. In addition, in both spectra there was a 
peak at 1658.8 m /z  corresponding to the same peptide 333-346 with 13C6 Arg plus two 
phosphorylations. As the phosphorylated peptide was not present in this protein in 
unstimulated cells, the amounts o f the unmodified peptide from same proteins in unstimulated 
and stimulated cells were compared instead. Interestingly, in spot 5 the ratio of the intensities 
of the peaks 1492.9 m /z  and 1498.9 m /z  was close to 1:1, suggesting that only few copies of 
the protein get phosphorylated, whilst in spot 6 it was as much as 30% (ratio of the intensities 
of the peaks 1492.9 and 1498.9 is 1.5). Furthermore, sample 5 contained a peak at 1757.8 and 
one at 1838.0 corresponding to peptides 170-185 and 170-185-P. Peptide 170-185 did not 
contain any arginine, therefore no conclusions could be made about the correlation between
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stimulation and phosphorylation, but this might contribute to the slight shift towards the more 
acidic pH compared to spot 6.
A scheme of the different peptides observed in the two isoforms of Hsp4, as well as its 
quantitative model, is represented in Figure 42.
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Figure 42. Phospho-kinetics of Hsp4
Distribution phosphorylation upon stimulation with EGF in different Hsp4 isoforms. Each 
“worm” represents a peptide observed in the MALDI-TOF spectrum of the corresponding 
protein. Phosphorylation on different residues is indicated as —P. The name of the specific 
isoform analysed is indicated on the left.
Heat shock protein 5
Spots 59, 60, and 61 contained the Heat shock protein 5 in different isoforms. In this case as 
well, the respective MALDI-TOF spectra were almost identical. Peptides 377-386, 377-386hR 
(at 1210.6 m /z and 1216.6 m /z  respectively) were present in the three spots. However, peptide 
377-386hR-P (1296.7 m /z) was only present in spots 59 and 60; this suggests that
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phosphorylation on Ser385 occurs selectively on some isoforms as a response to EGF 
stimulus.
The pair of peaks attributed to peptides 186-197 and 186-197hR (1217.6 m / 2  - 1223.6 m /2) 
were present in all three spots, whilst only the isoform in spot 59 contained 186-197 
monophosphorylated in unstimulated cells. Isoform in spot 60 kept the phosphorylation after 
stimulation and isoform 61 was not phosphorylated on this peptide at all. Phosphorylation on 
Thrl89 seemed to be related to each specific isoform, and its regulation upon EGF stimulus 
appeared to be selective.
Phosphorylation on Thrl89 behaved differently according to the isoform: it was present in 
Hsp5 isoform 59, not present at all in Hsp5 isoform 61, and present in a 1:1 (186-197P and 
186-197hP; at 1313.6 m / 2  and 1319.6 m /2) in Hsp5 spot 60. Phosphorylation on Ser385 was 
appearing after stimulation for isoforms 59 and 60 but not for 61. It was not possible to 
calculate the extent of phosphorylation indirectly, because the isotopic patterns of peaks 
corresponding to 186-197 and 377-386hR overlapped.
Peptide 563-573 (1316.6 m / 2) was present in all three spots, while 563-573PP (1476.6 m /2) 
was only present in spot 60. No conclusions could be drawn on the dynamics of 
phosphorylation upon stimulation because this peptide did not contain arginine, therefore 
these peptides are not included in the representation o f the dynamics of phosphorylation for 
all Hsp5 isoforms identified (Figure 43).
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Figure 43. Phospho-kinetics of Hsp5
Distribution of phosphorylation upon stimulation with EG F in different Hsp5 isoforms.
Each “worm” represents a peptide observed in the MALDI-TOF spectrum of the 
corresponding protein. Phosphorylation on different residues is indicated as —P. The name 
of the specific isoform analysed is indicated on the left.
Protein that act as metabolic enzymes
Nine spots corresponding to three different proteins were metabolic enzymes (Table 6). For 
proteins Pyruvate kinase and S-adenosylhomocysteine hydrolase no PTMs could be identified 
from their MALDI-TOF spectra, despite the high sequence coverage. Glucose 6-Phosphate 
dehydrogenase was present in two different isoforms, and although no changes upon 
stimulation could be seen, only spot 126 showed phosphorylation on Tyr361 and Thr362, (it
156
can not be assessed if this is regulated by EGF signal because this peptide did not contain any 
arginine).
Spot Protein that act as metabolic enzymes Gi N o Refseq Gene cov.
112 S-adenosylhomocysteine hydrolase 8392878 NP_058897 Ahcy 30%
113 S-adenosylhomocysteine hydrolase 8392878 NP_058897 Ahcy 40%
117 S-adenosylhomocysteine hydrolase 8392878 NP_058897 Ahcy 21%
126 Glucose6-phosphate dehydrogenase 204197 AAA41179 G6PD 29%
147 Glucose6-phosphate dehydrogenase 204197 AAA41179 G6PD 29%
189 Pyruvate Kinase, M2 isozyme 1346398 P11981 PKM2 33%
190 Pyruvate Kinase, M2 isozyme 1346398 P11981 PKM2 45%
200 Pyruvate Kinase, M2 isozyme 1346398 P11981 PKM2 44%
Table 6. Proteins that act as metabolic enzymes
Protein acting in cell motility
Proteins known to play a role in cells motility and structure are listed in Table 7. Gamma 
Actin, Septin2 and vimentin did not present any PTMs.
Spot Proteins involved in cell motility or structure Gi No Refseq Gene cov.
89 Gamma-actin. 809561 CAA31455 24%
116 Septin2 16924010 NP_476489 Sep-02 19%
13 Vimentin 14389299 N P_112402.1 Vim 35%
14 Vimentin 14389299 NP_112402.1 Vim 41%
Table 7. Proteins involved in cell motility or structure
Protein acting as signalling molecules
Four signalling proteins were identified (Table 8); of these RhoGDI-1 was present in two 
isoforms and showed one of the highest degrees of modification. The Signal Sequence 
Receptor delta does not contain any phosphorylation. Interestingly, RabGDI did not present 
any modifications either, suggesting a very different mechanism of regulation from RhoGDI.
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spot
Proteins that act as signalling 
molecules G iN o Refseq Gene Cov.
137 Collapsin response mediator protein 2(CRMP-2) 1351260 P47942 Dpysl2 33%
146 Collapsin response mediator protein 2(CRMP-2) 1351260 P47942 Dpysl2 22%
221 RhoGDI-1 1346398 NP_001007006 Arhgdia 62%
222 RhoGDI-1 1346398 NP_001007006 Arhgdia 46%
224
Rab6, member RAS oncogene 
family 13195674 NP_077249 Rab6 45%
228 Rabl, RAS-related protein 45433570 NP_112352 57%
33 RabGDI beta 1707891 P50399 GDI3 49%
295 signal sequence receptor 4(delta) 8394364 NP_058895 30%
Table 8. Proteins that act as signalling molecules
Collapsin response mediator protein
CRMP-2 was present in spots 137 and 146; only the isoform in 137 underwent 
phosphorylation on Thr74 after 2 minutes of stimulation with EGF (Figure 44). As for both 
isoforms the corresponding unphosphorylated peptide 64-75 was present in the spectra (peaks 
at 1294.7 m /z  and 1300.7 m /z), the ratio o f their corresponding peaks intensities before and 
after stimulation was calculated and the spectra normalised. In the isoform 137, the ratio of the 
unmodified peptide 64-74 from EGF treated cells to control cells was found to be 7:10. This 
indicated that 30% of this isoforms of CRMP-2 became phosphorylated on Thr74, 2 minutes 
after the cells have been stimulated with EGF. As expected, the ratio of the unmodified 
peptides 64-75 in isoform 146 was 1:1.
158
(64-75)x10 (64-75)x7 64-75
146
2' EGF
(6 4 -7 5 )x 1 (6 4 -7 5)x1
Figure 44. Phospho-kinetics of CRMP-2
Distribution phosphorylation upon stimulation with EGF in different CRMP-2 isoforms. 
Each “worm” represents a peptide observed in the MALDI-TOF spectrum of the 
corresponding protein. Phosphorylation on different residues is indicated as —P. The name 
of the specific isoform analysed is indicated on the left.
RhoGDI-1 was present in two adjacent spots. The coverage obtained was above 60% for both 
isoforms. A rg il7 and 172, which are expected to produce only very short tryptic peptides, 
were not observed in the present experiments. For peptides containing A rg lll , 152 and 180, 
pairs of arginine-containing peptides showed masses that were unexpected on the basis of the 
amino acid sequence o f RhoGDI-1, suggesting that these peptides carried additional post- 
translational modifications and some of these appeared to be other than phosphorylation. For 
this reason greater details are given on the analysis of both isoforms of RhoGDI. Comparison 
of the observed peptides with the exon structure of RhoGDI-1 showed that peptides were 
observed from all exons. This is good evidence that the full sequence of the protein was 
transcribed, even though only 66% of the sequence was covered by the tryptic peptides 
detected by MALDI-TOF MS (Figure 45). The experimental MW of about 30 kDa (theoretical 
23.5 kDa) was also consistent with translation of the full protein.
RhoGDI-1
RhoGDI-1: M A L D I-T O F  M S  analysis
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The two isoforms share the majority of the doublets. The doublet of peaks 1601.7 m /z -
1607.7 m /z  was assigned to the peptide 139-152 without any post-translational modifications. 
The doublet of peaks at 1629.8 m /z  - 1635.8 m /z  was assigned to dimethylated peptide 139- 
152. Peaks at 1454.8 m /z  and 1460.8 m /z  were assigned to peptide 100-111 and peaks at
1482.8 m /z  and 1488.8 m /z  were attributed to dimethylated peptide 100-111. Peaks at 952.5 
m /z  and 958.5 m /z  ions were assigned to dimethylated 173-180 peptide. No evidence was 
found for this peptide without methylation. Peaks at 1565.5 m /z  - 1571.6 m /z  were attributed 
to peptide 142-152 with four phosphorylations. Such a negatively charged peptide is very 
difficult to ionise, and it was not possible to confirm its identity by ESI for this very same 
reason. Nevertheless it is mentioned amongst the possible modifications found. Specifically 
found only in isoform 221 is the doublet at 1670.7 m /z  -1676.7 m /z , corresponding to peptide 
100-111 with a dimethylation and a diphosphorylation.
The isoform in spot 222 had two additional phosphopeptides specifically present only after 
EGF treatment. Despite the slightly lower coverage the following peaks were selectively 
present only in the spectrum of isoform 222: the peak at 1987.0 m /z  corresponding to peptide 
121-134 with three phosphorylations and the peak at 1234.6 m /z  corresponding to 
monophosphorylated 118-127. Interestingly, these peptides overlap on the sequence of the 
protein, confirming the phosphorylation on Seri 24. This is all summarised in Figure 46.
All peaks were confirmed to be part of doublets by comparison of the RhoGDI-1 spectrum 
from unlabelled cells.
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Figure 45. Summary of MS analyses of RhoGDI-1, spot 221
(A) Exon boundaries (solid rectangles) and Arg (open bars) or Lys (solid ovals) residues. (B) 
Unmodified peptides identified by MALDI-TOF MS. Open /  solid rectangles indicate 
peptides containing 12C /  13C arginine. Hatched rectangles indicate peptides cleaved at Lys. (C) 
Post-translationally modified peptides identified by MALDI-TOF MS and confirmed by 
MS/MS (see text).
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Figure 46. Phospho-kinetics of RhoGDI-1
Distribution o f phosphorylation upon stimulation with EG F in different RhoGDI-1 isoforms. Each “worm” represents a peptide observed in the 
M ALDI-TOF spectrum o f the corresponding protein. Phosphorylation on different residues is indicated as —P, while methylation is indicated by 
Me. The peptides highlighted in red correspond to the phosphopepti.de specific for each isoform. The name o f the specific isoform analysed is 
indicated on the left.
RhoGDI-1: E S I  M S / M S  analysis
ESI MS/MS analyses were performed to confirm the identity of the peptides and to assign the 
post-translationally modified residues (Table 9). Only the data from isoform 221 are reported: 
the most abundant spot was used for the analysis because only common peaks have been 
investigated.
The ion 1635.8 m /z  attributed to dimethylated peptide 139-152 was analysed as (MH+2)3+ 
(545.9 m /z). The identified sequence located the modification on Argl52; this was confirmed 
by sequencing the ion corresponding to the same peptide triply charged containing 12C6 Arg 
(Figure 48).
Argl80 was found to be present only in dimethylated form. Sequencing of the peptide 173-180 
analysing the 952.5 ion as (MH+1)2+ at 476.7 m /z, confirmed that the increase in mass of 
28Da was associated with a modification on Argl80 (Figure 49).
The dimethylated peptide 100-111 was sequenced by fragmentation o f the ions 1482.8 and
1488.8 m /z, doubly charged, (m /z= 494.9 and m/z=496.9) and the dimethylation of A rg lll 
confirmed (Figure 50, Figure 51). Peptide 100-111 containing both dimethylation and 
diphosphorylation was not sequenced because the phosphorylations could only be on Seri 01 
and Tyrl09.
It was not possible to sequence the tetraphosphorylated 142-152, probably because of its high 
negative charge.
The phosphorylation sites on 121-134 of RhoGDI-1 in spot 222 could not be uniquely 
located.
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Peptide 12C6 13C6 modifications parent charge isolated coverage
Arg Arg ion ion
A 139-152 X Arg dimethylation 1629.8 3+ 543.9 I D I< T D Y | M V G S Y G P R-
Me,
B 139-152 X Arg dimethylation 1635.8 3+ 545.9 I D K T D Y M V G s Y G P hR-
Me,
C 173-180 X Arg dimethylation 952.5 2+ 476.7 G S Y N I K s R-Me,
D 100-111 X Arg dimethylation 1482.8 3+ 494.9 Q s fJ V L K E G V E Y R-Me,
E 100-111 X Arg dimethylation 1488.8 3+ 496.9 Q s F V L | K E G V E Y hR-Me,
Table 9. Summary of the peptides of interest and correspondent ions selected for ESI M S/M S analysis of RhoGDI-1
The peptides analysed, the combination of modifications for each peptide, the molecular weight of the modified peptide, the charge of the 
ionised peptide, the corresponding m /z of the ion isolated and analysed, the coverage obtained are listed. For each peptide hR stands for 
13C labelled Arg; R-Me2 and K-Me2 stand for dimethylated arginine and lysine.
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Figure 47. ESI MS analysis of peptide A (as described in Table 9)
The ions belonging to the peptide are annotated in the spectrum and they are listed in the table, together 
with the theoretical values and the errors associated, expressed as difference in Da. A schematic 
representation of the peptide with the corresponding ions identified is reported on the top. For 
convenience the charge and the N H 3/H ,0  losses are not indicate in the spectrum and in the peptide 
scheme, but they can be found in the table. Me, is dimethylation.
fragment exper. Theor. A Da
a6-NH3 691.80 691.76 0.0
a82+ 469.50 470.04 0.5
a8 938.10 939.13 1.0
a92+ 499.00 498.59 -0.4
alO-
NH32+ 532.90 533.62 0.7
all-
NH32+ 614.50 615.21 0.7
al22+ 651.80 652.25 0.5
b5-H20 556.80 556.60 -0.2
b6 736.80 736.80 0.0
b82+ 483.30 484.07 0.8
b9-
NH32+ 503.10 503.59 0.5
b92+ 512.90 512.60 -0.3
b9 1006.20 1007.16 1.0
b l l2+ 636.50 637.73 1.2
bl22+ 665.90 666.25 0.4
bl2-
H20 2+ 704.90 705.80 0.9
bl32+ 714.60 714.81 0.2
y4 520.80 520.61 -0.2
y6 664.70 664.74 0.0
y9 1057.50 1058.25 0.8
ylO 1173.30 1173.34 0.0
yl32+ 758.40 758.86 0.5
yl3-NH3 1499.40 1499.70 0.3
ON
a 9  b 1 0  b11 b12
g | s | y | g I hR-Me
y13  y12
fragm ent exper. T h eor. A Da
a5 545.20 545.62 -0.4
a6 708.60 708.79 -0.2
a9 995.80 996.18 -0.4
a92+ 498.30 498.59 -0.3
al3 700.90 700.80 0.1
b2 229.00 229.12 -0.1
b3-H20 339.00 339.42 -0.4
b4-NH3 441.50 441.51 0.0
b6 736.30 736.80 -0.5
b7-NH3 850.60 850.97 -0.4
b8-NH3 949.80 949.12 0.7
blO 556.00 556.14 -0.1
b ll 1273.60 1274.44 -0.8
bl22+ 657.29 657.50 -0.2
Y1 209.30 209.30 0.0
y7-H20 751.90 751.91 0.0
y8-H20 882.10 883.11 -1.0
y9 1063.50 1064.30 -0.8
yl2-H?02+ 695.00 695.00 0.0
y !3 761.80 762.38 -0.6
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Figure 48. ESI MS analysis of peptide B (as described in Table 9)
The ions belonging to the peptide are annotated in the spectrum and they are listed in the table, together with the theoretical values and the errors 
associated, expressed as difference in Da. A schematic representation of the peptide with the corresponding ions identified is reported on the top. 
For convenience the charge and the N H3/H 20  losses are not indicated in the spectrum and in the peptide scheme, but they can be found in the 
table. Me2 is dimethylation, hR is 13C labelled Arg.
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fragment exper. theor. A Da
a62+ 318.50 318.34 0.2
b4-NH3 406.10 405.39 0.7
b5 534.50 535.58 -1.1
b6+H20 681.10 681.36 -0.3
b72+ 376.30 375.92 0.4
b7 751.20 750.80 0.4
b7-NH32+ 366.90 366.91 0.0
y2 290.10 290.34 -0.2
y3-NH3 401.70 401.49 0.2
y3 418.90 418.52 0.4
y4-H20 513.70 513.67 0.0
y5-NH3 628.70 628.75 0.0
y72+ 448.50 448.52 0.0
Figure 49. ESI MS analysis of peptide C (as described in Table 9)
The ions belonging to the peptide are annotated in the spectrum and they are listed in the table, together with the theoretical values and the errors 
associated, expressed as difference in Da. A schematic representation o f the peptide with the corresponding ions identified is reported on the top. 
For convenience the charge and the N H 3/H 20  losses are not indicated in the spectrum and in the peptide scheme, but they can be found in the 
table. Me2 is dimethylation.
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fragment exper. theor. A Da
a4 434.20 434.52 -0.3
a5 547.32 547.68 -0.4
a6-NH3 658.39 658.82 -0.4
a72+ 402.73 402.99 -0.3
a8-NH3 844.46 844.99 -0.5
a8-NH32+ 424.00 423.00 1.0
a9-NH32+ 472.27 472.57 -0.3
a92+ 480.78 481.08 -0.3
al02+ 545.30 545.64 -0.3
all-N H 32+ 619.00 618.71 0.3
b4 462.24 462.53 -0.3
b5 575.32 575.69 -0.4
b6-NH3 686.39 686.83 -0.4
b72+ 417.70 417.00 0.7
b7-NH3 815.43 815.90 -0.5
b8 889.48 890.03 -0.5
b9-NH3 486.26 486.57 -0.3
bl0-H2O 1099.58 1100.27 -0.7
b ll+ H 20 2+ 649.84 650.24 -0.4
y3 495.26 495.50 -0.2
y82+ 511.29 511.60 -0.3
yl02+ 634.36 634.76 -0.4
y ll2+ 677.87 678.30 -0.4
m/z
Figure 50. ESI MS analysis of peptide D (as described in Table 9)
The ions belonging to the peptide are annotated in the spectrum and they are listed in the table, together with the theoretical values and the errors 
associated, expressed as difference in Da. A schematic representation o f the peptide with the corresponding ions identified is reported on the top. 
For convenience the charge and the N H 3/H 20  losses are not indicated in the spectrum and in the peptide scheme, but they can be found in the 
table. Me2 is dimethylation.
b3 b6
a 
b7
y8
800
J.., rl X
1000
I.
m / z
I J U b J  
1200
ylG
fragment exper. theor. A Da
a3 334.90 335.39 -0.5
a8-NH32+ 422.80 423.00 -0.2
b2-NH3 199.20 199.19 0.0
b3 363.20 363.40 -0.2
b62+ 352.50 352.44 0.1
b7-NH32+ 408.10 408.48 -0.4
b92+ 496.40 495.09 1.3
blO- 549.90 550.64 -0.7
H20 2+
b ll 671.70 672.81 -1.1
y4 600.03 600.74 -0.7
y82+ 514.30 514.63 -0.3
y92+ 564.80 564.19 0.6
ylO 1273.90 1274.56 -0.7
y i i 1361.30 1361.63 -0.3
Figure 51. ESI MS analysis of peptide E (as described in Table 9)
The ions belonging to the peptide are annotated in the spectrum and they are listed in the table, together with the theoretical values and the errors 
associated, expressed as difference in Da. A schematic representation of the peptide with the corresponding ions identified is reported on the top. 
For convenience, the charge and the N H 3/H ,0  losses are not indicated in the spectrum and in the peptide scheme, but they can be found in the 
table. Me2 is dimethylation, hR is 13C labelled Arg.
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RhoGDI-1: Immunofluorescence study
In an attempt to clarify the role of the modifications in RhoGDI, immunofluorescence studies 
were performed to ascertain if PTMs would alter cellular location and the degree of overlap of 
GDI with Rac and RhoA, indicative of the binding.
The cytosolic distribution of RhoGDI-1 has been widely observed before (Gibson et al. 2001; 
Koch et al. 1997; Shisheva et al. 1994), however no immunofluorescence has been performed 
early on in EGF stimulation.
Interestingly RhoA and Rac showed a different distribution within the cell, and this is 
independent from EGF stimulation. Rac seemed to be concentrated around the cell membrane 
and can be seen in ruffles in accordance to published work (Topp et al. 2004) (Figure 53). 
RhoA was spread equally in the cytosol. However, no apparent changes in GDI location could 
be detected (Figure 52).
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Rho G D 11 RhoA o ver lap
EGF O'
EGF 2'
EGF 10'
Figure 52. RhoGDI-RhoA immunofluorescence
The first column represents the green channel, corresponding to the staining with RhoGDI-1 
antibody, the second column is the red channel, corresponding to RhoA antibody staining, 
and the third column is an overlap of the two. Each row corresponds to cells stimulated for 
the indicated times.
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R h o G D M  Rac o v e r la p
EGF O'
EGF 2'
»;
EGF 10'
Figure 53. RhoGDI-Rac immunofluorescence
The first column represents the green channel, corresponding to the staining with RhoGDI-1 
antibody, the second column is the red channel, corresponding to Rac antibody staining, and 
the third column is an overlap of the two. Each row corresponds to cells stimulated for the 
indicated times.
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Rab6 and Rab1
Rab6 and RAS-related proteins (similar to Rabl) showed phosphorylation. Rab6 was already 
partially phosphorylated on peptide 54-60 in quiescent cells, (corresponding peak at 1023.6 
m /z) and remained so after the stimulation (1029.6 m/z). RAS-related protein was partially 
phosphorylated before and after the stimulation in a similar way to Rab6 and in the same N- 
terminal region. A doublet at 1070.5 m /z -1076.5 m /z  corresponding to monophosphorylated 
72-79 was found. An additional diphosphorylated peptide present only in quiescent cells was 
also identified (1453.7 m /z  corresponding to 70-79). The following scheme represents both 
proteins (Figure 54).
224
(54-60)x10 (54-60)x10
2' EGF
(54-60)x1 (54-60)x7
228 2' EGF
(72-79)x10 (72-79)x10 70-79 (72-79)x6 (72-79)x7
Figure 54. Phospho-kinetics of Rabl and Rab6
Distribution of phosphorylation upon stimulation with EG F in different Rab proteins, Rab6 
(224) and similar to Rabl (228). Each “worm” represents a peptide observed in the MALDI- 
TOF spectrum of the corresponding protein. Phosphorylation on different residues is 
indicated as —P. The name of the specific isoform analysed is indicated on the left.
Proteins involved in protein synthesis
Seven different proteins involved in protein synthesis were found (Table 10). For most of 
those no phosphorylations could be identified. For the protein contained in spot 87 only one 
monophosphorylated peptide was recognised (369-381, at 1513.7 m/z), but it did not contain
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any arginine. It can only be suggested that this protein is phosphorylated on Thr377, but no 
connections of this event to the EGF signal can be made.
spot Proteins involved in protein synthesis G iN o Refseq Gene Cov.
87
Similar to Eukaryotic initiation factor 
4A-I 40786436 NP_955404 50%
151 Aspartyl-tRNA synthetase 16758642 NP_446251 Dars 13%
16
ATP synthase, H + transporting, 
mitochondrial FI complex, beta 
subunit 54792127 NP_599191 Atp5b 36%
243 Acidic ribosomal protein P0 11693176 NP_071797 Arbp 50%
44 Elongation factor 2 119176 P05197 EEF2 18%
119 Similar to Elongation factor 1-gamma 34861590 XP_215165
LOC2
93725 25%
81 RuvB-like protein 2 6755382 NP_035434 Ruvbl2 24%
Table 10. Proteins involved in protein synthesis
ATP synthase beta and RuvB-like protein 2
Interesting behaviour was observed for ATP synthase beta. One phosphopeptide was 
identified: peptide 242-254 is present diphosphorylated (at 2221.1 m /z) but it does not contain 
arginine, therefore no conclusion on the kinetic of these phosphorylations can be made. A 
third phosphorylation in response to EGF stimulus was found (peptide 240-254, at 2564.0 
m /z), and could be associated with the missed cleavage on Arg241.
RuvB-like protein 2 showed a single phosphorylation upon stimulation on 428-438 (428- 
438hR-P peak at 1476.7 m /z). The missed cleavage on Arg428 suggests that the 
phosphorylation might be close to it (maybe Tyr430).
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429-438
429-438 428-438
Figure 55. Phospho-kinetics of synthesis related proteins
Distribution of phosphorylation upon stimulation with EGF of ATPsynthase beta (16) and 
RuvB-like protein 2 (81). Each “worm” represents a peptide observed in the MALDI-TOF 
spectrum of the corresponding protein. Phosphorylation on different residues is indicated as 
—P. The name of the specific isoform analysed is indicated on the left.
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DISCUSSION 
Proteins involved in EGF signalling, not recognised by kinase 
substrate antibodies
The Phospho-SILAC method was applied to a wide range of proteins in order to investigate 
common behaviours in different classes of proteins upon stimulation with EGF.
Three enzymes, each present in 2-3 isoforms, and three structural proteins with up to two 
isoforms were identified, but despite the high coverage obtained no modifications could be 
found. All these proteins have been extracted using the phosphoprotein enrichment protocol 
(chapter 3), so they are likely to have at least a certain level of basal phosphorylation. However, 
no phosphopeptides were seen, and no unmodified peptides deviated from the 1:1 ratio, 
suggesting that none of the peptides identified could be a potential carrier. The 
phosphorylation must lie in the part of the protein which was not detected by MALDI-TOF 
MS. This seems particularly true for proteins like actin, which is known to undergo 
rearrangement and phosphorylation. Another point to be made is that these proteins are very 
abundant and therefore very low levels o f phosphorylation (below 10%) would not be 
detectable.
A range of interesting data was obtained for the subset of signalling proteins identified; this is 
due not only to the fact that these proteins are expected to be involved in the signalling 
through their phosphorylation, but also because they are generally smaller, and a larger 
coverage could be obtained.
Different chaperones, same phosphorylation site
The family of chaperones has proved very interesting and has been extensively discussed in
previous chapters. A total of 13 analysed spots contained chaperones (including Hsp8), two
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were found to be Hsp4 and three Hsp5. In short, Hsp4 and Hsp5 underwent phosphorylation 
changes upon EGF treatment, but not in sites recognised by the antibody used in the initial 
screening of the NRK49F phosphoproteome (chapter 4). Other chaperones did not present 
any changes in the first two minutes of stimulation.
All these proteins belong to the Hsc70/Hsp70 family, and have been aligned so that their level 
of similarity could be visualised (Figure 56). The Thr38, found to be phosphorylated in Hsp8, 
is conserved in the three proteins (together with the P in +1, creating the consensus for 
CDK/MAPK). However, Thr38 has been found to be phosphorylated only in Hsp8, which 
explains why only this protein is recognised by the antibody against phosphorylated substrates 
of MAPK. Hsp8 is also phosphorylated on Thrl63, which is aligned with Thrl89 in Hsp5. 
These two residues have both been found to be phosphorylated in this study, although with 
different dynamics. In addition, it needs to be stressed that the close surrounding of these 
proteins is identical, but the whole tryptic peptide is not, leading to two different masses in the 
two spectra analysed and giving more relevance to the attribution of this phosphorylation.
Another general conclusion is that all proteins identified belonging to the family of 
Hsc70/Hsp70 present differential phosphorylation in the N-terminal of the ATPase domain, 
suggesting that the regulation of the activity happens primarily in this domain.
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Hsp8 --------------------------------------------------------------------------------------------MSKGPAVGIDLGTTYSCVGVFQHGKV 26
Hsp5 MKFTVVAAALLLLCAVRAEEEDKKEDVGTVVGIDLGTTYSCVGVFKNGRV 50
Hsp4 --------------------------------------------------------------------------------------------------------MSWGIDLGFQSCYVAVARAGGI 23
k k k k k k  ^ k  ^k • k •
Hsp8 EIIANDQGNRTTPSYVAFT-DTERLIGDAAKNQVAMNPTNTVFDAKRLIG 75
Hsp5 EIIANDQGNRITPSYVAFTPEGERLIGDAAKNQLTSNPENTVFDAKRLIG 100
Hsp4 ETIANEYSDRCTPACVSFG-PKNRSVGAAAKSQVISNAKNTVQGFKRFHG 72
k k kk • # *  *  *  1 k  • k • *  • *  k k k  ^k •  k k k k  ^ k
Hsp8 RRFDDAVVQSDMKHWPFMWNDAGRPKVQVEYKG-ETKSFYPEEVSSMVL 124
Hsp5 RTWNDPSVQQDIKFLPFKWEKKTKPYIQVDIGGGQTKTFAPEEISAMVL 150
Hsp4 RAFSDPFVEAEKSNLAYDIVQLPTGLTGIKVTYMEEERNFTTEQVTAMLL 122
* .  * * .  .  .  .  * * . . . . * . *
Hsp8 TKMKEIAEAYLGKTVTNAWTVPAYFNDSQRQATKDAGTIAGLNVLRIIN 174
Hsp5 TKMKETAEAYLGKKVTHAWTVPAYFNDAQRQATKDAGTIAGLNVMRIIN 200
Hsp4 SKLKETAESVLKKPVVDCWSVPSFYTDAERRSVMDATQIAGLNCLRLMN 172
.  *  .  *  * *  *  .  *  *  * * * . * * . . .  * . . * . .  * * ***** . * . . *
Hsp8 EPTAAAIAYGLDK----- KVGAERNVLIFDLGGGTFDVSILTIEDGIFEV 219
Hsp5 EPTAAAIAYGLDK----- REG-EKNILVFDLGGGTFDVSLLTIDNGVFEV 244
Hsp4 ETTAVALAYGIYKQDLPALEEKPRNVVFVDMGHSAYQVSVCAFNRGKLKV 222
k ' kk ' k»kkk»  k • k •• k • k •••k k • • • •  k • • k
Hsp8 KSTAGDTHLGGEDFDNRMVNHFIAEFKRKHKKDISENKRAVRRLRTACER 269
Hsp5 VATNGDTHLGGEDFDQRVMEHFIKLYKKKTGKDVRKDNRAVQKLRREVEK 294
Hsp4 LATAFDTTLGGRKFDEVLVNHFCEEFGKKYKLDIKSKVRALLRLSQECEK 272
.* ** *** **. ...** .  ; *  * ;  * * .  . *  * .
Hsp8 AKRTLSS-STQASIEIDSLYEGIDFYTSITRARFEELNADLFRGTLDPVE 318
Hsp5 AKRALSS-QHQARIEIESFFEGEDFSETLTRAKFEELNMDLFRSTMKPVQ 343
Hsp4 LKKLMSANASDLPLSIECFMNDIDVSGTMNRGKFLEMCDDLLARVEPPLR 322
* .  . * .  .  * .  • • *  . * * .  * * .  * .
Hsp8 KALRDAKLDKSQIHDIVLVGGSTRIPKIQKLLQDFFNGKELNKSINPDEA 368
Hsp5 KVLEDS DLKKSDIDEIVLVGGSTRIPKIQQLVKE FFNGKEPS RGINPDEA 393
Hsp4 SILDQSKLKKEDIYAVEIVGGATRIPAVKEKISKFFG-KELSTTLNADEA 371
*  I  I  • * * * • •  *  I *kkk»kkkk  • • •  • k k k k • k k k k
Hsp8 VAYGAAVQAAILSGDKSENVQDLLLLDVTPLSLGIETAGGVMTVLIKRNT 418
Hsp5 VAY GAAVQAGVLSGD— QDTGDLVLLDVCPLTLGIETVGGVMTKLIPRNT 441
Hsp4 VTRGCALQCAILSPAFKVRE FSITDWPYPISLRWNSPAEEGSS DCEVFP 421
* .  * > * . * > > . * *  .  .  * . . *
Hsp8 TIPTKQTQTFTTYSDNQPGVLIQVYEGERAMTKDNNLLGKFELTGIPPAP 468
Hsp5 WPTKKSQIFSTASDNQPTVTIKVYEGERPLTKDNHLLGTFDLTGIPPAP 491
Hsp4 KNHAAPFSKVLTFYRKEPFTLEAYYSSPQDLPYPDPAIAQFSVQKVTPQS
• k • • k  k • •  • * k * • k
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Hsp8 RG-VPQIEVTFDIDANGILNVS -----------------------------------------------------------------AVDKSTGKENK 500
Hsp5 RG-VPQIEVTFEIDVNGILRVT -----------------------------------------------------------------AEDKGTGNKNK 523
Hsp4 DG S S S KVKVKVRVNV HGIFSVS SAALVEVHKSEESEEPMETDQNAKEEEK 521
*
Hsp8 ITITNDK ----------------------------------------------------------------------------------------------------------------------------------------------------------------------- 507
Hsp5 T T T T M n O  _ 530X  1 X  I  IN L » v
Hsp4 MQVDQEEPHTEEQQPQTPAENKAESEEMETSQAGSKDKKMDQPPQAKKAK 571
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Hsp8 ----------------- GRLSKEDIERMVQEAEKYKAEDEKQRDKVSSKNSL 542
Hsp5 ----------------- NRLTPEEIERMVNDAEKFAEEDKKLKERIDTRNEL 565
Hsp4 VKTSTVDLPIESQLLWQLDREMLGLYTENEGKMIMQDKLEKERNDAKNAV 621
. * * . . . * . * ...........* •
Hsp8 ESYAFNMKATVED------------------------- 555
Hsp5 ESYAYSLKNQIGDK----------------------- 579
Hsp4 EEYVYEMRDKLSGEYEKFVSEDDRNNFTLKLEDTENWLYEDGEDQPKQVY 
* * . . .
671
Hsp8 ---------------- EK 557
Hsp5 581
Hsp4 VDKLAELRTLGQPIKTRFQESEERPKLFEELGKQIQQYMKVISSFKNKED
*
721
Hsp8 LQGKINDEDKQKILDKCNEIISWLDKNQTAE--- ---------- KEEFEHQ 595
Hsp5 LGGKLSPEDKETMEKAVEEKIEWLESHQDAD--- ---------- IEDFKAK 619
Hsp4 QYEHLDAADMTKVEKSTNEAMEWMNSKLNLQNKQSLTADPWKTKEIEAK 
* • : : : : : :
771
Hsp8 QKELEKVCNPIITKLYQ-------------------- --SAGGMPGGMPGGFP 626
Hsp5 KKELEEIVQPIISKLYG-------------------- --SGG------------- 639
Hsp4 IKELTNICSPIISKPKPKVEPPKEEPKHAEQNGPVDGQGDNPGTQAAEHG 821
★ 'k •k •• ★ ★ ★ • ★ *
Hsp8 GGGAPPSGGASSGPTIEEVD 64 6
Hsp5 ---- PPPTGEEDTSEKDEL- 654
Hsp4 ADTAVPSDGDKKLPEMDID- 84 0 
★ ★ •
Figure 56. Protein sequence alignment of Hsp8, Hsp5 and Hsp4
Residues in red have been found to be phosphorylated, and the phospho-residues common to 
different isoforms were further highlighted in yellow. In green, the ATPase domain; in blue the 
sequence recognised by TPR-containing cochaperones. Alignment obtained using Clustal W 
1.82 with default settings.
Proteins involved in protein synthesis
ATP synthase beta is the catalytic subunit of ATP synthase producing ATP from ADP in 
presence of a proton gradient across the mitochondrial membrane (Vendemiale et al. 1995). 
No connection at the level of PTMs has yet been made with EGF signalling, although some 
observations relate long treatment with nafenopin to decreased the expression of ATP 
synthase beta (Chevalier et al. 2000). The general architecture of the enzyme is conserved 
among species; in E.Coli this consists of a globular catalytic moiety F(l) (corresponding to 
beta), protruding out of the inner side of the membrane, a membrane integral proton 
translocating moiety F(o) (alpha), and a stalk connecting F(l) to F(0) (Gaballo et al. 2002).
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The most closely related structure is lm ab (rat liver Fl-ATPase). The amino acids of interest 
are all conserved. All the residues found to be phosphorylated lie on the surface of the protein. 
In particular Tyr247 establishes intra-molecular interactions, but is also close to the subunit 
alpha and could easily host a phosphate moiety. Ser253 is exposed, but very distant from the 
membrane domain. The residue that can most likely influence the binding with the alpha 
subunit is Thr240 when phosphorylated.
Ruv2-like protein is a DNA Helicase, and although much is known about it, no clear 
connections with EGF signalling have been made. However, phosphorylation has been 
observed in the xeroderma pigmentosum group B (XPB) helicase, involved in nucleotide 
excision repair (NER) and transcription. The Ser751 residue of XPB was found to be 
phosphorylated in vivo and this phosphorylation was shown to inhibit DNA repair (Coin et al.
2004). Structures are available for the catalytic domains of the RuvB2-like protein but not for 
the C-terminal region where a potential phosphorylation on Tyr430 is placed.
Signalling proteins
Seven spots were identified as signalling proteins, namely Collapsin Response Mediator Protein 
2, two members of Rab protein family, RabGDI beta and RhoGDI-1.
Collapsin response mediator protein^RMP-2^ which also has been independently identified as 
Ulip2/CRMP-62/TOAD-64/DRP-2, is one of at least five isoforms (Arimura et al. 2004; 
Goshima et al. 1995). CRMP-2 is known to be expressed exclusively and highly in the 
developing nervous system and shows the ability to convert immature neurites and preexisting 
dendrites to axons. A discussion with Dr. Goshima has highlighted the possibility that this 
protein is present in lung epithelial cells (Ito et al. 2000; Kagoshima et al. 2001). His recent 
observations suggest that CRMP-2 has roles in cell polarity as well as in mediating external
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signals could play a role in fibroblasts as well. A large complex including atypical protein 
kinase C (aPKC) complex accumulates at the tip of the axon, and its polarised localisation and 
aPKC activity are important for axon specification (Shi et al. 2003). aPKC can also 
phosphorylate GSK-3[3 and inactivate its kinase activity, and GSK-3P is important for 
polarisation of migrating fibroblasts (Etienne-Manneville et al. 2003). CRMP-2 is 
phosphorylated in the brain by Rho-kinase on Thr555 (Arimura et al. 2004) and 
phosphorylation on Thr509, Ser522 and Ser518 has also been reported in relation with 
Alzheimer disease (Gu et al. 2000). However, in fibroblasts CRMP-2 is not phosphorylated on 
Ser522 upon stimulation with EGF (data not shown). Very recendy, it has been shown that 
GSK-3p participates in neuronal polarisation through CRMP-2 by phosphorylation of CRMP- 
2 at Thr514. NT-3 and brain-derived neurotrophic factor (BDNF) inhibit GSK-3P via the 
phosphatidylinositol-3-kinase (PI3-kinase)/PKB pathway, thereby reducing phosphorylation 
levels of CRMP-2 at Thr514, leading to axon elongation and branching (Yoshimura et al.
2005). In a recent review a model has been built that inserts CRMP-2 as a crucial signal protein 
in the growth factor signalling for axon development.
RhoGDI-1
Arginine methylation of RhoGDI-1 has not been previously reported. The present results 
suggest that RhoGDI-1 is partially dimethylated on A rg lll and 152 and fully dimethylated on 
Argl80. In fact, for A rg lll and Argl52 both unmodified and dimethylated forms were 
observed. For Argl80, the boundaries of the tryptic peptides were such that definite evidence 
for the dimethylated forms was obtained, but not for the unmodified residues. Comparison of 
the labelled and unlabelled peptides shows that the ratio for methylated peptides fluctuates 
around the value of 1:1, independently from EGF treatment. This indicates that stimulation
181
with EGF has no substantial effect on dimethylation of the arginine residues 111, 152 and 180 
at short times.
For both isoforms multiple phosphorylations on the peptide 142-152 was observed equally 
before and after stimulation with a ratio close to 1:1.
However, only isoform 222 presented phosphorylation on Seri 24 and two additional 
phosphorylations on two of the following residues: Tyrl28, Thrl32 and Tyrl33. At the same 
time isoform 222 showed diphosphorylation on methylated 100-111, on SerlOl and TyrllO, 
which seemed to decrease slightly upon stimulation.
The only other residues known to be phosphorylated in RhoGDI-1 are SerlOl and Serl74. 
Very recently, it has been shown that phosphorylation of both SerlOl and Serl74 by the kinase 
Pak-1 leads to dissociation of Rac/RhoGDI-1 complexes, but not of RhoA/RhoGDI-1 
complexes (DerMardirossian et al. 2004). SerlOl and 174 are both located away from the 
Rac/RhoGDI-1 interaction surface and can apparently be phosphorylated in the complex, so 
that the mechanism of dissociation is not entirely clear (DerMardirossian et al. 2004). This 
phosphorylation will be isoform-specific since the two serines are changed to threonine in 
RhoGDI-2 and to Val and Pro in RhoGDI-3. Phosphorylation of SerlOl/174 by Pak-1 and 
dissociation of Rac/RhoGDI-1 complexes was reported following stimulation of HeLa cells 
with EGF (DerMardirossian et al. 2004). In the present experiments only phosphorylation on 
SerlOl was observed, although with different dynamics, and in the presence of dymethylation 
and an additional phosphorylation on TyrllO. This suggests that for EGF stimulation, 
downstream pathways involving RhoGDI-1 may be dependent on the cell type.
A crude examination was performed to understand if the PTMs on RhoGDI-1 could result in a 
change in cellular location upon stimulation. Both GDI and GTPases are widely present in the
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cytosol and no changes could be visualised upon stimulation. This is probably due to the fact 
that only a small fraction of GTPases and RhoGDI-1 is involved at any time in signalling.
The post-translational modifications observed are in agreement with the known structure and 
functional roles of RhoGDI-1. The structure of RhoGDI-1 consists of a C-terminal 
immunoglobulin-like domain with a pocket that binds the geranyl-geranyl modification at the 
C-terminus and a flexible N-terminus which becomes helical on interaction with Rho family 
proteins (Gosser et al. 1997; Keep et al. 1997). The structures of four complexes of RhoGDI-1 
with Rho family proteins have been solved by X-ray crystallography. These vary in how well 
the flexible 59 residue N-terminus of RhoGDI-1 and the C-terminal basic and isoprenylated 10 
residue region of the G-protein are resolved. RhoGDI-1 with Racl (PDB 1HH4) (Grizot et al. 
2001) has two copies of the complex, in both cases some density for the geranyl-geranyl group 
is seen, but it is not fully connected to the C-terminus of the Rho protein. Cdc42 (PDB ldoa) 
(Hoffman et al. 2000) has the best defined C-terminus of the G-protein with full connectivity 
for the C-terminal methylated cysteine and the geranyl-geranyl group. Both these structures 
have more or less the full RhoGDI-1 resolved. A low resolution structure with RhoA (PDB 
lccO) (Longenecker et al. 1999) shows neither the N-terminus of RhoGDI-1 nor the C- 
terminal part of RhoA. The structure of Rac-2 with RhoGDI-2 (PDB lds6) (Scheffzek et al. 
2000) shows some of the N-terminus of RhoGDI-1 but did not resolve the isoprenylation 
region of the G-protein.
The sites of the present modifications can be mapped onto the above mentioned structures. 
Seri 48 lies in the interface between the G-protein and the GDI, where it forms a hydrogen 
bond to a side chain nitrogen of His 104 of the Rac or Cdc42 G—proteins. Phosphorylation 
would disrupt this interaction. In RhoA this histidine is not conserved, suggesting that 
phosphorylation of Seri 48 may help RhoGDI-1 to discriminate amongst Rho family members.
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Tyrl44 hydrogen bonds to Argl86 of Cdc42 two residues away from the geranyl-geranylated 
C-terminal cysteine. This area of the Rho family of G-proteins is rich in basic residues and the 
most variable between family members. The phosphorylation sites thus have the potential to 
alter the stability of the G-protein/GD I complex, potentially in an isoform-specific manner. In 
the two different copies in the Racl /RhoGDI-1 crystal structures, different basic residues 
Lysl88 and Argl87 (1 and 2 residues from the C-terminus respectively) are close to Tyrl44, 
but further than hydrogen bonding distance. This area is unresolved in the other two 
structures. The effect o f phosphorylation could potentially either increase the affinity for the 
basic residues or decrease the affinity by disrupting hydrogen bonding interaction to the same 
basic residues. Tyrl44 is a phenylalanine in RhoGDI-2, therefore this phosphorylation may 
discriminate amongst RhoGDI-1 isoforms.
Thrl42 interacts directly with Argl86 of Cdc42 (PDB ldoa), and in this case as well a 
phosphorylation might have a strong influence in lowering the binding; Seri 48 is bound to 
have very much the same effect. Tyrl49 does not interact directly with the GTPase, but its 
phosphorylation very likely strengthens the phosphorylation effect of Seri 48. A dimethylated 
arginine was identified at the C-terminal of the corresponding tryptic peptide.
Interesting modifications were also observed in a different portion of the protein. TyrllO is 
tightly inserted in the geranyl-geranyl pocket and its phosphorylation might inhibit the entrance 
with the geranyl-geranyl group and the binding as a consequence. Very interestingly, next to 
this phosphorylation site dimethylated A rg lll was identified. This is pointing to the surface 
but is over 7 A from the nearest RhoGDI-1 atom. SerlOl was already known as a functional 
phosphorylation site in RhoGDI-1, although the position in the structure does not appear to 
be immediately related to the interaction between the two proteins.
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A set of phosphorylation was found to be switched on after stimulation, and was specific for 
one of the two isoforms of RhoGDI. Seri24 is very close to the interface with the Rho 
protein, and establishes a long interaction with Arg66 of Cdc42. Phosphorylation on Seri 24 
most certainly changes the affinity of the binding, although it is not possible to predict in 
which direction. Supporting the importance of Seri 24 interaction with Arg66, it has been 
shown that R66E Cdc42 mutants fail to form a complex with GDI (Gibson et al. 2001).
Tyrl28 and Thrl32 (better candidates than Thrl33) synergically bind the geranyl-geranyl of the 
G-protein bound, and their phosphorylation is likely to push the isoprenic tail towards the 
surface favouring membrane binding and GDI dissociation.
Modification of this residue might alter the affinity in a non-isoform specific manner. The 
arginine methylations are located in beta sheets of RhoGDI, are entirely surface exposed, and 
do not point into the interface. This suggests that methylation of the arginine residues may be 
controlling the interactions with different phosphokinases and/or other proteins that influence 
the physiological roles of RhoGDI.
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Figure 57. RhoGDI-1 in complex with Cdc42 structure ldoa
Geranyl-geranyl is in brown, GDP in green. The top panel represent enlargements of the 
same structure with the residues of interest annotated. Potentially phosphorylated residues on 
RhoGDI-1 are in blue, dimethylarginines in red. Interacting residues on Cdc42 are in pink.
186
Rab proteins
The role of the phosphorylation in Rab proteins regulation is not yet clear. Although many 
members of the Rab family have been shown to be phosphorylated (Bailly et al. 1991; 
Fitzgerald et al. 1999), no record of phosphorylation of RabGDI three isoforms are available. 
This has been confirmed in this study: Rabl is phosphorylated at the interface of the 
interaction with GDI, whilst GDI remains unphosphorylated, or at least has a very low level of 
basal phosphorylation.
A number of Rab proteins structures and their complexes with GDI have recently become 
available (An et al. 2003; Rak et al. 2003).
1UKV_Y is the structure based on the closed sequence to Rabl (spot 228) (Chain Y, Structure 
of RabGDI in complex with Rab prenylated Yptl GTPases-the yeast counterpart of Rabl). 
The homology between the two sequences is 81%, and all the residues of interest are 
conserved. As shown in Figure 58, all possible phosphorylated residues are aligned along the 
interface between Rab and RabGDI and do not interfere with the binding to GDP. All 
potential amino acids are accessible and mobile and they are likely to play a role in the strength 
of the complex with RabGDI rather than interacting with GDP molecule. Particularly, in 
quiescent cells there is a mixture of diphosphorylated peptide 70-79 and monophosphorylated 
peptide 72-79. The fact that diphosphorylation might be connected with inhibition of cleavage 
on Arg71 suggests that Thr72 is a stronger candidate. After stimulation, however, there was a 
lower level of monophosphorylated and unmodified peptide while diphosphorylated peptides 
were not present anymore. This suggests that a much higher degree of modification is 
associated to this part of the protein after stimulation. Indeed, there are two serines, two 
threonines and two tyrosines packed in a very short peptide (8 residues). Amongst those, only 
T74 lies in a consensus sequence for PKB (protein sequence was screened using Motifscan
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programme. All possible phosphorylation sites have all been highlighted on the sequence 
(Figure 58, A).
The structure 1D5C_A (Crystal Structure of Rab6 complexed with GDP) was the most 
representative for Rab6, the homology between the sequences being 84%. Thr54 and Tyr56 
are candidates for the monophosphorylation on Rab6; the kinetics related to this modification 
were not clear, and implied that more modification on the same peptide might occur. 
Interestingly, upon stimulation only 10% on the peptide 54-60 and only 70% of the 
monophosphorylated remain unmodified. This suggests that there might be dephosphorylation 
on the same peptide, but no corresponding peaks could be found in the MALDI-TOF 
spectrum. It appears that the candidate residues Thr52 and Tyr54 are both very accessible, but 
the role of phosphorylation is not obvious because they lie far from the binding site and from 
the GDP (Figure 58, C).
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Figure 58. R abl and Rab6 structures
(A) Rabl complex with RabGDI structure 1UKV_Y. Residues Thr72, Thr74, Tyr77, Tyr78, 
Ser75, and Ser76 are highlighted as potential phosphorylation sites in regulating the binding 
upon EGF stimulus. GDI protein is in yellow; (B) Rab6 structure 1D5C_A. Residues Thr53 
and Tyr54 highlighted. GDP is in green, Prenylation is in pink.
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CHAPTER 7 
DISCUSSION
Sum m ary
The work presented in this thesis is an original proteomics approach to the study of EGF 
signalling. First, a reliable method for enriching the phosphoproteome has been established 
(chapter 3). Second, a subset of phosphoproteins of potential target for some kinases super 
families was identified. In order to understand the role of these proteins a body of additional 
information was needed, including the identification of the phosphoproteins of interest and 
the allocation of their phosphorylation sites.
In order to complement this qualitative data with quantitative information on each 
phosphorylation site, proteomics technology currendy in use was stretched by creating a new 
combined method, called the Phospho-SILAC strategy. The application of this strategy 
allowed exact identification of phosphorylation sites on many proteins and, in most cases, the 
description of the kinetics of phosphorylation on each single site. The consistent use of 2D 
PAGE as a separation method allowed separation of the phospho-isoforms for most of the 
proteins identified and consequendy facilitated an understanding of the subde differences 
between different isoforms of the same protein.
The Phospho-SILAC strategy was applied to selected highly abundant proteins identified as 
potential kinase targets (as described in chapter 4). A detailed analysis of heat shock proteins 
and Enolase-1 was presented and extensively discussed in chapter 5. General conclusions on 
the behaviour of highly abundant phosphoproteins are expressed in this section.
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In order to offer a more comprehensive quantitative analysis of the phosphorylation events 
which occur in the cell upon EGF stimulation, the Phospho-SILAC strategy was also applied 
to the whole phosphoproteome. The most abundant proteins were selected in order to obtain 
a more complete set o f quantitative data. The analysis of these data led to general conclusions 
concerning the dynamics of phosphorylation events connected to EGF, with special focus on 
small GTPases and their effectors. An interesting model of the regulation of some GTPases by 
post translation modification is offered in this chapter.
The lim ita tions of th e  Phospho-SILAC strategy
Some difficulties were encountered in the application of the Phospho-SILAC strategy. These 
have influenced the results obtained with this approach. The specific limitations of each of the 
techniques used have been discussed in the corresponding chapters (3, 4 and 5) and are 
summarised here with suggestions of possible ways to overcome them.
A chromatographic procedure has been developed to enrich phosphoproteins based on IMAC. 
The classic limitations, such as poor protein solubility at low pHs and interference of acidic 
proteins which were encountered in the earlier attempts, were overcome (chapter 3). However, 
the leakage of a few proteins containing 32P (assumed to be entirely phosphoproteins) could 
not be avoided. At the same time, very few spots which did not contain 32P were systematically 
found in each gel. Nevertheless, a sophisticated bioinformatics analysis demonstrated that 
acidic proteins, typical contaminants for IMAC, were not systematically isolated. This proved 
that the specificity of the enrichment was high. On the whole, the limitations described did not 
influence the quality of the enrichment, because most of the phosphoproteins were well 
separated and could be easily selected from the gel.
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The SILAC tagging has been described in chapter 1 and in the introduction to chapter 5. 
Although SILAC is one of the most recognised techniques for the relative quantification of 
proteins it contains some inherent boundaries, which become even more relevant when 
applied to the quantification of single peptides.
Fundamentally, only peptides containing one of more arginines can be quantified, and this 
constitutes on average ca. 50% of the total tryptic peptides obtained from a protein. This is 
particularly relevant in the performed experiments because phosphorylated peptides lacking 
the arginine were sometimes identified. In these cases it was not possible to correlate the 
phosphorylation event with the EGF stimulus.
Another limitation in the analysis of labelled proteins is that there might be overlapping 
doublets. Although this is a problem mainly restricted to very abundant proteins because of 
the corresponding spectra being very rich in signals, it still prevented the quantification of 
some of the peptides.
Normalisation of the intensities in the MALDI-TOF spectra was necessary for every 
experiment. Small changes in the amounts of protein lysates loaded on the gel needed to be 
compensated by recalibration of the ratio of the doublets. This was possible because it was 
assumed that there are no changes in protein expression within the first two minutes of 
stimulation and, as a consequence the ratio of corresponding unmodified peptides must be 1:1. 
However, manual processing was essential because some unmodified peptides (which had been 
found to be modified as well) had to be excluded from the calibration. These peptides were 
used instead for indirect quantification (chapter 5, introduction) because their ratio 
compensated for the ratio of the corresponding modified peptides.
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The main disadvantage of the strategy presented is the lack of appropriate software that would 
recognise doublets and calculate the ratio of their intensities. The entire analysis was carried 
out by hand, thus increasing the awareness of the requirements that new software must meet. 
It is essential to determine a priority in the attribution of the peaks from a MALDI-TOF 
spectrum as the allowance of a high degree of modified residues, such as arginine labelling and 
serine, threonine and tyrosine phosphorylation leads to a higher level of non-specific 
attributions. In order to limit this problem, database searches were always performed first 
allowing only labelled arginine as a possible modification. Ideally, an appropriate software 
application should be able to recognise doublets not only on the basis of the differences in 
masses between two peaks but also on the isotopic profile of the two, which is expected to be 
identical (for identical peptides). Another point to be considered is that peptides containing 
oxidised methionine can hardly give a real estimation of the relative abundance of the two 
peptides at different times because the process of oxidation happens during sample processing 
and is not necessarily the same for the two labelled and unlabelled peptides (in fact, mixtures 
of oxidised and unmodified methionines containing peptides were often found).
Furthermore, some typical limitations of the majority of proteomics approaches could not be
overcome in the presented approach. It is known that when proteins are separated on 2D gel
the most abundant proteins will give the strongest spots and will be the easiest to identify. Low
abundant proteins often remain obscured. By enriching the phosphoprotein fraction, this
problem is only partially overcome. As phosphorylation is a very common modification, the
complexity of the sample is only relatively reduced when phosphoproteome is isolated. In fact,
a large fraction of highly abundant proteins was identified. However, this is a double edged
sword. Highly abundant proteins are usually structural or multi-functional proteins. It is
reasonable to think that multi-tasking proteins tend to be modified to a very high degree,
probably in order to discriminate amongst the different roles they play in time and space.
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Fortunately, the analysis of abundant proteins was often very thorough, especially when more 
isoforms were involved. For this reasons abundant proteins must not be dismissed, and what 
has always been viewed as a limitation of the proteomics approach might actually be regarded 
as a favourable factor. Indeed, abundant proteins proved to be a valuable source of 
information not otherwise available at the genome level.
General observations on phosphorylation dynamics 
in th e  cell
The Phospho-SILAC method was applied to a wider range of proteins in order to investigate if 
there is a common behaviour in different classes of proteins upon stimulation with EGF. 56 
spots have been analysed and 24 different proteins have been identified. As many as 13 of 
these proteins presented multiple phospho-isoforms (chapter 6). As expected, many proteins 
do not present any changes upon stimulation with EGF. In the fraction chosen 40% show 
some kind of change, this percentage including proteins previously known to be changing their 
phosphorylation state upon EGF stimulation (chapter 4).
Phospho-isoforms are often present in a typical train pattern on the 2D gel where each spot 
corresponds to the same protein (same primary structure) with a different degree of 
phosphorylation. Phosphorylation sites were frequently in common with at least two of the 
isoforms, but their kinetics were different. These isoforms could be described as a population 
of the same protein that becomes phosphorylated at different rates. For instance, one of Hsp8 
isoforms was not phosphorylated on Thrl63, one in ten molecules of another isoform became 
phosphorylated after 5 minutes, and up to three in ten molecules of a third isoform did the 
same. It looks as though these isoforms become phosphorylated in a wave, maybe to modulate 
and keep the process under control (chapter 5). To further support this, the Hsp8 isoforms
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which became immediately dephosphorylated before two minutes of EGF stimulation are the 
most acidic isoforms, and therefore likely the most phosphorylated; the proteins at higher pi 
followed the same process though more slowly (chapter 4). Subsequent results suggested that 
this dephosphorylation occurs on Thr38 (chapter 5).
Interestingly, similar observations can be made for Enolase-1: less than 10% for one Enolase-1 
isoform became phosphorylated whilst up to 40% of another phospho-isoform became 
phosphorylated on the same residue.
This behaviour is probably biologically significant rather than caused by the experimental 
processing of the cells; in fact, the cells are synchronised in order to exclusively connect the 
response to EGF stimulation. Although the cells are resting and quiescent, a distribution of 
different phospho-isoforms of the same proteins is already present. This automatically leads to 
a differentiated response of these isoforms to the stimulus. These phospho-isoforms are most 
likely the result of protein functional partitioning. These events could be seen as a regulatory 
process of the cell which does not recruit all its proteins in the response to one stimulus, but 
keeps some inactive (or only partially activated) for other possible functions. Another process 
that became particularly evident, and that is in line with this latter deduction, is that the 
stoichiometry of the phosphorylation is very rarely 100%, but rather between 10-50%.
Chaperones involved in EGF signalling
In chapter 4 an immuno screening for serine/threonine phosphorylation of the total 
phosphoproteome was described. The phosphorylated serines and threonines selected for this 
analysis are in a well known consensus motif recognised by proteins kinases. However, due to 
the inherent limitations of this approach, mainly chaperones and structural proteins were 
found. In the discussion to chapter 4, evidence was given to show that each of the highly
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abundant proteins found in the screening is strongly related to stress induced signalling. These 
observations led to the conclusion that phosphorylation and oxidation are strongly related in 
signalling. It is not easy to hypothesise on the molecular mechanisms mediating this 
connection, especially because they are not necessarily direct, but might be finely regulated 
through a net of different isoforms. The oxidation and reduction of protein cysteine sulfhydryl 
(SH) groups work as a molecular switch to start or stop signalling in combination with 
phosphorylation. It is known that oxidation of cysteine SH groups on protein tyrosine 
phosphatases switches off the action of protein tyrosine phosphatases (Cho et al. 2004). This 
event may not, however, signal for initial autophosphorylation o f previously unphosphorylated 
PTKs, whereas it certainly prevents dephosphorylation of once-phosphorylated PTKs. New 
mechanisms for oxidative stress-mediated PTK activation assume that intracellular specific 
cysteine SH groups on PTK proteins can be another target of oxidative stress for inducing a 
conformational change necessary for initial activation of PTKs (Nakashima et al. 2002). 
Considering that redox events trigger phosphorylation events, it can be suggested that 
phosphorylation/dephosphorylation of the chaperones and other proteins involved in the 
redox network influences the stability of the chaperone substrate-binding form, therefore 
regulating the redox reactions. As a consequence, an initial phosphorylation of some 
chaperones upon growth factor stimulus passes on the activation of kinases and phosphatases 
to propagate the signal further. Although this might not be the key path for the response to 
EGF signal, it could well support the other better known cascades.
These results, together with previous evidence (see chapter 1) hinted that chaperones play a
significant role, possibly complementary to the one of other signalling proteins. For this
reason, Hsp70/Hsc70 family was successfully analysed to further understand which
phosphorylations are involved in their regulation and to obtain quantitative data on potential
phosphorylation on TP, as observed in the immuno screening. Indeed, it was concluded that
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Hsp8 is phosphorylated on Thr 38 (followed by proline). A model was proposed according to 
which this phosphorylation regulates the hydrolysis of ATP and the chaperone activity itself 
(refer to discussion of chapter 5). The investigation was extended to more chaperones 
belonging to the same family in order to identify some common behaviour, reaching the 
conclusion that different proteins belonging to the same superfamily of Hsc70 are 
phosphorylated mosdy on conserved residues. A specific case was highlighted, Hsp8 and 
Hsp5, which share only 63% homology, have one phosphorylated residue in common (Thr 
163-on Hsp8 sequence), although this follows different phosphorylation kinetics (for details, 
see Discussion to chapter 6).
Hsp8 forms 1:1 complexes with Stress induced phosphoprotein 1 which are regulated by 
phosphorylation events (van der Spuy et al. 2001). It is difficult to understand which isoforms 
of these proteins are involved. Although phosphorylation on Stress induced phosphoprotein 1 
was further analysed using the Phospho-SILAC method, it showed no modifications.
Rab/RabGDI vs. Rho/RhoGDI-1 in teractions
Combining the results obtained from the analysis of the two Rab proteins and RhoGDI-1 
together with data available from literature, some new observations can be made. 
Rho/RhoGDI-1 protein interaction appears mostly regulated by phosphorylation on GDI, 
whilst Rab/RabGDI is regulated via phosphorylation on Rabs. These two complexes regulate 
different biological processes, but are mechanistically very similar. The data show that 
RhoGDI-1 presented some phosphorylations on residues interacting with the geranyl-geranyl 
or the GTPase bound to it. At the same time it also has phosphorylation sites along the surface 
that interact with the GTPase’s amino acidic chain. It seems that the two sets of 
phosphorylation move in the same direction, which is dissociation for the GTPase and 
exposure of the geranyl-geranyl group. Dissociation of the GDI molecules causes exposure of
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the geranyl-geranyl group, resulting in the GTPase’s binding to the membrane and 
consequently triggering the signal response. Some data suggest that phosphorylation on the G- 
protein increases the affinity of the RhoA and Cdc42 with RhoGDI. This suggests that at the 
same time phosphorylation on RhoGDI-1 lowers such affinity.
As for the Rab/RabGDI beta complex, opposite conclusions to the ones reached for 
Rho/RhoGDI-1 complex could be made. Both Rab6 and Rabl were identified and 
phosphorylation changes were found for both. For Rabl in particular, it appears obvious that 
such phosphorylations interfere with the affinity of the complex. On the other hand, RabGDI 
beta was identified and half of its sequence covered, but it was not possible to find any 
putative sites. They are likely to be present, but are probably not as abundant as in RhoGDI.
C onclusions and outlook
EG F signalling was investigated using an innovative proteomics approach. Looking at the 
larger frame of proteomics (Stannard et al. 2004) it becomes clear that revealing signalling 
pathways and cellular functions at a molecular level is far more complex than previously 
anticipated. This is due to function partitioning of the proteins, their multitasking and 
moonlighting and there is evidence that this accounts for isoforms and splicing variants 
(Godovac-Zimmermann et al. 2005; Kleiner et al. 2005; Stannard et al. 2004). The analysis 
presented in this thesis provides numerous leads to understand the role of the 
phosphorylations observed, some supported by biological experiments and structural 
observations. More sophisticated information has been obtained here concerning EGF 
signalling than has been achieved in previous proteomics experiments. Above all, the 
importance of quantitative proteomics in the study of EGF signalling has been demonstrated 
and the information obtained can be used and built upon in further investigations.
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It is often believed that advanced current proteomics methods are readily available. This is 
usually true for micro-organisms, but certainly not for eukaryotes. This needs to be addressed 
by the further development of methods for MS/MS of proteins rather than peptides as protein 
surrogates, as this analysis lacks information on isoforms. These improvements need to involve 
methods for protein isoform isolations and protein MS in order to achieve new information on 
protein-protein interaction and complexes in cellular signalling.
The logical steps based on the work explained in this thesis would include a set of molecular 
biology experiments in which the amino acids described here would be mutated in order to 
understand their role in the cell, or simply in order to confirm the predictions made here based 
on general observations on phosphorylation sites and their locations on the structures. This 
would certainly contribute further to the knowledge of EG F signalling.
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